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1.1 Definition of minor histocompatibility antigens 
Allogeneic stem cell transplantation (SCT) from a related or unrelated donor is 
a well-established and effective therapy for advanced hematological malignan-
cies1. Besides the required graft versus leukemia (GvL) response, donor cells may 
initiate graft versus host disease (GvHD). GvHD is caused by disparities between 
tissue antigens expressed by patient and donor. Donor T cells recognize tissue 
antigens expressed by patient cells but not by donor cells, resulting in a vigor-
ous T cell response. Likewise, following tissue or organ transplantation, tissue 
antigen disparities can cause graft rejection by patient T cells recognizing tissue 
antigens expressed by the graft but not by patient cells. In the beginning of the 
20th century, Little and Tyzzer2 discovered these tissue antigens by the observa-
tion that the rejection of tumour grafts by inbred mouse strains was regulated 
by independently segregating gene loci. The congenic mouse strains generated 
by Snell in the 1940s3, made identification possible of single loci responsible for 
tumour graft rejection. The chromosomal segment determining susceptibility 
or resistance to tumour or tissue transplants was said to contain a Histocom-
patibility (H) locus. H loci strongly differed in the speed with which tumour 
graft rejection was induced. Snell identified thirteen H loci. The H-2 locus was 
characterized by the strongest rejection and therefore was later named Major 
Histocompatibility Complex (MHC)4,5. All other Histocompatibility loci were 
grouped under the name Minor Histocompatibility (mH) loci, although incom-
patibility for a number of mH loci could be as strong as MHC incompatibility6. 
This is illustrated by the fact that polymorphic mH loci are capable of inducing 
mH specific MHC restricted T cell responses7,8. The total number of murine mH 
loci is estimated to be over several hundreds6,9. Murine mH antigens have been 
shown to be encoded by almost every autosomal chromosome, on the Y chro-
mosome and on the mitochondrial genome10,11.
 In human the existence of mH antigens was found after the discovery 
of the Human Leucocyte Antigens (HLA); the human analogue of the murine 
MHC12. In HLA identical settings, bone marrow transplantations still resulted 
in GvHD13,14 indicating histo-incompatibility beyond HLA. T cells obtained after 
HLA identical marrow transplantations indeed defined human mH antigens. 
Generation of MHC class I restricted cytotoxic T lymphocyte (CTL) lines or 
–clones has made in vitro definition of single human mH antigens possible15-17. 
The generation of multiple human mH specific T cell clones within one donor 
recipient combination indicated the existence of a high number of different hu-
man mH antigens18,19. In addition to HY specific T cell clones, T cell clones spe-
cific for autosomally encoded mH antigens were found13,16. Furthermore, family 
segregation studies demonstrated that several mH antigens were encoded by 
germline genes20-23.
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1.2  Characteristics of minor histocompatibility 
antigens
1.2.1 mH antigens are peptides presented by MHC molecules
In the 1980s it became clear that T cells recognize peptides in the context of 
MHC molecules. To determine whether mH antigens are also peptides in com-
plex with MHC, cells expressing a defined mH antigen have been enzymatically 
digested into protein extracts after which the fragments were separated by re-
verse phase HPLC. Then the peptides were loaded on mH antigen negative tar-
get cells and tested by mH antigen specific CTLs. These CTLs recognized material 
from a distinct position of the HPLC elution profile, while their activity was 
absent when the material was treated with proteases of broad specificity, which 
shows the peptidic nature of the mH antigens24. Furthermore, the CTLs were 
only active when the restricting MHC molecule was expressed by the target cell, 
which indicates that the isolated peptides were naturally presented in the con-
text of MHC25,26. Similarly, human mH antigens were also shown to be peptides 
presented by MHC molecules. This was demonstrated by immunoprecipitation 
of the mH antigen presenting MHC class I molecules followed by acid treat-
ment, separation of the peptides from the MHC molecules and fractionation 
of the peptides on reverse phase HPLC27-29. The Goulmy group was the first to 
purify HLA-A2 molecules that contain the natural human mH peptide HA-230. 
Using these and other sophisticated techniques, our group and others have 
subsequently identified an as yet relative small number of human mH loci29-45 
encoded by genes on the Y chromosome31,32,34-37,40,44,45 and by autosomal genes 
i.e.: HA-1, HB-1, HA-8, BCL2A1, UGT2B17 and HA-329,33,38,41-43.
1.2.2 The origin of mH antigens 
The small number of human mH antigens identified to date revealed to con-
sist of peptides derived from naturally processed intracellular proteins. These 
peptides are encoded by the Y chromosome or autosomal chromosomes and 
are presented by MHC class I and class II molecules. The peptide sequences 
of mH antigens HA-1, HA-2, HA-3, HA-8, HB-1, BCL2A1, UGT2B17 and sev-
eral human HY mH antigens have been elucidated29-31,34,35,38,42,43,45-48. HY antigens 
were found to be derived from the genes SMCY, DFFRY, DBY, UTY, RPS4Y and 
TMSB4Y, located on the Y-chromosome with an homologous gene on the X-
chromosome31,32,34,35,37,40,44,45. These HY antigens are all derived from household 
or transcription proteins except for the TMSB4Y antigen (described in section 
1.2.5). The SMCY gene encodes an hypothetical transcription factor, the gene 
is involved in protein synthesis and the DFFRY, DBY and UTY genes are all 
involved in spermatogenesis49. In contrast, the mH antigens HA-1, HA-2, HA-3, 
HA-8, HB-1, BCL2A1 and TMSB4Y are encoded by onco-related genes45,49. HA-1 
is derived from the di-allelic KIAA0223 gene located on chromosome 1929, en-
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coding a Rho-like GTPase-activating protein (GAP) while HA-2 is derived from 
a di-allelic gene encoding a novel human class I myosin protein39. HA-3 is a 
product of the lymphoid blast crisis (Lbc) oncoprotein43. The HA-1, HA-2 and 
HA-3 proteins are potentially linked together in one signaling cascade involved 
in cytoskeletal rearrangement49. The HA-8-containing protein contains a Pum-
ilio repeat region implicated in translational regression. Deletion of one of the 
major members of the Pumilio family (PUF) leads to disturbance of primary 
spermatocytes, which then develop into rapidly growing tumours50. The gene 
encoding HB-1 shows only significant expression in acute lymphoblastic leuke-
mia B cells and not in mature non-malignant B cells33. BCL2A1 is a member of 
the anti-apoptotic BCL-2 protein family that suppresses apoptosis induced by 
the p53 tumour suppressor protein51. Finally, the X-chromosome homologue 
of TMSB4Y, known as thymosin 4, encodes a protein that plays an important 
role in the organization of the cytoskeleton and is highly expressed in metastatic 
melanoma cells52,53. All T cells specific for mH antigens encoded by onco-related 
genes except HA-2, were isolated from patients with hematological malignan-
cies. In contrast, T cells specific for the mH antigens derived from household or 
transcription proteins have generally been isolated from patients suffering from 
an hematological disorder; not a malignancy49. 
1.2.3 Mechanisms for generation of mH antigens
1.2.3.1 mH antigens due to gene polymorphisms
Minor H antigens generally originate from amino acid polymorphisms in self-
proteins. The first self protein derived mH antigen determined was maternally 
transmitted antigen (MTA)54. This murine mH antigen was maternally inherited 
and thus of mitochondrial origin. CTLs were generated against four different 
alleles of MTA which differed from each other by one amino acid in the pre-
sented peptide55. In several human MHC class I restricted mH antigens single, 
dual or triple amino acid polymorphisms have been found29,31,34,35,38,39,43,56. These 
amino acid polymorphisms result in two allelic counterparts of the mH antigen, 
of which generally only one is capable of generating a CTL response. However, 
recognition of both alleles from the same mH locus has also been described56,57. 
The two allelic counterparts of the HA-1 locus that have been previously de-
scribed, result from a Histidine (H) to Arginine (R) substitution. Recently, two 
additional polymorphisms in the HA-1 locus have been reported. Namely an 
Aspartic acid (D) to Glutamic acid (E) substitution and a Glycine (G) to Serine (S) 
substitution at different positions (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.
cgi?locusId=23526). These additional amino acid polymorphisms may lead to 
additional HA-1 antigens. To date, only the HA-1H allele has been found to be 
immunogenic. 
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1.2.3.2 mH antigens due to gene deletion
The fact that deletion of a gene can give rise to a mH antigen disparity was first 
illustrated by Speiser et al. who showed that the nuclear myxovirus resistance 
protein Mx in mice could act as a mH antigen58. In Mx- mice both Mx+ skin 
graft rejection and Mx directed CTL response was observed. The allelism was 
a consequence of the absence or presence of the Mx protein, since in the Mx- 
mice a part of the Mx gene was deleted59,60. cDNA expression cloning provided 
the first evidence that gene deletion can be a mechanism for generating human 
mH antigens. Using this technique, a novel human mH antigen was identified 
encoded by UGT2B17, an autosomal gene in the multigene UDP-glycosyltrans-
ferase 2 family that is selectively expressed in liver, intestine, and antigen-pre-
senting cells. The UGT2B17 antigen is immunogenic because of differential pro-
tein expression in donor and recipient cells as a consequence of homozygous 
gene deletion in UGT2B17 negative individuals42.
1.2.3.3 mH antigens encoded by an unconventional ORF
Evidence has been accumulating that cryptic polypeptides derived from non-
coding regions or encoded in alternative open reading frames (ORF) occasion-
ally encode CTL epitopes for tumour or viral antigens in humans or mice61. All 
as yet identified mH epitopes are encoded by conventional ORFs. However, a 
novel HY antigen encoded in the 5’-untranslated region of the TMSB4Y gene 
was identified recently45. Probably, this novel HLA-A33 restricted mH antigen 
TMSB4Y is not derived from a functional polypeptide, but is a subsidiary trans-
lation product of the TMSB4Y transcript. This is the first demonstration of a mH 
antigen encoded outside a conventional ORF of a nonmutated gene.
1.3 Processing and presentation for the generation 
of minor histocompatibility antigens in 
complex with MHC class I
1.3.1 Antigen processing and presentation by MHC class I 
molecules
To be presented on the cell surface, intracellular proteins must be degraded into 
small peptides, which is generally known as antigen processing. Since this thesis 
focuses on mH antigen HA-1 presented by MHC class I, the processing and 
presentation of MHC class I binding peptides (figure 1) will be discussed only. 
MHC class I presented peptides are mainly generated in the cytosol by the 26S 
proteasome62, an approximately 2000 kDa multiprotein. The intracellular protein 
turnover is controlled by the 26S proteasome by a nonlysosomal, ATP- and 
ubiquitin-dependent pathway. Proteins are recognized and unfolded by the 19S 
caps of the proteasome after being marked for degradation by conjugation with 
ubiquitin. Subsequently, the 20S catalytic core of the 26S proteasome degrades 
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the unfolded proteins. This degradation results in peptides of mainly hepta- to 
nonameric lengths. The 20S proteasome consists of 2 outer rings of 7  sub-
units and 2 inner rings of 7  subunits. The  subunits preferentially cleave the 
C-terminus of aromatic, aliphatic, basic and glutamic acid residues. Following 
proteasomal peptide cleavage and TAP translocation (described below), further 
N-terminal trimming by aminopeptidases takes place in the endoplasmatic re-
ticulum (ER)63-65. C-terminal trimming in the ER has not been demonstrated. The 
proper generation of the correct COOH terminus by an early major proteasome 
cleavage site is thus indispensable for efficient epitope generation66-69. The fact 
that the positions of certain amino acid residues in the protein can influence 
peptide processing in various manners is utilized by several peptide process-
ing prediction programs70 (http://www.cbs.dtu.dk/services/NetChop/;  http://
www.paproc.de/). Furthermore, peptide degradation takes place by proteases in 
the cytosol71-73.
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Figure 1
The MHC class I processing and presentation pathway
The transporter associated with antigen processing (TAP) is a heterodimer of 
the subunits TAP1 and TAP2, which are encoded in the MHC complex. Fol-
lowing peptide generation, TAP transports preferentially 8-12 amino acids long 
peptides, via an ATP-dependent process to the lumen of the ER74,75. Like pro-
tein degradation, this TAP translocation is dependent on the positions of cer-
tain amino acid residues in the peptides to be transported76. In the ER human 
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MHC class I heavy chain and 2M assemble to an unstable heterodimer, which 
is facilitated by chaperones such as calnexin77. Subsequently, the heterodimers 
dissociate from these chaperones and bind to calreticulin, another chaperone. 
This complex then binds to tapasin and TAP, after which MHC-peptide bind-
ing takes place78. The resulting stable trimolecular complex of peptide, 2M and 
MHC class I heavy chain then dissociates from TAP, moves to the Golgi ap-
paratus and is eventually expressed on the cell surface. Generally, MHC class 
I molecules bind 9 amino acid long peptides in their groove, however, shorter 
and longer peptides have been described. The restricted peptide length is caused 
by the conserved end residues of the heavy chain-1 and -2 helixes that close 
the ends of the MHC class I groove and interact with the N- and C-terminus of 
the peptide. Furthermore, the MHC class I groove consists of six pockets named 
A to F. Pockets A and F respectively accommodate the N- and C-terminus of 
the peptide in all MHC alleles, whereas the pockets B to E vary in size and hy-
drophobicity for the different MHC alleles. This leads to different requirements 
for the amino acid sequence of the peptide in order to bind to the MHC mol-
ecule79,80. The MHC binding amino acid anchors are generally positioned at the 
second and/or third position and the ninth or last position of the peptide81,82, 
forcing the peptide to bulge in the middle. This in turn leads to further varia-
tion of peptide conformation and thereby to variation of specific T cell receptor 
(TCR) interactions. The different sequence characteristics known to be involved 
in MHC-peptide binding are taken into account by binding prediction algo-
rithms83-85 (http://bimas.dcrt.nih.gov./; http://syfpeithi.bmi-heidelberg.com/).
 Since the positions of specific amino acid residues in proteins can influ-
ence peptide processing and TAP translocation, single amino acid substitutions 
of reciprocal mH alleles can interfere with cell surface expression. Causes of 
such “immunological null allelism” have been demonstrated for the allelic coun-
terparts of mH antigens HA-3, which is destroyed by proteasomes, and HA-8, 
which is poorly translocated into the ER38,43. The formation of mH antigens 
is thus dependent on correct antigen processing. Furthermore, MHC-peptide 
binding and dissociation rates are dependent on peptide motives. The peptide 
motives thus determine the MHC-peptide complex stability, which is important 
for epitope recognition86.
1.3.2 T cell recognition of MHC presented mH peptides
The generation and loading of antigenic peptides takes place in different com-
partments of the cell, resulting in different sets of peptides presented by MHC 
class I or MHC class II molecules. MHC class I molecules present peptides 
derived from intracellular proteins such as mH proteins, whereas MHC class 
II molecules generally present peptides derived from exogenous proteins and 
transmembrane proteins. TCRs recognize their antigens as peptide fragments in 
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the groove of the MHC molecules. CD8+ cytotoxic T cells generally recognize 
antigen in the context of MHC class I molecules which are expressed on the cell 
surface of virtually all nucleated cells. CD4+ T helper cells generally recognize 
antigen in the context of MHC class II molecules, which are only expressed by 
cells such as (amongst others) macrophages, dendritic cells, and B lymphocytes 
that possess a specialized antigen presenting function. Both CD8+ and CD4+ T 
cell responses against mH antigens presented by respectively MHC class I and 
MHC class II molecules have been described87.
 The TCR heterodimer consists of two transmembrane glycoprotein 
chains, - and , which are attached by a disulfide bond. The extracellular por-
tion of each chain consists of domains resembling the immunoglobulin variable 
(V) binding domain, -joining (J) domain and -conserved (C) domain. The crystal 
structures of both TCR subunits have been elucidated88,89. The V binding sites 
of the TCR chains determine the antigen specificity of the T lymphocytes. For 
instance, all TCRs specific for HA-1H in the context of HLA-A2 described thus 
far, express the same TCR -chain BV7S9, illustrating the important role of this 
chain in HA-1H specificity90,91. On the contrary, several different TCR -chains 
have been found in separate HA-1H specific HLA-A2 restricted T cell clones90 
(chapter 6). The TCR repertoire is formed by selection in the thymus. Through-
out thymic development, maturing thymocytes are continuously interrogated 
by their TCR to ensure proper expression of TCRs specific for non-self antigens 
and to exclude TCRs specific for self-antigens. Furthermore, the strength of TCR 
signals transmitted in a given thymocyte influences survival or elimination. In 
utero, the antigens encountered during thymic development may include ma-
ternal antigens not inherited by the child. Therefore, the TCR repertoire against 
non-inherited maternal antigens (NIMAs) may be debilitated92. However, pos-
sibly  the encounter of maternal mH antigens in the thymus is too low to result 
in the elimination of their specific TCRs. Subsequently, T cell priming against 
mH NIMAs may take place in utero.
 CTL recognition of a mH epitope in context of MHC class I is not only 
dependent on the immunogenicity of the mH peptide but also on its processing 
and presentation, as described in section 1.3.1. For instance, CTLs specific for 
either HA-2 in the context of HLA-A2, HA-3 in the context of HLA-A1 or HA-8 
in the context of HLA-A2 are capable of recognizing both concerned allelic 
counterparts if the mH peptides are administered synthetically30,38,39,43. Both allelic 
peptides from each mH locus contain a common amino acid motive since they 
are both recognized by the same TCR. However, the mH epitopes are presented 
by MHC class I molecules, whereas their allelic counterparts are not or at very 
low concentration present on the cell surface. Thus, the HA-2, HA-3 and HA-8 
specific CTLs recognize those mH peptides that are correctly processed and 
presented.
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1.4 Clinical relevance of minor histocompatibility 
antigens
1.4.1 GvHD and GvL
As previously mentioned, allogeneic stem cell transplantation (SCT) from a re-
lated or unrelated donor is a well-established and effective therapy for ad-
vanced hematological malignancies1. Following transplantation, donor T cells 
may initiate graft versus host disease (GvHD). If the donor is HLA mismatched 
this is caused by cytotoxic T cell responses to patient HLA, disparate from 
donor HLA. Two pathologically distinct types of GvHD are known, namely 
acute- and chronic GvHD. The acute form may occur during approximately the 
first 100 days following SCT whereas the chronic form may occur after the 3rd 
month following SCT. The latter may develop de novo or follow acute GvHD. 
Both types of GvHD occur in different grades dependent on the severity of 
the disease. Following SCT from an HLA-genotypically identical sibling donor, 
patients still develop acute or chronic GvHD in 35-65% of the cases93,94. The 
suggestion that incompatibility for mH antigens thus plays an important role in 
causing GvHD, was confirmed by the observation that GvHD following HLA-
identical SCT significantly correlates with the disparity for a single mH antigen95. 
Both T cells recognizing mH antigens and recognizing leukemia associated anti-
gens were isolated from SCT patients96,97. In addition, several studies described T 
cells that recognized mH antigens expressed by leukemic cells98,99, indicating that 
mH specific T cells are not only important in the induction of GvHD but also 
in the induction of the Graft versus Leukemia (GvL) effect. In agreement with 
this finding, the occurrence of GvHD was associated with a decreased leukemia 
relapse rate100, which is the result of donor T cells eliminating residual leukemic 
cells101. In order to prevent GvHD, T cell depletion of human bone marrow was 
introduced. This not only resulted in a dramatic reduction of GvHD, but un-
fortunately also in an increase of graft rejection and leukemia relapse rates102,103. 
Relapsed leukemia patients can be successfully treated with donor lymphocyte 
infusion (DLI). The association of the GvL effect with GvHD after DLI further 
indicates the important role of mH antigens in both the GvL effect and GvHD104-
106. Donor CTLs specific for an immunogenic hematopoietic restricted mH allele 
will specifically recognize malignant recipient cells and induce a GvL response 
with only a low risk of GvHD. 
1.4.2 Tissue distribution
To determine whether mH antigen expression is restricted to certain areas of the 
body, tissue distribution has been evaluated for several murine and human mH 
antigens, using mH antigen specific T cell clones107,108. Several mH antigens were 
found to be expressed only by certain cell types, while others are expressed 
ubiquitously. Epa-1 is a murine mH antigen expressed only by macrophages, 
epidermal cells and fibroblasts109, whereas the mH antigens H-4 and HY are 
  General introduction            19 
expressed by all murine organs26. CTL-mediated lysis of tissue-derived cells and 
cultured cell lines was used as an in vitro assay for mH antigen expression of 
several human tissues. The human mH antigens HA-1 and HA-2 were found 
to be expressed only by cells of hematopoietic origin, including leukemic cells, 
hematopoietic progenitor cells, dendritic cells and Langerhans cells98,99,107,110. In 
contrast, the human mH antigens HA-3, HA-4 and HY were expressed by all 
cells tested, which included cells of hematopoietic origin, immature thymocytes, 
fibroblasts, keratinocytes, melanocytes, epithelial cells and endothelial cells107. 
 Cell surface presentation of mH antigens has been found to be an 
important cause for GvHD induction. mH antigens presented by different cell 
types might play different roles in the induction of GvHD. Mainly epithelial 
cells are affected during GvHD, however, only half of the murine mH antigens 
causing GvHD were found to be present on skin cells, whereas all of these 
mH antigens were present on lymphocytes or monocytes108. Possibly these he-
matopoietic cells are sited in peripheral tissues which are, as a consequence, 
destroyed during GvHD111. Differential tissue distribution of mH antigens may 
also be an important feature in targeting specific cell types using mH specific 
donor CTLs. For instance, the human mH antigens HA-1 and HA-2, expressed 
by cells of hematopoietic origin only, may be targeted specifically to induce a 
GvL response. When all remaining patient hematopoietic cells have migrated 
out of the peripheral tissues prior to administration of the mH specific donor 
CTLs, this GvL response can be generated without causing GvHD.
1.4.3 Population frequency
To map the prevalence of mH disparities between recipient and donor, defin-
ing population frequencies of the immunogenic mH alleles is important. The 
mH antigens HA-1, HA-2, HA-4 and HA-5 were shown to be the product of 
single Mendelian genes segregating independently from the HLA complex21. The 
frequencies of a number of mH antigens have been determined by the frequen-
cies of T cell clones recognizing the relevant mH antigens. For instance, the 
leukemia associated HLA-B44 restricted mH antigen HB-1 is expressed by 28% 
of the HLA-B44 positive individuals47. Furthermore, the HLA-A1 and HLA-A2 
restricted mH antigens HA-1, HA-2, HA-3, HA-4 and HA-5 were found at fre-
quencies of 69%, 95%, 88%, 16% and 7% respectively17. These mH allele popula-
tion frequencies determine the chance of finding recipient-donor combinations 
expressing mH disparities that are suitable to avoid GvHD but perhaps induce 
a GvL response.
1.4.4 Clinical importance of mH antigen HA-1 association with 
GvHD and GvL
Among all mH antigens identified so far the mH antigen HA-1 is the most ideal 
candidate for immunotherapy of hematological malignancies. This because HA-1 
is highly immunogenic, hematopoietic restricted, expressed in high levels on 
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leukemic cells and its frequency is 69% among the HLA-A2 positive population. 
Recently several in vitro and clinical studies indicated its role in the GvL effect. 
For instance, HA-1 specific CTLs effectively lyse all types of leukemic cells in-
cluding CML, CLL, ALL and AML cells. In clinical studies it has been shown that 
the emergence of HA-1 specific CTLs after DLI shows a close association with 
the clinical response112. Similarly, HA-1 specific CTLs were isolated from CML 
patients with complete remission after DLI113.
 HA-1 is also associated with GvHD95,114-116. This is illustrated by the 
fact that HA-1 specific CTL clones have been isolated from patients with severe 
GvHD15,17. These HA-1 specific CTL clones may be part of a general immune 
response, which does not exclude that they contribute to a GvL effect.
1.5 The minor histocompatibility antigen HA-1 as 
a tool for immunotherapy
1.5.1 Identification of HA-1
The HA-1 specific CTL clones originally isolated from patients with severe 
GvHD were restricted by HLA-A217. Subsequently, using HA-1 specific CTLs 
it was shown that the mH antigen HA-1 was present in 69% of the HLA-A2 
positive population17 and was a product of single Mendelian genes segregat-
ing independently from the HLA complex21. To identify the mH antigen HA-1, 
HLA-A2 molecules were purified from an HA-1 expressing EBV-transformed B 
lymphoblastoid cell line (EBV-LCL). The HLA-A2 bound peptides were isolated 
and fractionated after which the fractions were analyzed for their capacity to 
reconstitute HA-1 specific lysis. The results demonstrated that the HLA-A2 re-
stricted mH antigen HA-1 was the nonameric peptide VLHDDLLEA. Database 
searches revealed that the peptide VLHDDLLEA is identical at 8 out of 9 amino 
acids with the peptide VLRDDLLEA encoded by the cDNA sequence KIAA0223. 
Subsequent analyses revealed indeed that the HA-1 antigen is derived from 
the di-allelic KIAA0223 gene. It appeared that two nucleotide differences in the 
KIAA0223 sequence result in the single amino acid sequence difference between 
the immunogenic CTL epitope VLHDDLLEA and the VLRDDLLEA counterpart. 
These two nucleotide differences are positioned at the 3’ end of exon A; the 
H to R substitution is located at amino acid position 139 of the HA-1 locus. 
Recently, two additional polymorphisms in the HA-1 locus have been found. 
Namely a Aspartic acid (D) to Glutamic acid (E) substitution at amino acid 
position 259 and a Glycine (G) to Serine (S) substitution at amino acid posi-
tion 439 (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=23526). Other 
nucleotide differences found within the HA-1 locus do not lead to amino acid 
change. Genomic identification of the mH antigen HA-1 locus by allele specific 
PCR revealed that the polymorphic KIAA0223 gene is located on chromosome 
19. Thus the identification of the gene encoding the HA-1 protein revealed the 
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first example of a human non-sex linked mH antigen that is derived from a 
polymorphic gene. 
 Binding studies of HA-1 peptides to recombinant HLA-A2 molecules 
revealed that peptide VLRDDLLEA has a 10 to 12 fold lower binding affin-
ity compared to immunogenic peptide VLHDDLLEA. Furthermore, peptide 
VLRDDLLEA could not be detected by peptide elution from HLA-A2 molecules 
of HA-1R homozygous EBV-LCLs, indicating absent or very low cell surface 
expression of HA-1R in HLA-A229.
1.5.2 HA-1H directed immunotherapy
Since the polymorphic mH antigen HA-1 is exclusively expressed on hemato-
poietic cells107 including leukemic cells98, adoptive immunotherapy by selectively 
infusing HA-1 specific donor CTLs may mediate a strong GvL effect  with a low 
risk for GvHD96,117. Since HA-1H can be presented by HLA-A217,29, this approach 
would be feasible following an HLA-A2 matched HA-1 mismatched SCT. The 
identification of the nonameric HA-1H peptide VLHDDLLEA has made the in 
vitro generation of large numbers of HA-1H specific donor CTLs possible for 
the use of adoptive immunotherapy. HLA-A2 restricted HA-1H specific CTLs 
have been generated from HLA-A2 HA-1RR peripheral blood mononuclear cells 
(PBMCs) in vitro, using autologous dendritic cells (DCs) pulsed with HA-1H pep-
tide as antigen presenting cells (APCs). These HA-1 specific CTLs efficiently lysed 
HA-1H expressing leukemic cells but not the fibroblasts from the same individu-
al. Furthermore, autologous DCs retrovirally transduced with a sequence of the 
HA-1H allele, have been used as APC to successfully induce HLA-A2 restricted 
HA-1H specific CTLs from HLA-A2 HA-1RR PBMCs in vitro118. 
 However, upon transfer the HA-1 specific donor CTLs may eliminate 
not only patient leukemic cells but also residual HA-1 expressing patient hema-
topoietic cells residing in peripheral tissues. These residual HA-1 expressing pa-
tient hematopoietic cells may thus be responsible for the destruction of the pe-
ripheral tissues in which they remain and therewith for the induction of HA-1 
related GvHD95. A time lapse between SCT and DLI is required for the remaining 
patient’s autologous hematopoietic cells to migrate out of the peripheral tissues. 
The main response of the subsequently infused donor HA-1 specific CTLs will 
then be directed towards the remaining patient leukemic cells specifically with-
out destroying the peripheral tissues, inducing the desired GvL effect without 
causing GvHD. 
 Thus in an HLA-A2 HA-1RR donor / HLA-A2 HA-1HH or HA-1HR pa-
tient SCT setting, adoptive immunotherapy with generated HLA-A2 restricted 
HA-1H specific donor CTLs, specifically targets the hematopoietic cells from the 
patient, including leukemic cells. This approach provides a feasible option for 
adoptive immunotherapy of relapsed leukemia with a low risk of GvHD as has 
been described112,119,120. Since the mH antigen HA-1 was further found to be ab-
errantly expressed in epithelial cancer cells121 it may also be a useful carcinoma 
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cell-specific target antigen following SCT. Patient/donor pairs expressing the 
useful HA-1 mismatch can be identified and selected using prospective genomic 
typing for the HA-1 alleles122. 
1.5.3 Alternative strategies for HA-1H specific CTL generation
Next to the in vitro generation of sufficient numbers of HA-1H specific CTLs for 
the use of leukemia specific immunotherapy, alternative strategies may be used. 
Boosting the HLA-A2 HA-1RR stem cell donor with an HA-1H peptide vaccina-
tion prior to transplantation may be a useful method to induce the generation 
of large numbers of HLA-A2 restricted HA-1H specific donor CTLs in vivo123. 
Boosting the HLA-A2 HA-1H patient with HA-1H peptide following subsequent 
SCT may however result in the induction of a local GvH response since the 
peptide may be bound by HLA-A2 molecules expressed by non-hematopoietic 
patient cells.
 Furthermore, genetic transfer of the HLA-A2 restricted HA-1H specific 
TCR chains may be a less time consuming strategy compared to in vivo or in vitro 
HA-1H specific CTL induction, to introduce HA-1H specificity into large numbers 
of cytotoxic T cells of the donor (chapter 6). This approach has already been 
described for the mH antigen HA-2124. When HLA-A2 restricted HA-2 TCRs 
were transferred into T cells from HLA-A2-negative donors, the HA-2 TCR-
modified T cells exerted  antileukemic reactivity without signs of anti-HLA-A2 
alloreactivity. Therefore, the option of mH antigen specific TCR transfer has 
been previously proposed as a strategy to circumvent the undesired induction 
of allo-HLA-specific T cells in HLA-A2 mismatched SCT settings124. In addition, 
several other studies describing successful redirection of recipient T cell speci-
ficity by TCR transfer have been published previously125-128. Introduction of an 
MHC class I-restricted TCR into CD8+ peripheral T cells resulted in antigen 
specific cytolytic activity and cytokine secretion by these T cells. Furthermore, 
TCR-modified T cells displayed the avidity and fine specificity of the transferred 
TCR129,130 and were capable of eradicating tumour cells in vivo131. 
1.6 Aim of the study
As described, HA-1 directed adoptive immunotherapy may separate GvHD 
from GvL response119. The HA-1H specific immunotherapy is currently feasible 
only for HLA-A2 HA-1HH or HA-1HR patients who relapsed following an SCT 
from an HLA-A2 HA-1RR donor. Thus the feasibility of this therapy depends 
both on the presence of recipient-donor disparity for the mH antigen HA-1132 
and on HLA-A2 expression. HLA-A2 is expressed by approximately 45% of the 
population133. Of the HLA-A2 positive population 16% is HA-1H homozygous 
and 54% is HA-1 heterozygous, whereas 30% is HA-1R homozygous17,122. This 
suggests that approximately 70% of the HLA-A2 positive- or 32% of the total 
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patient population could be candidates for HA-1H specific immunotherapy if 
they have an HLA matched HA-1RR stem cell donor. However, the therapy is not 
guaranteed for all of these patients. For instance, the anonymous UCB donors 
cannot be traced again for use of DLI or adoptive immunotherapy following 
transplantation. Moreover, the success rate of HA-1H specific HLA-A2 restricted 
CTL induction is donor dependent118. 
 This thesis describes several attempts and possibilities to extend the pa-
tient population that can benefit from HA-1 specific immunotherapy. First, the 
development of a feasible immunotherapy directed towards the HA-1R coun-
terpart would significantly broaden this patient population. However, HLA-A2/
HA-1R expression on the cell surface could not be found by peptide elution29. 
We investigated several possible causes for the absence of cell surface HLA-A2/
HA-1R expression in order to evaluate the option of HA-1R directed immuno-
therapy (chapter 2). 
 Another possibility to extend the patient population that can ben-
efit from HA-1 directed immunotherapy is to investigate whether the HA-1H/R 
polymorphic region contains peptides that can be presented by MHC class I 
molecules other than HLA-A2. The generation of CTLs specific for HA-1 in the 
context of various MHC class I molecules would extend this population to 
patients not expressing HLA-A2. In order to find novel HA-1 epitopes in MHC 
class I both from the HA-1H and HA-1R allele, competition-based cellular pep-
tide binding assays were performed (chapters 3 and 4). All possible nonameric- 
and several decameric HA-1 peptides containing the H to R polymorphism were 
synthesized and tested for binding to MHC class I molecules. 
 Because of the reduced severity and reduced incidence of GvHD fol-
lowing umbilical cord blood (UCB) transplantation, UBC SCT is becoming a 
popular alternative treatment in case of hematological malignancies when no 
HLA identical SCT donor is available134-136. Relapse rates following UCB SCT do 
not seem to be higher than relapse rates following adult SCT135. However, since 
donor cells cannot be obtained following anonymous UCB transplantation, no 
specific immunotherapy is yet available for patients who relapsed following an 
UCB SCT. Chapter 5 investigates the feasibility of generation of HA-1 specific 
CTLs from UCB.  
 In general, CTL induction for adoptive immunotherapy is time-con-
suming, requires well trained personnel and specialized centers. In order to 
increase the success rate of HA-1 specific immunotherapy, HA-1 specific TCR 
transfer is proposed as an alternative method to generate HA-1H specific HLA-
A2 restricted CTLs. Chapter 6 describes attempts to transfer HA-1H specificity by 
transduction of HA-1H specific TCRs to T lymphocytes both from adult donors 
and from cord blood.
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Abstract
The polymorphic minor histocompatibility antigen (mHag) HA-1 locus encodes 
two nonameric peptides that differ only in one amino acid (aa) i.e. Histidine 
(H) versus Arginine (R) from each other at aa position 139 of the HA-1 locus. 
The HA-1H peptide is presented on the cell surface in HLA-A2 molecules and 
induces strong cytotoxic T cell (CTL) responses from HA-1R individuals. Though 
the HA-1R peptide binds to the HLA-A2 molecules, it cannot be detected on the 
cell surface. We searched for the mechanisms that could explain the loss of cell 
surface expression of the HA-1R peptide. Intracellular antigen processing by 
proteasomes and translocation of both HA-1 peptides into the Endoplasmatic 
Reticulum (ER) were identical. Namely, equal amounts of HA-1H and HA-1R 
nonameric peptides were generated by in vitro digestion of 28 aa long HA-1H and 
HA-1R peptides with 20S immuno- or constitutive-proteasomes. Both HA-1H 
and HA-1R peptides were translocated equally well into ER by TAP molecules. A 
discrepancy was observed in peptide binding, where the HA-1R peptide showed 
a 10 fold lower binding affinity to TAP-associated HLA-A2 molecules. The most 
striking difference between the two peptides was found in their dissociation rates, 
where HA-1R dissociated from HLA-A2 more than 10 fold faster than HA-1H. 
Our results indicate that the lack of cell surface expression of HA-1R is not due 
to interference with antigen processing and presentation by MHC class I but to 
the extreme instability of cell surface HLA-A2/HA1R peptide complexes.
Introduction
Disparities in minor histocompatibility antigens (mHag) between Stem Cell (SC) 
donor and recipient give rise to Graft versus Host Disease (GvHD) and Graft 
versus Leukemia (GvL) activities after HLA identical SC transplantation (SCT)1. 
mHags are polymorphic peptides presented on the cell surface by MHC class 
I or II molecules capable of inducing strong cellular immune responses from 
mHag negative individuals. The polymorphic mH peptides are derived from 
allelic cellular proteins encoded by autosomal genes or by the genes located 
on the Y chromosome2. The immunogenicity of mHags is determined by their 
MHC binding capacity and by the capability of the intracellular antigen pro-
cessing machinery to digest these polypeptides into proper sizes that can be 
translocated into the endoplasmic reticulum (ER) where they can bind to MHC 
molecules.
 The mHag HA-1 is an hematopoietic system-specific antigen that has 
been identified as a nonameric peptide eluted from HLA-A2 molecules3 which 
induces HLA-A2 restricted cytotoxic T cell (CTL) responses4. The HA-1 pep-
tide is derived from an intracellular protein encoded by a di-allelic gene on 
chromosome 193. The difference between the HA-1 CTL epitope and its allelic 
counterpart comprises a single Histidine (H) to Arginine (R) substitution at aa 
position 3 of the nonameric peptide. Peptide elution studies from HA-1H and 
HA1R homozygous cell lines have revealed that the HA-1H peptide is expressed 
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at approximately 80 copies per cell. In contrast, HA-1R peptide could not be 
detected on the cell surface3. The HA-1R peptide displays 10 fold less binding as 
compared to the HA-1H peptide3,5. However, this relative binding difference may 
not fully account for the absence of cell surface expression of HA-1R. We there-
fore investigated the impact of the HA-1H/R polymorphism on molecular and 
cellular mechanisms important for the intracellular generation and cell surface 
expression of MHC class I bound peptides. To this end we analyzed a) the in 
vitro digestion of 28-32 aa long HA1H/R peptides by 20S immuno-and house-
hold-proteasomes, b) the in vitro TAP translocation of 9-13 aa long HA-1H/R 
peptides, c) the HA-1H/R peptide binding affinity to TAP-associated MHC class I 
molecules and d) the dissociation rates of HLA-A2/HA-1H and HLA-A2/HA-1R 
complexes.
Materials and Methods
Cell lines and clones
The HLA-A2 restricted HA-1-specific CD8+ CTL clones 3HA15 and 5W38 were 
both isolated from patients suffering from GvHD after HLA-identical SCT4,6. 
The HA-1H specific CTLs were maintained and used in cytotoxicity and epitope 
reconstitution assays as described previously7. 
Synthetic peptides
Peptides were synthesized on an AMS 1400 multiple peptide synthesizer (Gilson 
Medical Electronics) using solid-phase FMOC chemistry and Wang resins. Pep-
tides were HPLC purified to > 98 % on a C-8 column. Purity and identity of all 
synthetic peptides were confirmed using ESI with an LCQ MS.
Fluorescent HA-1H and HA-1R peptides
Fluorescent analogs of HA-1H and HA-1R peptides were synthesized by replac-
ing the aa L at position 7 or E at position 8 with a fluorescein (Fl)-labeled Cys-
derivative. These replacements did not affect binding of the HA-1H/R peptides 
to HLA-A2 in competition based binding assays (data not shown). Fluorescent 
labeling was performed with 4-(iodoacetamido) fluorescein (Fluka Chemie AG, 
Buchs, Switzerland) at pH 7.5 (Na-phosphate in water/acetonitrile 1:1). The fluo-
rescent peptides were desalted over Sephadex G-10, purified by C18 RP-HPLC 
and analyzed by MALDI-MS (Lasermat, Finnigan, UK).
Prediction of proteasomal digestion
Proteasomal cleavage prediction of the HA-1H and HA-1R alleles was performed 
using the NetChop  (http://www.cbs.dtu.dk/services/NetChop/)8 and PAProc 
(http://www.paproc.de/) programs. NetChop analyses  were performed with 
the C-term 2.0 network and a threshold of 0.5. PAProc analyses were run with 
the human type III algorithm. 
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Proteasomal digestion assays 
20S proteasomes from HeLa, and EBV-LCL ROF were prepared and purified 
(purity > 95%) as described before9. To determine the proteasome-mediated 
cleavage, 10 µg of 28 or 32 aa long, > 98% pure HA-1H and HA-1R synthetic 
peptides were incubated with 1 µg of purified 20S proteasomes in 100 µl assay 
buffer (20 mM HEPES/KOH (pH 7.8), 2 mM MgAc2, 5 mM DTT) at 37°C for 
different time periods ranging from 0.25 to 24 hours. The proteolysis products 
were analyzed by electrospray ionization mass spectrometry on a hybrid qua-
druple time-of-flight mass spectrometer, (Q-TOF; Micromass, Manchester, UK), 
equipped with an on-line nano-electrospray interface as described elsewhere10. 
Streptolysin-O-mediated peptide transport assay 
In vitro assays of TAP-mediated peptide transport were performed as previ-
ously described11. In short, serial dilutions of peptides of interest were tested 
for their ability to compete for TAP-dependent translocation of a 125I-iodinated 
model peptide in streptolysin-O- permeabilized EBV-LCLs, and the results are 
expressed as the IC50 values (the concentration of the test peptide that inhibits 
the translocation of the radiolabeled peptide with 50%). 
 
Peptide binding to TAP-associated MHC class I molecules
Peptide loading on MHC class I from the class I-loading complex was per-
formed essentially as described12. Briefly, TAP and associating proteins were 
isolated from cell lysates of  5.107 35S-methionine/cystein labeled HLA-A2+ 
JY EBV-LCLs, using protein G-beads coated with rabbit anti-human TAP1 and 
TAP2 sera. Ten percent of the beads was loaded on 12.5% SDS-PAGE without 
further treatment. The remainder was split into equal portions and incubated 
with serial concentrations of VLHDDLLEA or VLRDDLLEA peptides that were 
dissolved in 10 µl DMSO. TAP molecules were also incubated with DMSO alone 
to serve as negative control. The TAP precipitates were thus incubated for 16 h 
at 4°C in digitonin lysis mixture. Subsequently these precipitates were incubated 
in NP40 lysis mixture for 2 h at 37°C. The intact MHC class I/peptide com-
plexes were then immunoprecipitated from the supernatant with monoclonal 
antibody (moab) W6/32 and analyzed by 12.5% SDS-PAGE.
Class I MHC-peptide dissociation assay
The dissociation rates of the recombinant-HLA-A2 molecules complexed 
with fluorescent peptides VLHDDLC*EA, VLRDDLC*EA, VLHDDLLC*A 
and VLRDDLLC*A were determined using HPLC. The fluorescent peptide 
FLPSDC*FPSV, known to display high affinity for HLA-A2 was tested as a posi-
tive control. Fluorescent peptides (1nM) were added to a freshly made mixture 
of recombinant HLA-A2 (20 nM), eta2Microglobuline (2M) (150 nM; Sigma, 
Zwijndrecht, The Netherlands), and protease inhibitors (Complete; Roche, Al-
mere, The Netherlands) in binding buffer (75 mM NaCl, 100 mM Phosphate pH 7, 
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 1 mM CHAPS). The HLA- peptide mixture was kept in the dark and shaken 
gently for 48 hours at room temperature. To determine the level of binding at 
t=0, 75 µl of each mix was injected on HPLC (Column GCP100 Synchopack 250 
x 4.0 mm ID) furnished with fluorescence detector. Immediately thereafter, the 
HLA binding of fluorescent peptides was inhibited by adding 10,000 fold non-
fluorescent peptides. The level of fluorescent peptides bound to HLA was then 
determined at t= 0.5, 1, 2, 4, 6, 8 and 24 h. The dissociation rates were distracted 
from the percentages heavy chain/FL-peptide complexes still intact at the dif-
ferent time points.
Results
Proteasome-mediated generation of the HA-1H CTL epitope
The major pathway for the generation of antigenic peptides in the cytosol is 
degradation by proteasomes13. The proteasome dependent generation of the 
HA-1 peptide, was analyzed with the proteasome–specific inhibitor lactacystin. 
Figure 1 shows that lactacystin had no effect on the CTL lysis of target cells 
pulsed with the synthetic HA-1 peptide. However, lactacystin inhibited CTL 
recognition of the natural HA-1H ligand in a dose dependent manner. These 
results indicate that the generation of the HA-1H CTL epitope is dependent on 
intracellular proteasomal activity. 
 To subsequently test the generation of the HA-1H CTL epitope by pro-
teasomes, a 29 aa-long HA-1H peptide was incubated with 20S proteasomes 
derived from EBV-LCLs for 1 and 3 h (figure 2). Degradation products generated 
by proteasomal activity were fractionated by HPLC. Each HPLC fraction was 
tested for the capacity to reconstitute recognition of HLA-A2+, HA-1H negative 
target cells by HA-1H specific CTLs. In both 1h. and 3h. proteasomally digested 
samples, a single fraction (#35) reconstituted the HA-1H specific CTL activity. 
Fraction 35 from the sample digested for 3h triggered significantly enhanced 
CTL responses, indicating the active generation of HA-1H nonameric peptides in 
time. The presence of the nonameric HA-1H peptide in fraction #35 was con-
firmed by mass spectometric analysis (data not shown). 
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Figure 1.
Inhibition of HA-1 specific lysis by proteasome inhibitor lactacystine. 
HA-1H and HA-1RR EBV-LCL were treated overnight with the indicated concentrations 
of lactacystine prior to use as target cells for the HA-1H specific CTL clone 3HA15. The 
lactacystine treated HA-1RR EBV-LCL were pulsed with 1 µg/ml of the HA-1H peptide for 
1 h during the 51Cr labeling. Results shown are at an effector to target (E:T) ratio of 10:1. 
Similar inhibition levels were observed at E:T ratios of 5:1.
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Figure 2. 
Reconstitution of the minor H antigen HA-1 with HPLC-fractionated peptides. 
Peptide fractions were generated by proteasomal digestion of a 29 aa long HA-1H peptide 
for 1 h and for 3 h. Aliquots of each fraction were pre-incubated with 51Cr-labeled HLA-A2+, 
HA-1RR cells and tested for their ability to reconstitute epitope activity of the HA-1H specific 
CTL clone 5W38 at an E:T ratio of 10:1. 
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Generation of HA-1H and HA-1R nonameric peptides by proteasome-mediated digestion
The allelic counterpart of mHag HA-3 appears to be destroyed by proteasomes14. 
To assess whether the HA-1H/R polymorphism may affect the proteasomal 
cleavage of the HA-1 peptides, we first subjected the aa sequences of HA-1H 
and HA-1R to a computational analysis with the proteasomal cleavage predic-
tion programs NetChop and PAProc. Whereas the PaProc program predicted 
the destruction of the HA-1R putative epitope (table I), the NetChop program 
predicted no differences between HA-1H and HA-1R peptides (data not shown). 
Subsequently, we subjected 28 aa-long HA-1H and HA-1R peptides to in vitro 
digestion by 20S immunoproteasomes purified from EBV-LCL ROF and by con-
stitutive proteasomes from HeLa cells. The degradation products were analyzed 
by mass spectrometry (tables IIa and IIb). Digestion of HA-1H and HA-1R pep-
tides with immuno- or constitutive proteasomes revealed some cleavage sites 
within the epitope for both HA-1H and HA-1R peptides. The cleavage site at the 
N terminus of the H/R polymorphic aa was more predominant in the HA-1R 
peptide as predicted by the PAProc program. However, this cleavage site did not 
destroy the HA-1R peptide because the digested products of both 28-meric HA-1H 
and HA-1R peptides contained significant and similar amounts of material cor-
responding exactly with the mass of the nonameric HA-1H and HA-1R peptides. 
Subsequent MS/MS sequencing analysis confirmed the presence of the nona-
meric sequences HA-1H (VLHDDLLEA) and HA-1R (VLRDDLLEA) in the relevant 
fractions, demonstrating that the HA-1H/R polymorphism did not affect the pro-
teasome mediated generation of the right sizes of the HA-1H/R peptides. 
Table I. 
Predicted cleavage sites in the HA-1H/R polymorphic region by PaProc human proteasome 
type II algorithm
HA-1H ADVARFA,EGLEK,L,KEC,VLHDDLLEA,RRPRAHEC,LGEALRV
HA-1R ADVARFA,EGLEK,L,KEC,VL,RDDLLEA,RRPRAHEC,LGEALRV
The predicted cleavage sites in 40 aa long stretches of HA-1H and HA-1R polypeptides 
are indicated.  Algorithms based on human proteasome type I or type III, and NetChop 
software revealed no differences between HA-1H and HA-1R peptides.
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Table IIa.
In vitro digestion of a 28 aa long HA-1H peptide by 20s proteasomes
  Substrate:        % fragment generated              
  28 aa HA-1H polypeptide   by 20s Proteasomes
      derived from
  GLEKLKECVLHDDLLEARRPRAHECLGE  
      HeLa  EBV
  Fragments
  GLEKLKECVLHDDLLEARRPRAHECLGE   1.68  2.11
  GLEKLKECVLHDDLLEARRPRAHECLG  2.63  2.39
  GLEKLKECVLHD    0.83  1.26
  GLEKLKECVL    0  1.65
     LEKLKECVLHDDL   1.25  1.05
     LEKLKECVLHDDLLEARRPRAHECLG 0  1.61
       EKLKECVLHDDLLEARRPRAHECLGE 3.80  4.93
         KLKECVLHDDLLEARRPRAHECLGE 78.12      78.24
             KECVLHDDLLEARRPRAHECL  1.86  1.19
                  CVLHDDLLEARR   0.98  0.13
                    VLHDDLLEARRPRAHE  1.23  0.43
                    VLHDDLLEARRPRAH  1.01  0.52
          VLHDDLLEARRPRA  0.47  0.56
.                   VLHDDLLEA              3.24  1.02
                             DLLEARRPRAHE  1.27  1.36
                             DLLEARRPRA  1.20  0.58
The aa sequences corresponding to the HLA-A2 restricted HA-1H CTL epitope and its HA-
1R allelic counterpart are indicated in bold. The rows shaded in gray indicate the protea-
somal digestion products that correspond with the nonameric HA-1H CTL epitope and its 
allelic counterpart. Proteasomal digestions was carried out for 3 h at 37°C. The amounts 
of the generated fragments are indicated as the percentage of all fragments found in 
the digested substrate. The indicated peptides were identified by their molecular masses 
calculated from the m/z peaks of the single or multiple charged ions and were confirmed 
by mass spectrometric sequencing analyses. Similar results were obtained using 32meric 
HA-1H/R peptides FAEGLEKLKECVL H/R DDLLEARRPRAHECLGEA as substrates. 
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Table IIb.
In vitro digestion of a 28 aa long HA-1R peptide by 20s proteasomes    
  Substrate:    % fragment generated              
  28 aa HA-1R polypeptide           by 20s Proteasomes
            derived from
  GLEKLKECVLRDDLLEARRPRAHECLGE  
      HeLa  EBV
  Fragments 
  GLEKLKECVLRDDLLEARRPRAHECLG 3.36  3.28
  GLEKLKECVL    1.11  1.73
  GLEKLKECVLRD    2.00  1.65
       EKLKECVLRDDLLEARRPRAHECLGE 60.34      67.90
         KLKECVLRDDLLE   1.55  1.81 
           LKECVLRDDLLEARRPRAHECLGE 0.98  2.15
             KECVLRDDLLEARRPRAHECLGE 4.03  5.69
                 CVLRDDLLEARR   1.86  1.94
                    VLRDDLLEARRPRAHE  0.56  0.30 
                    VLRDDLLEARRPRAH  1.10  0.72
                    VLRDDLLEARRPRA  0.45  0.89
                    VLRDDLLEA   2.58  1.05 
                        RDDLLEARRPRAHE  0.82  0.53 
                        RDDLLEARRPRAH  0.48  0.34          
                        RDDLLEARRPRA  0.43  0.54
                          DLLEARRPRAHE  1.53  0.28
                          DLLEARRPRAH  0.48  0.34
                          DLLEARRPRA  1.71  0.71
                          DLLEARRPR   0.25  0.22
                               LEARRPRAHE  0.52  0
                               LEARRPRAH  0.54  0
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Efficient TAP-translocation of  both  HA-1H and HA-1R peptides
It has been shown that defective translocation of antigenic peptides into the 
ER by TAP molecules can be also a mechanism why the mHag peptides are 
not available for cell surface expression15. We therefore compared the TAP-
dependent transport of various synthetic length-variants of HA-1H and HA-1R 
peptides. Both nonameric HA-1H and HA-1R peptides were transported equally 
well by the TAP transporter (table III). Although a 12-meric HA-1H peptide was 
transported significantly better than the corresponding HA-1R peptide, this dif-
ference may not be relevant because these 12-meric HA-1H/R peptides were not 
generated by proteasomes (table II). These results indicate that TAP translocation 
could not explain the differential expression of the HA-1H and HA-1R peptides 
on the cell surface.
Table III.
In vitro TAP translocation of HA-1H and HA-1R peptides
 Sequence  No. of aa  IC50 (µM)
 
 KECVLHDDLLEARRP  15  >100
 KECVLRDDLLEARRP  15  >100
 KECVLHDDLLEA  12   8
 KECVLRDDLLEA  12  53
   ECVLHDDLLEA  11  >100
   ECVLRDDLLEA  11  45
     CVLHDDLLEA  10  92
     CVLRDDLLEA  10  87
       VLHDDLLEA     9  17
       VLRDDLLEA     9  10
Different lengths of HA-1H and HA-1R peptides were tested for their ability to compete for 
translocation of the radioiodinated model peptide TVNKTERAY in streptolysin O-permea-
bilized EBV-LCLs. The IC50 values represent the concentration of the test peptide that 
inhibits the transport of the model peptide with 50%. The HLA-A2 restricted nonameric 
HA-1H CTL epitope is indicated in bold.
HA-1H/R peptide binding to TAP-associated HLA-A2 molecules
In vitro competition based peptide-binding assays have shown that the HA-1R 
peptide can compete with reference peptides for binding to HLA-A2 molecules3,5. 
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However, peptide binding to recombinant HLA molecules or to HLA molecules 
already present on the cell surface may not be representative for intracellular 
peptide binding to TAP-associated HLA molecules in the ER, which is necessary 
for cell surface expression of the MHC-peptide complex. Therefore, we mea-
sured HA-1H and HA-1R peptide binding to TAP-associated HLA-A2 molecules 
in a cell free system. The HA-1R peptide, like the HA-1H peptide, bound to TAP-
associated HLA-A2 molecules, but only at 10 fold higher concentrations (fig-
ure 3). These results are similar to the MHC-peptide binding results described 
previously3,5.
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Figure 3. 
Binding of HA-1H and HA-1R peptides to TAP-associated HLA-A2.
JY EBV-LCL cells, positive for HLA-A2, were biosynthetically labeled with 250 µCi 35S-
methionine/cystein and then lysed. TAP and associating proteins were isolated using pro-
tein G-beads coated with rabbit anti-human TAP1 and TAP2 sera. Ten percent of the 
beads were loaded on 12.5% SDS-PAGE without further treatment (left column), while the 
remainder was split into equal portions and incubated over night at 4°C with 100, 10, 1, 
0.1 or 0 µM peptide VLHDDLLEA or VLRDDLLEA. Subsequently NP40 lysis mixture was 
added and the lysate was incubated for 2 hr at 37°C. MHC class I/peptide complexes 
were then isolated from the supernatant with moab W6/32 and analyzed by 12.5 SDS-
PAGE.
Dissociation rates of HLA-A2/HA-1H/R peptide complexes 
Competition based peptide-binding assays mainly reflect the rate of formation 
of the HLA-peptide complexes. However, it has been established that, MHC 
class I peptide binding affinity is mainly controlled by the rate of dissociation of 
the HLA-peptide complexes, rather than the rate of formation of the complex16. 
Thus, instability of the MHC-peptide complex could be a reason why the HA-1R 
peptides are not present in cell surface HLA-A2 molecules. We therefore tested 
whether the H/R substitution in the HA-1 peptides influences the stability of the 
HLA binding. The dissociation rates of the HLA-A2/HA-1H and HLA-A2/HA-1R 
complexes were compared in a cell free HLA-binding assay using recombinant 
HLA molecules and fluorescent analogs of the HA-1H and HA-1R peptides (figure 
4). As expected, the dissociation rates of HLA-A2/HA-1H complexes were slow. 
After 24h still 65% of the HLA-A2/VLHDDLC*EA and 40% of the HLA-A2/
VLHDDLLC*A peptide complexes were intact. In contrast, the HLA-A2/HA-1R 
complexes dissociated rapidly. No intact HLA-A2/HA-1R complexes were found 
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after 2 hours, indicating that the rapid dissociation rates contribute significantly 
to the absence of HLA-A2/HA-1R peptides from the cell surface.
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Figure 4. 
Dissociation rates of HA-1H and HA-1R peptides.  
Recombinant HLA-A2 molecules were incubated with the indicated fluorescent peptides 
for 48 hours. At t=0 fluorescent peptides were diluted out by the addition of 10,000 fold 
non fluorescent peptides. The amount of bound fluorescent peptide was determined at 
the indicated time points. The intact HLA-peptide complexes were expressed as percent-
age of the intact complexes  at t=0. The peptide FLPSDC*FPSV was used as a positive 
control.
Discussion
Generation of class I restricted mHags from polymorphic intracellular proteins 
is dependent on their proper handling by several intracellular processes includ-
ing ubiquitinilation, degradation by proteasomes into peptides and transloca-
tion of the peptides into the ER, as well as the capacity of the peptides to bind 
HLA molecules. Previous studies on viral CTL epitopes have revealed that even 
a single amino acid exchange in a viral protein can interfere with intracellu-
lar processing and can result in the absence of cell surface expression of the 
MHC/peptide complexes17-19. With the biochemical identification of a number of 
autosomally encoded human mHags it became also evident that single amino 
acid substitutions can have a significant impact on the cell surface expression of 
the allelic counterparts. To date, such a “functional null allelism” has been dem-
onstrated for four mHags: the HA-1, HA-2, HA-3 and HA-83,14,15,20. It appears 
that distinct mechanisms can account for the loss of cell surface expression of 
the allelic peptides. For instance, in case of HA-8 the allelic peptide is poorly 
translocated into the ER, whereas in case of HA-3 the allelic counterpart appears 
to be destroyed by proteasomes. The allelic counterpart of the BCL2A1 antigen 
might not be produced endogenously as a result of the fact that the COOH 
terminus is not properly formed by proteasomes21. In contrast, cell surface ex-
pression of the UGT2B17 antigen is lost as a consequence of homozygous gene 
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deletion in UGT2B17 negative individuals22. Furthermore, the novel HLA-A33 
restricted mHag TMSB4Y is not derived from a functional polypeptide, but 
is probably encoded outside a conventional open reading frame (ORF) of a 
nonmutated gene23. The results in this study reveal another mechanism and 
show that absence of HA-1R cell surface expression in the context of HLA-A2 
molecules is due to the low association and extremely rapid dissociation rates 
of HLA-A2/HA-1R complexes. Previously, we have shown that the HA-1R pep-
tide binds with ten fold lower affinity to recombinant HLA-A2 molecules as 
compared to the HA-1H peptide3. Although the peptide binding to recombinant 
HLA molecules may not be representative for intracellular peptide binding to 
TAP-associated HLA molecules in the ER, we show in this study that the HA-1R 
peptide also binds with ten fold lower affinity to intracellular TAP-associated 
HLA-A2. However, this ten fold affinity difference is unlikely to account for the 
complete absence of HLA-A2/HA-1R complexes on the cell surface as the HA-1H 
peptide is expressed at 80 copies per cell3.  Moreover, it was previously shown 
for a set of naturally processed peptides that the MHC binding affinities were 
not directly related to their cell surface density (reviewed in24). Furthermore low 
affinity peptides can represent important T cell epitopes25,26. However, a com-
mon feature of these CTL epitopes with low MHC binding affinity is that they 
slowly dissociate from MHC, which of course has a major impact on the cell 
surface expression of the MHC/peptide complexes. 
 Our results revealed that while the HA-1H peptide dissociates slowly 
from the HLA-A2 molecules, the dissociation rate of HLA-A2/HA-1R peptide 
complexes was high. No detectable HLA-A2/HA1R complexes were left within 
two hours. This extremely rapid dissociation rate may be explained by a dif-
ferent configuration of the HA-1R peptide compared with the HA-1H peptide 
resulting in a less stable HLA-A2/HA1R complex27, and can result in the loss of 
HLA-A2/HA-1R cell surface expression.
 Furthermore, our results rule out other important possibilities. First, we 
could not demonstrate any significant differential effect of the HA-1H/R poly-
morphism on proteasome-mediated digestion. Although the PAProc software 
predicted a major cleavage site in the HA-1R peptide by human type II pro-
teasomes, this cleavage site appeared not to destroy the generation of relevant 
peptides. Both immuno-and constitutive-proteasomes generated the HLA-A2 
binding nonameric peptides of HA-1H and HA-1R in significant and equal 
amounts. We detected a second cleavage site within the HA-1H/R polymorphic 
region. This cleavage site between two D residues, which was also predicted by 
the NetChop program (data not shown) is present in both HA-1H and HA-1R 
peptides but did not prevent the generation of the HA-1H CTL epitope and of its 
allelic counterpart. Thus, our results are in line with previous findings that once 
the relevant peptides are generated by proteasomal cleavage, other cleavage sites 
found within the epitope weigh less heavily for the cell surface expression of the 
peptides10. 
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Our results also demonstrated that the TAP translocation of HA-1 peptides 
is not affected by the HA-1H/R polymorphism. As TAP can transport different 
lengths of peptides up to 15-mers28, we tested the TAP translocation of 9-15-
meric HA-1H/R peptides. The nonameric HA-1H/R peptides, as well as several 
longer variants of the HA-1H/R, were equally transported by TAP. Only the 
12-meric HA-1R peptide (KECVLRDDLLEA) was transported less efficiently as 
compared to the corresponding HA-1H peptide. However, this difference may be 
irrelevant since these 12-meric peptides were not generated by in vitro protea-
some-mediated-digestion of 28 or 32-meric HA-1H and HA-1R peptides. Taken 
together, our data indicate that the loss of surface expression of HA-1R peptide 
is not caused by differential antigen processing or TAP translocation, neither 
is it caused by gene deletion or an ORF shift. As the exact lengths of HLA-A2 
binding nonameric peptides were generated by proteasomes, we did not study 
the possibility whether the HA-1H/R polymorphism  may have an impact on N 
terminal trimming by aminopeptidases in the ER29-32. 
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Abstract
We report the development, validation and application of competition based 
peptide binding assays for 13 prevalent HLA class I alleles. The assays are based 
on peptide binding to HLA molecules on living cells carrying the particular al-
lele. Competition for binding between the test peptide of interest and a fluores-
cein-labeled known HLA class I binding peptide is used as read out. The use of 
cell membrane bound HLA class I molecules circumvents the need for laborious 
biochemical purification of these molecules in soluble form. Previously, we have 
applied this principle for HLA-A2 and HLA-A3. We now describe the assays 
for HLA-A1, HLA-A11, HLA-A24, HLA-A68, HLA-B7, HLA-B8, HLA-B14, HLA-
B35, HLA-B60, HLA-B61 and HLA-B62. Together with HLA-A2 and HLA-A3, 
these alleles cover over 95% of the Caucasian population. Several allele-specific 
parameters were determined for each assay. Using these assays we identified 
novel HLA class I high affinity binding peptides from HIVpol, p53, PRAME and 
minor histocompatibility antigen (mHag) HA-1. Thus, these convenient and ac-
curate peptide binding assays will be useful for the identification of putative CTL 
epitopes presented on a diverse array of HLA class I molecules. 
Introduction
The identification of HLA restricted cytotoxic T lymphocyte (CTL) epitopes is 
crucial for our understanding of immunity in bacterial or viral infections, auto-
immune diseases and cancer as well as for the development of defined vaccines 
that induce CTL and the monitoring of such immunotherapies. The peptide-
binding based prediction of CTL epitopes in protein sequences has led to the 
identification of CTL epitopes in viral proteins1,2 bacterial proteins3 and tumor 
antigens4. Often these CTL epitopes are presented in HLA-A2, being the class 
I allele that predominates in the Caucasian population. However, an ongoing 
search for new CTL epitopes restricted by other prevalent HLA class I  molecules 
is necessary for the development of immunotherapies covering all class I hap-
lotypes and multi-epitope vaccines (table I).
 The peptide binding groove of HLA molecules contains highly poly-
morphic allele-specific pockets that accommodate side chains of the so-called 
anchor residues of the bound peptide5,6. The peptide binding groove of HLA 
class I molecules is closed at both sides6 and thus HLA class I accommodates 
peptides with a length of 8 - 11 amino acids (aa). Allele-specific peptide binding 
motifs were defined by the analysis of naturally presented peptide pools eluted 
from class I molecules7,8.  Each HLA class I molecule displays a preference for 
certain aa at the major (primary) peptide anchor positions (relative position 2 
and the C-terminus for most HLA class I molecules) that bind in the binding 
pockets. Amino acids at other positions in the peptide can significantly con-
tribute to binding by their engagement in secondary pockets9-16. The knowledge 
of allele specific peptide binding motifs has led to the development of peptide 
binding prediction algorithms by several groups17-19. Although these algorithms 
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are extremely helpful to select potential HLA class I binding peptides, experi-
mental determination of the HLA class I binding capacity is still considered 
necessary due to the partly undefined contributions to binding of each possible 
aa in every position of the peptide. 
Table I.
Phenotype frequency distribution of HLA class I antigens for which assays were devel-
oped expressed as percentages among major populationsa 
    
 HLA                    Population     
 class I Black Caucasoid Oriental Amerindian
         
 A1 9 26 7 11
 A2 29 44 47 43
 A3 13 22 6 8
 A11 3 13 30 4
 A24 6 20 42 52
 A68 18 8 3 12
 B7 15 17 7 5
 B8 9 14 3 2
 B14 7 6 1 3
 B35 11 20 10 32
 B60 1 6 17 5
 B61 0 6 9 23
 B62 2 8 16 21
aPhenotype frequencies for the HLA antigens have been deduced using the gene frequen-
cies as given by Marsh et al38.
 Peptide-HLA class I binding assays employ either cell-bound class 
I molecules20-28 or solubilized class I molecules29-34. Assays using cell-bound 
HLA class I molecules are either based on upregulation of class I molecules 
in processing defective cell lines22,23,26 or on reconstitution of HLA class I mol-
ecules24,25,27,28. Cell-free assays are quantitative and are based on competition for 
binding between a labeled reference peptide and a test peptide32. We previously 
applied the competition principle in easy to perform cell-bound HLA class I 
binding assays for HLA-A2 and HLA-A327. In these assays, EBV transformed 
B cell lines (B-LCL) expressing the class I allele of interest are used from which 
naturally bound class I peptides are eluted to obtain free class I molecules. 
Subsequently, B-LCL are incubated with a mixture of a fluorescein (Fl)-labeled 
reference peptide, known to bind efficiently to the allele of interest, and titrated 
amounts of a competing test peptide. Cell-bound fluorescein is determined by 
flowcytometry and the inhibition of binding of the Fl-reference peptide is calcu-
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lated as readout. We now report the adoption of this principle for an additional 
set of highly prevalent HLA class I alleles (HLA-A1, -A11, -A24, -A68, -B7, -B14, 
-B8, -B35, -B60, -B61, -B62). Together with HLA-A2 and HLA-A3, these alleles 
cover over 95% of the Caucasian populations. For each assay, the allele-specific 
parameters were established: a) a suitable reference peptide with known bind-
ing capacity for the allele, b) the optimal position of the Fl-label in the reference 
peptide, c) the required concentration of the labeled peptide, d) the pH of the 
elution buffer used for acid stripping of class I molecules, e) a B-LCL expressing 
the HLA class I molecule of interest and f) exclusion of binding of Fl-reference 
peptide to co-expressed class I molecules on the used B-LCL. The assays were 
used to identify several HLA class I binding peptides derived from HIV-1pol, 
p53, PRAME and mHag HA-1. Finally, we analyzed the predictive power of a 
commonly used peptide binding prediction algorithm for a set of HLA-A2 bind-
ing peptides to assess the need to actually assay the peptide binding affinity after 
prediction of binding.
Materials and Methods
Cell lines
The Epstein-Barr virus transformed B-lymphoblastoid cell lines (B-LCL) used 
for the binding assays were either obtained from the international histocompat-
ibility workshop cell line repository or newly generated from PBMC of healthy 
blood donors. All B-LCL were cultured in complete culture medium consist-
ing of IMDM (Biowithaker, Verviers, Belgium) supplemented with 8% fetal calf 
serum (FCS) (Gibco BRL, Breda, The Netherlands), 100 IU/ml penicillin and 2 
mM L-glutamine.
Peptides
Peptides were synthesized by solid-phase strategies on an automated multiple 
peptide synthesizer (Syro II, MultiSyntech, Witten, Germany) using Fmoc-chem-
istry. Peptides were analyzed by reversed-phase HPLC and mass spectrometry, 
dissolved in 50 µl dimethyl sulfoxide, diluted in 0.9% NaCl to a peptide con-
centration of 1 mM and stored at –20°C until usage. Fluorescein-labeled ref-
erence peptides were synthesized as Cys-derivative. Labeling was performed 
with 5-(iodoacetamido)fluorescein (Fluka Chemie AG, Buchs, Switzerland) at pH 
7.5 (Na-phosphate in water/acetonitrile 1:1 vol/vol). The labeled peptides were 
desalted over Sephadex G-10 and further purified by C18 RP-HPLC. Labeled 
peptides were analyzed by mass spectrometry. 
Selection of test peptides for binding assays
Peptides derived from HIV-1pol, p53, PRAME and mHag HA-1 that contain 
HLA class I peptide binding motifs were selected using either the BIMAS peptide 
binding algorithm available via the internet (http://bimas.cit.nih.gov/molbio/
hla_bind/)18 or an algorithm that was developed in our department17.
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Mild acid elution of HLA class I bound peptides on B-LCL
Mild acid treatment of B-LCL to remove naturally HLA class I bound peptides 
was performed with minor modifications according to the principle first de-
scribed by Sugawara et al.35 and elaborated by our group27. B-LCL were har-
vested and washed in phosphate buffered saline (PBS) and the pellet (2 – 15x106 
cells) was put on ice for 5 min. The elution was performed by incubating the 
cells for exactly 90 s in ice-cold citric-acid buffer (1:1 mixture of 0.263 M citric 
acid and 0.123 M Na2HPO4, adjusted to the pH listed in table II). Immediately 
thereafter, cells were buffered with ice-cold IMDM containing 2% FCS, washed 
once more in the same medium and resuspended at a concentration of 4x105 
cells/ml in IMDM medium containing 2% FCS and 2 µg/ml human 2-micro-
glublin (2M) (Sigma, St. Louis, MO, USA).
Table II. 
Allele specific characteristics of HLA class I binding assays.
                 
 HLA class I Reference peptides used in the assays  Assay Cell line                               pHe 
 allelea  FL-labeled seq.b  [FL-pep.] Original seq. Ref.c Name HLA class I type 
 A1 (A*0101) YLEPAC(Fl)AKY 150 nM YLEPAIAKY  32 CAA A*0101, B*0801, Cw*0701 3.1
 A2 (A*0201)d   FLPSDC(Fl)FPSV 150 nM FLPSDFFPSV  39 JY  A*0201, B*0702, Cw*0702 3.2
 A3 (A*0301)d  KVFPC(Fl)ALINK 150 nM KVFPYALINK 32 EKR A*0301, B*0702, Cw*0702 2.9
 A11 (A*1101) KVFPC(Fl)ALINK 150 nM KVFPYALINK  32 BVR  A*1101, B*3501, Cw*0401 3.1
 A24 (A*2402) RYLKC(Fl)QQLL 150 nM RYLKDQQLL 40 Vijf  A*2402; B*0702, Cw*0702 3.1
 A68 (A*6801) KTGGPIC(Fl)KR 150 nM KTGGPIYKR 41 A68HI  A*6801, B*4402, Cw*0704 3.1
 B7 (B*0702) APAPAPC(Fl)WPL 150 nM APAPAPSWPL N.P.  JY  A*0201, B*0702, Cw*0702 3.1
 B8 (B*0801) FLRGRAC(Fl)GL 50 nM FLRGRAYGL 42 Vavy  A*0101, B*0801, Cw*0701 3.1
 B14 (B*1402) DRYIHAC(Fl)LL  150 nM DRYIHAVLL  43 CHE  A*2402, A*3301, B*1402, Cw*0201 4.0
 B35 (B*3501) NPDIVC(Fl)YQY 150 nM NPDIVIYQY 44 BVR  A*1101, B*3501, Cw*0401 2.9
 B60 (B*4001) KESTC(Fl)HLVL 125 nM KESTLHLVL 36 DKB  A*2402, B*4001, Cw*0304  3.1
 B61 (B*4002) GEFGGC(Fl)GSV 50 nM GEFGGFGSV 36 Swei007 A*2902, B*4002, Cw*0202 3.1
 B62 (B*1501) YLGEFSC(Fl)TY 150 nM YLGEFSITY 36 BSM A*0201, B*1501, Cw*0304 2.9
                 
        
a HLA class I allele of binding assay. Mostly, B-LCL were used expressing the most com-
mon subtype of the allele (see HLA class I type).
b A non-anchor residue was substituted with a cysteine derivatized by a fluorescein group, 
denoted as C(Fl).
c Most reference peptides were derived from the SYFPHEITI database19; here the original 
reference is cited. For HLA-B7, APAPAPSWPL (human p53 84-93) was found as high af-
finity binder in a molecular binding assay (N.P. = not published).
d Characteristics of HLA-A2 and HLA-A3 binding assays have been published before27.
e Optimal pH of the elution buffer used for stripping naturally bound peptides.
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HLA class I competition binding assays
Eight serial twofold dilutions of each competitor test peptide in PBS/BSA 0.5% 
were made (highest concentration 600 µM, 6-fold assay concentration). In the 
assay, test peptides were tested from 100 µM to 0.8 µM. The Fl-labeled reference 
peptide was dissolved in PBS/BSA 0.5% at 6-fold final assay concentration (see 
table II). In a well of a 96-well V-bottom plate 25 µl of competitor peptide was 
mixed with 25 µl Fl-labeled reference peptide. Subsequently, the stripped B-LCL 
were added at 4x104/well in 100 µl/well. After incubation for 24 h at 4°C, cells 
were washed three times in PBS containing 1% BSA, fixed with 0.5% parafor-
maldehyde, and analyzed with FACScan flowcytometry (Becton Dickinson) to 
measure the mean fluorescence (MF). The percentage inhibition of Fl-labeled 
reference peptide binding was calculated using the following formula: 
(1-(MFreference + competitor peptide – MFbackground) / (MFreference peptide – MFbackground)) x 100%. 
The binding affinity of competitor peptide is expressed as the concentration 
that inhibits 50% binding of the Fl-labeled reference peptide (IC50). IC50 was 
calculated applying non-linear regression analysis (with software CurveExpert 
1.3, SPSS Science Software, Erkrath, Germany). An IC50  5 µM was considered 
high affinity binding, 5 µM < IC50  15 µM was considered intermediate affinity 
binding, 15 µM < IC50  100 µM was judged low affinity binding and IC50 > 
100 µM was regarded as no binding. These IC50 cutoff values are based on our 
experience with HLA-A2 and HLA-A3 binding ligands and CTL epitopes27.
Results
Selection of HLA class I alleles
The HLA-A2 and HLA-A3 alleles cover around 70% of the Caucasian popula-
tion27. To enlarge the haplotype coverage we chose to develop binding assays for 
11 additional alleles (HLA-A1, -A11, -A24, -A68, -B7, -B8, -B14, -B35, -B60, -B61 
and -B62) with high prevalence among most populations (table I). Together with 
HLA-A2 and HLA-A3, these alleles cover over 95% of the Caucasian population, 
as calculated from a group of 1000 HLA-typed Dutch blood donors.
Selection of optimal fluorescein labeled reference peptides
For each allele one or two peptides to be used as fluorescein (Fl)-labeled refer-
ence were derived from aa sequences shown to bind strongly to the particular 
allele. These peptides were originally identified as naturally presented class I 
ligand, CTL epitope, or consensus sequence, with the exception of the peptide 
for HLA-B7 (table II). For each peptide several labeled variants were made by 
substituting at various positions a non-anchor residue for a fluorescein con-
jugated cysteine. Fl-labeled reference peptides were titrated on B-LCL homozy-
gously expressing the class I molecule of interest to identify for each allele the 
one which best retained their high binding capacity as well as to determine an 
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optimal concentration of the Fl-labeled peptide to be used in the competition 
assay. As exemplified for HLA-B61 two peptides were selected, GEFGGFGSV 
(histone acetyltransferase 127-13536), of which the phenylalanine at position 6 
was substituted rendering GEFGGC(Fl)GSV and GEFVDLYV (ribosomal protein 
S21 6-1336), of which both GEFVC(Fl)LYV and GEFVDC(Fl)YV were tested (figure 
1A). Differences in binding capacity occurred depending on which original se-
quence was used and the particular residue that was substituted. The difference 
in binding capacity between the two variants of GEFVDLYV can be explained 
by altered contribution to overall binding affinity of the fluorescein conjugated 
cysteine as compared to the original residue depending on (position of) the 
residue that is substituted. The Fl-labeled reference peptide GEFGGC(Fl)GSV, 
displaying highest binding capacity, was chosen as the labeled reference peptide 
for the assay (figure 1A and table II). Optimal Fl-labeled reference peptides for 
the other alleles were likewise determined (table II). For each Fl-labeled peptide 
sub-optimal saturating concentrations were used in the assay to optimally en-
able competition by the test peptides (table II). The maximal binding of Fl-la-
beled reference peptides at the chosen concentration after 24 h incubation at 4°C 
resulted in a mean fluorescence (MF) of at least 5 times the background staining 
with PBS, as shown for HLA-B61 in figures 1A and 1B.
Selection of HLA class I expressing cell lines
B-LCL homozygously expressing the allele of interest were used for the assays 
(table II). Control B-LCL were tested to exclude binding of the Fl-labeled refer-
ence peptide to co-expressed class I molecules. As exemplified for the HLA-B61 
binding assay, the Fl-labeled reference peptide GEFGGC(Fl)GSV did efficiently 
bind to B-LCL Sweig007 (HLA-A29, -B61, -Cw2) whereas binding to control B-
LCL Mann and 4B5 expressing HLA-A29 and HLA-Cw2 respectively was absent 
(figure 1B). This indicates that binding of the Fl-reference peptide to HLA-A29 
and HLA-Cw2 can be excluded and binding on Sweig007 was exclusively ac-
complished via binding to HLA-B61. B-LCL functioning optimally in assays for 
binding to HLA-A1, -A11, -A24, -A68, -B7, -B8, -B14, -B35, -B60 and -B62 were 
likewise found as listed in table II. 
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Figure 1
Determination of the optimal Fl-labeled HLA-B61 binding reference peptide and exclusion 
of binding of the Fl-labeled peptide to alleles other than HLA-B61 that are expressed on 
B-LCL Swei007 (HLA I type: HLA-A29, -B61, -Cw2). 
(A) Binding affinities of 3 Fl-labeled HLA-B61- binding reference peptides. The peptides 
were titrated at the indicated concentrations on B-LCL Swei007. After incubation for 24 h 
at 4°C fluorescence was measured with flowcytometry. (B) Exclusion of binding of the 
Fl-labeled reference peptide GEFGGC(Fl)GSV for HLA-B61 to co-expressed alleles on 
Swei007. The Fl-reference peptide was incubated for 24 h at 4°C with B-LCLs Swei007, 
Man (expressing HLA-A29) and 4B5 (expressing HLA-Cw2) and fluorescence was mea-
sured with flowcytometry at a FACScan. Results of one representative experiment of at 
least three performed are shown.
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Determination of the optimal elution - pH for each allele
We previously observed differences in the pH required for optimal elution of 
naturally bound peptides from HLA-A2 and HLA-A327,28. Therefore, several pHs 
were tested for each new allele in order to find optimal conditions for removal 
of endogenous peptides, enabling efficient reconstitution of HLA class I – pep-
tide complexes. For 8 of the 11 alleles for which novel assays were developed 
elution at pH 3.1 produced the best results. However, for HLA-B14, -B35 and -
B62 a different pH was chosen. For instance, elution of naturally presented pep-
tides in HLA-B35 at pH 2.0 resulted in a considerable higher level of Fl-labeled 
reference peptide binding than application of pH 2.4 – 4.0 (figure 2). However, at 
pH lower than 2.8 cell viability decreased dramatically. We therefore chose pH 
2.9 as an optimal compromise between these two phenomena. The optimal pH 
for every allele is listed in table II.
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Figure 2.
Determination of optimal pH of the elution buffer for HLA-B35. 
The elution buffer was adjusted to the various pHs and elution of naturally presented pep-
tides from the surface of B-LCL BVR was performed at the indicated pHs as described 
in Materials and Methods. Subsequently, B-LCL BVR was incubated with the HLA-B35 
binding Fl-labeled reference peptide NPDIVC(Fl)YQY for 24 h at 4°C and was measured 
with flowcytometry at a FACScan. Results of one representative experiment of at least 
three performed are shown.
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Optimization and validation of the competition assays
A general improvement of the assay protocol was realized, compared to the 
published protocol27, by adding FCS during incubation. Addition of 2% FCS im-
proved binding of the Fl-labeled reference peptide (figure 3) and increased cell 
viability from 30% to 90% after 24 h (data not shown), which greatly enhanced 
cell recovery for FACS sample preparation. To validate each assay the nonla-
beled reference peptide and/or another positive control peptide, known from 
literature to be either a naturally presented ligand or CTL epitope, were tested in 
8 serial twofold dilutions (100 µM – 0.8 µM) for competition with the Fl-labeled 
peptide. The competition of binding of the HLA-B60 Fl-labeled reference pep-
tide by the non-labeled reference peptide KESTLHLVL is shown in figure 4 as 
an example. Unmodified reference peptides and other positive control peptides 
were able to inhibit at least 50% of binding of the Fl-labeled reference peptide 
at concentrations lower than 5 µM (IC50 < 5 µM) (table III). These results are in 
line with those obtained with high affinity binding positive control peptides in 
the published binding assays for HLA-A2 and HLA-A327.
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Figure 3.
Influence of incubation without or with addition of 2% FCS on binding of the Fl-labeled 
reference peptide. 
B-LCL JY expressing HLA-A2 was incubated with titrated amounts of the HLA-A2 – bind-
ing Fl-labeled reference peptide FLPSDC(Fl)FPSV for 24 h at 4°C without or with addition 
of 2% FCS in the medium. Subsequently, fluorescence was measured with flowcytometry 
at a FACScan. Results of one representative experiment of at least three performed are 
shown.
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Figure 4.
Competition of binding of the HLA-B60 Fl-labeled reference peptide KESTC(Fl)HLVL by 
the non-labeled original aa sequence KESTLHLVL to validate the HLA-B60 assay.
The unlabeled peptide was titrated in 8 serial twofold dilutions (100 µM – 0.8 µM) on B-
LCL DKB (HLA-B60+) together with the Fl-labeled peptide (125 nM) and was incubated for 
24 h at 4°C. Fluorescence was measured with flowcytometry at a FACScan and the data 
were analyzed by regression analysis using software program CurveExpert 1.3 to deter-
mine the precise IC50 value expressed at a logarithmic scale. Results of one representative 
experiment of at least three performed are shown.
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Table III. 
Positive control peptides used to validate binding assays
 HLA class I Positive control peptidesa     
 allele Sequence Source  Ref. IC50 (µM) 
 HLA-A1 YLEPAIAKY Consensus sequence  32 
 HLA-A2 FLPSDFFPSV  HBV cAg 18-27  39 0.5
 YIGEVLVSV mHag HA-2  45 3.5
 HLA-A3 KVFPCALINK  Consensus sequence  32 0.7
 QVPLRPMTYK HIV-1nef 73-82  46 0.2
 HLA-A11 QVPLRPMTYK HIV-1nef 73-82  46 2.0
 KQSSKALQR BCR-ABL b3a2  47 5.7
 HLA-A24 RYLKDQQLL HIV-1env gp41 583-591  40 1.8
 AYIDNYNKF   Consensus sequence  48 0.6
 HLA-A68 KTGGPIYKR Influenza A NP 91-99  41 1.3
 HLA-B7 APAPAPSWPL Human p53 84-93  N.P. 0.5
 SPSVDKARAEL Human SMCY 950-960 (mHag HY)  49 0.7
 HLA-B8 FLRGRAYGL EBNA-3 339-347  42 0.2
 GFKQSSKAL  BCR-ABL b3a2 fusion region  47 1.5
 HLA-B14 ERYLKDQQL HIV-1env gp41 584-592  50 7.5
 HLA-B35 NPDIVIYQY HIV-1 RT 330-338  44 1.2
 HLA-B60 KESTLHLVL Ubiquitin 63-71  36 1.9
 HLA-B61 GEFGGFGSV Histone acetyltransferase 127-135  36 0.2
 GEFVDLYV  40S ribosomal protein S21 6-13  36 0.3
 HLA-B62 YLGEFSITY 40S ribosomal protein S15 114-122  36 0.6
         
a The unlabeled reference peptides were used as positive control peptide for all alleles 
except for HLA-A11 and -B14. For several alleles additional positive control peptides were 
tested. (N.P. = not published)
Identification of novel HLA class I binding peptides
The binding assays described herein were used for the identification of novel 
HLA class I binding peptides derived from various protein sequences (HIV-1pol; 
p53; PRAME; mHag HA-1). For several alleles, candidate class I binding peptides 
were selected complying with the different HLA class I binding motifs of inter-
est and their binding capacity was assessed. For these alleles we successfully 
identified peptides binding with high or intermediate affinity (table IV). Four 
peptides of HIV-1pol were found to bind with high affinity in HLA-A11 (IC50 
≤ 5 µM), whereas one peptide displayed intermediate affinity (5 µM < IC50 ≤ 
15 µM). In HLA-A24, 3 peptides from HIV-1pol bound with high affinity, one 
peptide with intermediate affinity and 2 with low affinity (15 µM < IC50 ≤ 100 
µM). Six peptides of p53 displayed high affinity binding to HLA-B7. Seven out 
of eight peptides derived from PRAME, predicted to bind in HLA-B35, displayed 
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Table IV. 
Identified HLA class I binding peptides
 Allele Sequence Source IC50 (µM)
a 
  HIV-1pol  
 HLA-A11 AIKKKDSTK 221-229 4
 GIPHPAGLK 252-260 1
 QLDCTHLEGK 781-790 9
 AVFIHNFKR 898-906 2
 KIQNFRVYY 938-946 4
  HIV-1pol  
 HLA-A24 FWEVQLGI 242-249 20
 RYQYNVLPQGW 298-309 1.4
 QYNVLPQGW 300-308 1
 PFLWMGYEL 381-389 1.2
 GYELHPDKW 386-394 20
 LWKGEGAVVI 957-966 6.5
  human p53 
 HLA-B7 LPENNVLSPL 26-35 1.2
 SPALNKMFCQL 127-137 0.9
 RPILTIITL 249-257 0.2
 LPPGSTKRAL 299-308 0.2
 SPQPKKKPL 315-323 0.6
  PRAME 
 HLA-B35 LPRELFPPL 48-56 0.7
 LPRRLFPPLF 48-57 1.6
 FPPLFMAAF 53-61 0.8
 RPRRWKLQV 113-121 >100
 IPVEVLVDLF 173-182 0.1
 LPTLAKFSPY 246-255 0.1
 CPHCGDRTFY 487-497 1.5
 EPILCPCFM 499-507 0.3
  mHag HA-1 
 HLA-B60 KECVLHDDL 134-142 5.3
 KECVLRDDL 134-142 3.9
 KECVLHDDLL 134-143 1
 KECVLRDDLL 134-143 1.6
       
a Bindings affinity can be classified according to the following cutoffs. High affinity: IC50  
5 µM; Intermediate affinity: 5 µM < IC50  15 µM; Low affinity: 15 µM < IC50  100 µM; No 
binding IC50 > 100 µM.
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high binding affinity for HLA-B35. Furthermore, we found four peptides of 
minor histocompatibility antigen (mHag) HA-1 that bound with high affinity 
in HLA-B6037. For the other alleles as well, several high affinity binding peptides 
(derived from PRAME and BCR-ABL) were successfully identified by applying 
the present binding assays (manuscript in preparation). In summary, in all as-
says peptides could be classified in the range from high affinity binding to no 
observable binding affinity. 
Correlation between peptide binding prediction and peptide binding capacity
While peptide binding prediction algorithms are extremely useful to select po-
tential HLA class I binding peptides, the currently prevailing view is that these 
predictions are not accurate enough to bypass binding measurements. We chose 
to analyze the binding prediction for HLA-A2 (-A*0201), because a refined bind-
ing motif is known for this extensively studied allele10,12,18. Previously, we identi-
fied 19 high and 27 intermediate affinity HLA-A2 binding peptides of tumor 
antigen PRAME (length 509 aa) out of 65 nona- and 63 decamers selected4 by 
using the BIMAS peptide binding prediction algorithm18. Analysis of the data 
revealed that a relatively low prediction score did not necessarily exclude high 
affinity binding. Examples of this group of peptides were decamers SLYSFPEPEA 
(PRAME 142-151) and FLKEGACDEL (PRAME 182-191) that ranked 35th and 
46th in binding-prediction for HLA-A2 (BIMAS algorithm) respectively (data not 
shown). Despite these low scores, SLYSFPEPEA bound second best (IC50 1.9 µM) 
and FLKEGACDEL bound with high affinity as well (IC50 3 µM, ranking 5
th for 
binding)4. Low prediction scores in these cases were caused by the lack of a ca-
nonical C-terminal anchor in SLYSFPEPEA and residues with a predicted delete-
rious effect on binding (E at P7 for SLYSFPEPEA and K at P3 for FLKEGACDEL). 
Conversely, a high prediction score for HLA-A2 did not necessarily correlate 
with high affinity binding. Fifty percent of the predicted 16 best binding 9-mers 
and 18.7% of the 10-mers from the analogous group displayed only low or no 
binding affinity at all (table V). For instance, nonamer KMILKMVQL (PRAME 
224-232) that ranked 5th in binding-prediction for HLA-A2 actually failed to 
bind (IC50 > 100 µM)
4. A possible explanation is that the strong deleterious ef-
fect on binding of glutamine at position 9 of the peptide18 may also results from 
this aa in position 812, but is not incorporated in the binding prediction score18. 
Taken together we conclude that binding prediction for this particular set of 
peptides did not accurately correlate with binding affinities, confirming the need 
for actual peptide binding assays.
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Table V. 
Accuracy of binding prediction in HLA-A*0201 of 128 peptides in PRAME
 Binding predictiona  Binding affinity measured by HLA-A2 assayc  
 Length    Rankingb  High Intermediate Low  No binding
  
 9-mers ranked 1-16 6 (37.5%) 2 (12.5%) 6 (37.5%) 2 (12.5%)
 ranked 17-32 1 (6.2%) 4 (25%) 10 (62.5%) 1 (6.3%)
 ranked 33-48 1 (6.2%) 4 (25%) 6 (37.5%) 5 (31.3%)
 ranked 49-65 0 (0.0%) 0 (0.0%) 7 (41.0%) 10 (59.0%)
 total (ranked 1-65) 8 (12.3%) 10 (15.4%) 29 (44.6%) 18 (27.7%)
 10-mers ranked 1-16 6 (37.5%) 7 (43.7%) 3 (18.7%) 0 (0.0%)
 ranked 17-32 1 (6.2%) 6 (37.5%) 7 (43.8%) 2 (12.5%)
 ranked 33-48 4 (25%) 4 (25.0%) 5 (31.2%) 3 (18.7%)
 ranked 49-63 0 (0.0%) 0 (0.0%) 6 (40.0%) 9 (60.0%)
 total (ranked 1-63) 11 (17.5%) 17 (27.0%) 21 (33.3%) 14 (22.2%)
                 
aPrediction by BIMAS algorithm, accessible via http://bimas.cit.nih.gov/molbio/hla_
bind/18.
bRanking: no. 1 is peptide with highest prediction score, which is predicted to bind best.
cBinding affinity classified according to the following cutoffs. High affinity: IC50  6 µM; 
Intermediate affinity: 6 µM < IC50  15 µM; Low affinity: 15 µM < IC50  100 µM; no binding 
IC50 > 100 µM.
Discussion
Measurement of peptide HLA class I binding affinity can be exploited for the 
identification of HLA class I presented epitopes as is needed for e.g. vaccine 
development and insight in autoimmunity and graft versus host reactions. For 
these purposes especially HLA class I molecules with a prevalent distribution 
among different human populations are of interest (table I). The current report 
presents a concise summary of binding assays that were developed for 13 high-
ly prevalent HLA class I molecules according to a competition based strategy 
which utilizes a fluorescein labeled class I binding reference peptide and cell 
surface expressed HLA class I molecules. 
 This type of binding assay has several advantages over molecular HLA 
class I binding assays. First, the assays are rapid and convenient, because there 
is no need for time-consuming production and purification of soluble HLA 
class I molecules. Furthermore, the readout is not dependent on either radioac-
tive peptide labeling or conformation specific antibodies, of which the latter 
are not available for every allele, but instead on fluorescein labeled reference 
peptides the synthesis of which is straightforward. Finally, as equipment a flow-
cytometer suffices. 
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 We show that the concept of the assay can be adapted for basically 
every HLA class I allele of interest. Therefore the present report can also be 
read as an instruction for the development of class I binding assays that are still 
lacking. Several important allele-specific features need to be determined for each 
allele. Differences in binding capacity of the Fl-labeled reference peptides were 
observed depending on which residue was substituted for a Fl-labeled cysteine 
(figure 1A).  However, when a proper non-anchor residue was chosen for sub-
stitution (figure 1A), the substitution did not appear detrimental for binding. Ex-
ceptionally, we met problems in finding a suitable Fl-labeled reference peptide. 
For example, we did not succeed thusfar in obtaining a sufficiently binding Fl-
labeled peptide for HLA-B44 (data not shown). We used B-LCL homozygously 
expressing HLA class I molecules of interest, as B-LCL are broadly available in 
the scientific community and can easily be generated from PBMC. The required 
exclusion of binding of the FL-labeled reference peptide to co-expressed alleles 
was accomplished with the use of properly selected negative control B-LCL 
(figure 1B). Like in other competition based assays, in our assays, the measured 
binding affinity of the test peptides is relative to the binding capacity of the Fl-
labeled reference peptide. Therefore, we used well defined HLA class I ligands 
or CTL epitopes as reference peptides (table II). As we have shown before for 
the HLA-A2 and HLA-A3 binding assays27, the kinetics of peptide binding in 
our assays at 4°C with an incubation time of 24 h followed the same pattern as 
those in assays applying soluble HLA molecules. Also, the ranking of peptides 
according to their IC50 was comparable to the ranking found in cell free bind-
ing assays27. Validation of the newly developed assays with either the unlabeled 
reference peptide or other defined class I binding peptides, showed IC50 values 
below or around 5 µM (figure 4 and table III), which is in line with previously 
published results27.
 We were able to use the assays described for the identification of novel 
HLA class I binding peptides as exemplified for HIVpol derived peptides bind-
ing in HLA-A11 and HLA–A24, peptides of p53 with high affinity for HLA-B7, 
PRAME derived peptides binding in HLA-B35 and peptides from mHag HA-1 
with high affinity for HLA-B60 (table IV). These peptides have been used for 
CTL inductions to identify new class I presented epitopes37. 
 An analysis of the motif-based peptide binding prediction in HLA-A2 
revealed that rankings of the peptide binding prediction and binding capacity 
(IC50) did not accurately correlate (table V). This is caused by the incomplete 
knowledge of the contribution of each aa in every position of a peptide to HLA 
class I binding and therefore we consider actual peptide binding assays com-
pulsory for precise assessment of peptide binding capacity to all HLA class I 
molecules. The currently presented peptide binding assays will be conveniently 
applicable for this purpose.
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Abstract 
The polymorphic minor histocompatibility antigen HA-1 locus encodes two 
peptides HA-1H and HA-1R with a single amino acid difference. Whereas the 
immunogenicity of the HA-1R allele has not yet been shown, the nonameric 
HA-1H peptide induces HLA-A2 restricted cytotoxic T cells in vivo and in vitro. It 
is not known whether the mHag HA-1H or HA-1R associates with other HLA 
class I molecules. Therefore, the polymorphic regions of both HA-1 alleles were 
analyzed to identify HLA class I binding peptides that are properly processed 
by proteasomal degradation. Peptide binding analyses were performed for all 
nonameric HA-1H/R peptides for binding to nine HLA class I molecules that 
have more than 10% prevalence in the Caucasian population and for seven 
nonameric/decameric HA-1H/R peptides that were predicted to bind to HLA-A3, 
-B14 and -B60. Only the nonameric KECVLH/RDDL and decameric KECVL
H/RD-
DLL peptides showed strong and stable binding to HLA-B60. In vitro digestion of 
29 amino acid long HA-1 peptides by purified 20S proteasomes revealed proper 
cleavage at the COOH termini of both HLA-B60 binding HA-1H and HA-1R pep-
tides. In subsequent analyses, dendritic cells pulsed with the nonameric HA-1R 
peptide did not induce CTLs that recognize the natural HLA-B60/HA-1R li-
gand. In contrast, dendritic cells pulsed with the nonameric HA-1H peptide in-
duced IFN- secreting T cells specific for the natural HLA-B60/HA-1H ligand in 
three HLA-B60+ HA-1RR individuals, demonstrating the immunogenicity of the 
HLA-B60/HA-1H ligand. In conclusion, this study shows a novel HLA-B60 re-
stricted T cell epitope of the minor histocompatibility antigen HA-1 locus.
Introduction
Differences in minor histocompatibility antigens (mHags) between HLA identi-
cal stem cell (SC) donor and recipient may lead to alloimmune T cell responses 
post SC transplantation (SCT). The mHag specific T cells are key players in both 
the Graft versus Host Disease and the Graft versus Leukemia reaction1. It is 
important to understand the basis of the mHag induced alloimmune responses 
for both latter Graft versus Host reactivities. Now that mHags can be character-
ized, information on issues such as mHag processing and presentation will give 
insight into their potential clinical relevance. With the molecular identification 
of the autosomally encoded mHag HA-1, it was shown for the first time that a 
human mHag is encoded by a locus with two alleles with a single amino acid 
difference2. The difference between the HA-1 alleles comprises a histidine (H) to 
an arginine (R) substitution. Although nonameric peptides of both the HA-1H 
and the HA-1R alleles bind to HLA-A2, the HA-1R allele fails to be expressed 
at the cell surface. In contrary, the HA-1H peptide is presented at the cell sur-
face and is known to induce HLA-A2 restricted CTLs both in vivo and in vitro3,4. 
Because of its hematopoietic system restricted expression, the mHag HA-1 can 
be used for the treatment of relapsed leukemia after HLA identical HA-1 mis-
matched SCT4,5. 
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Since the HA-1 specific immunotherapy is currently restricted to HLA-A2 posi-
tive patients, we have investigated whether the HA-1H/R polymorphic region 
contains peptides that can be presented by other HLA molecules. We analyzed 
the binding capacities of HA-1 polymorphic peptides to nine HLA-A and -B 
molecules that have a frequency of > 10% in the Caucasian population. Since 
cognate T cell epitopes of mHags do not always confirm the predicted MHC class 
I binding motifs6,7, all nonameric HA-1H/R peptides (n=18) were tested for bind-
ing to these frequent HLA alleles. The peptide binding analyses were extended 
with two decameric HA-1H/R peptides that contained binding motives for HLA-
A3 and with five nonameric/decameric peptides that were predicted to bind 
to HLA-B14 or to -B60. After the binding studies, cellular processing was ex-
ecuted by in vitro proteasome digestion of 29 amino acid long HA-1H and HA-1R 
peptides. To enlarge the patient population for HA-1 specific immunotherapy, 
the HLA-B60 binding peptides were analyzed for their in vitro immunizing po-
tential. Peptide loaded dendritic cells (DCs) were used to induce T cell responses 
from healthy individuals.   
Materials and Methods
HA-1 peptides
HA-1H and HA-1R peptides were synthesized using an automated multiple 
peptide synthesizer (Syro II, Multisyntech, Witten, Germany) according to the 
known HA-1 amino acid sequence2. The purity of the peptides was > 90%. The 
peptides were dissolved in dimethyl sulfoxide (DMSO), diluted in 0.9% NaCl 
and stored at –20°C until use.
Prediction of HLA peptide binding
The polymorphic HA-1H and HA-1R regions were screened with the HLA-pep-
tide binding prediction software of BIMAS (BioInformatics & Molecular Analy-
sis Section, NIH, Bethesda, MD; url: http://bimas.dcrt.nih.gov./) for octameric, 
nonameric or decameric HA-1 peptides capable to bind to HLA class I mol-
ecules. The selection of peptide candidates was made by comparison of the 
computed scores with that of the HLA-A2 restricted HA-1H CTL epitope with 
amino acid (aa) sequence VLHDDLLEA (score of 79.6). This score corresponds 
to the estimated half-time of dissociation of complexes containing the peptide at 
37°C at pH 6.5.  Five HA-1H/R peptides with scores ranging from 32 (intermedi-
ate binding score)  to 176 (strong binding score) were selected to assay for bin-
ding to the relevant HLA class I molecules. The predicted HLA class I /HA-1H/R 
peptide associations and their computed binding scores are presented in table 
I. In addition, we selected two decameric HA-1H/R peptides that contained an-
chor residues for binding to HLA-A3 but were not predicted by the BIMAS 
software.
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Table I. 
Peptides of the HA-1 polymorphic region tested for binding to different HLA class I moleculesa
          HA-1H/R polymorphic region sequence  
  E K L K E C V L H/R D D L L E A R R Binding predicted to
 Peptide                 (BIMAS score)b
  no.
 1 E K L K E C V L H         
 2 E K L K E C V L R         
 3  K L K E C V L H D        
 4  K L K E C V L R D        
 5   L K E C V L H D D       
 6   L K E C V L R D D            
 7    K E C V L H D D L      HLA-B60 (176)  
 8    K E C V L R D D L      HLA-B60 (176)  
 9    K E C V L H D D L L     HLA-B60 (160)  
 10    K E C V L R D D L L     HLA-B60 (160)
 11     E C V L H D D L L                        
 12     E C V L R D D L L     HLA-B8 (32),  -B14 (90)  
 13      C V L H D D L L E             
 14      C V L R D D L L E      
 15       V L H D D L L E A   HLA-A2 (79.6)  
 16       V L R D D L L E A    
 17       V L H D D L L E A R  HLA-A3  
 18       V L R D D L L E A R  HLA-A3
 19        L H D D L L E A R   
 20        L R D D L L E A R        
 21         R D D L L E A R R 
 22         R D D L L E A R R 
a Peptides 1-8, 11-16 and 19-22 were assayed for binding to  HLA-A1, -A2, -A3, -A11, 
-A24, -B7, -B8, -B35, -B62 regardless of prediction. Polymorphic amino acids are indi-
cated in bold.
b Prediction of HLA/peptide associations was executed using BIMAS software except 
for peptides 17 and 18, which were not predicted by BIMAS but contain HLA-A3 anchor 
amino acids at position 2 and 10.
HLA peptide binding assays
We used the competition-based HLA peptide binding assay as described previ-
ously, with some modifications8. Briefly, HLA typed EBV-LCLs were washed 
with PBS, kept on ice for 5 min. and treated with an ice-cold 0.132 M citric 
acid/0.062 M Na2HPO4.2H2O elution buffer for 90 sec
8. The pH of the elution 
buffer was optimized for each HLA molecule to enable maximal elution of HLA 
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bound peptides (chapter 3). Immediately after mild acidic treatment, the cells 
were washed with 12 ml Iscove’s modified Dulbecco’s medium (IMDM, Bio 
Whittaker, Belgium) containing 2% FCS and resuspended in IMDM contain-
ing 2% FCS, 1.5 µg/ml 2 microglobulin (Sigma, St. Louis, MO, USA). 4x10
4 
acid treated EBV-LCLs were then incubated in 96-well-V-bottom plates (Costar, 
Cambridge, MA, USA) with fluorescent-labeled reference peptide (25 µl/well, fi-
nal concentration: 150 nM) mixed with serial dilutions of competitor (test) pep-
tides (25 µl/well; final concentrations: 100 to 0.78 µM) in a total volume of 150 
ml. All reference peptides were deduced from previously reported peptides that 
show strong binding to the respective HLA class I molecules9. After incubation 
for 24 h at 4°C, the cells were washed twice with 100 µl/well PBS/1% FCS and 
fixed with 0.5% paraformaldehyde in PBS. The mean fluorescence expressed by 
the cells was determined by a FACScalibur flow cytometer (Becton-Dickinson, 
St.Louis CA, USA). Percentage inhibition of the HLA binding of the fluorescent 
reference peptide is calculated with the formula:
(1-(MFreference + competitor peptide – MFbackground) / (MFreference peptide – MFbackground)) x 100%. 
The relative binding affinity of the peptides is expressed as the peptide concen-
tration that inhibits 50% of the binding of the reference peptide (IC50). 
Proteasomal cleavage of the HA-1 polymorphic region
Twenty-nine amino acid long HA-1H and HA-1R peptides were purified to > 
95% by reverse phase HPLC. 10 µg/ml of the peptides were incubated with 20S 
proteasomes isolated from EBV-LCLs for 15 min, 30 min and 45 min as de-
scribed elsewhere10-12. The proteolysis products were analyzed by tandem mass 
spectrometry as previously described13. 
Dendritic cell culture
Monocyte derived DCs (MoDCs) were generated from healthy individuals by 
culturing peripheral blood derived CD14+ monocytes with 1000 U/ml IL-4 
(Genzyme, Cambridge, MA, USA) and 800 U/ml GM-CSF (donated by Dr. S. 
Osanto, LUMC, Leiden, The Netherlands) for 6 days as described elsewhere14. 
On day 6, the DCs were maturated by culturing on irradiated (750 Gy) CD40 
ligand-transfected mouse fibroblasts at a DC to fibroblast ratio of 2:1 or by 
adding 50% of monocyte-conditioned medium14. Mature DCs were pulsed with 
HA-1 peptides for 2 hours at 37°C in Aim-V medium (Invitrogen, Breda, The 
Netherlands) before their use as stimulator cells.
 
In vitro induction of HLA-B60/HA-1 specific T cell responses
Peptide pulsed DCs were cocultured with autologous PBMC at a DC to PBMC 
ratio of 1:10 in IMDM, 10% human serum supplemented with 1 U/ml IL-2 
(Cetus, Emeryvill, CA, USA) and 1 U/ml IL-12 (R&D systems, Minneapolis, MN, 
USA). On day 5, 20 U/ml IL-2 was added. On day 7, the T cell lines (TCL)  were 
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depleted of CD4+ cells using immunomagnetic beads (Dynal AS, Oslo, Norway) 
and were restimulated with irradiated (150 Gy) peptide pulsed mature DCs (DC:
T cell ratio, 1:10) or with irradiated (150 Gy) peptide pulsed monocytes (mono-
cyte:T cell ratio, 1:3). Twenty-four hours and 96 hours after restimulation, me-
dium containing 20 U/ml IL-2 was added. TCL were subsequently restimulated 
every 7 days and  were tested for HA-1 specific activity in Interferon- (IFN-) 
ELISPOT assays15 before each restimulation.  
Results
Effective binding of nonameric and decameric HA-1H and HA-1R peptides to HLA-B60
Three categories of HLA molecules were selected for the peptide binding assays: 
those molecules with a frequency of more than 10 % in the Caucasian popula-
tion, those with binding motifs and those that were predicted to bind nona-
meric / decameric HA-1H/R peptides. All nonameric HA-1H and HA-1R peptides 
(n=18) were tested for binding to the so called frequent HLA class I molecules 
HLA-A1, -A2, -A3, -A11, -A24, -B7, -B8, -B35, -B62. The peptide analysis was 
extended with two decameric HA-1H/R peptides with a binding motif for HLA-
A3 and with five nonameric/decameric peptides predicted to bind either to 
HLA-B14 or -B60 (table I). The HLA-A1, A11, -A24, -B7, -B8, -B14, -B35 and -
B62 molecules did not bind nonameric HA-1H/R peptides, despite the predictions 
of BIMAS software for intermediate to strong binding of peptide ECVLRDDLL 
to HLA-B8 or to -B14 (table I). The decameric HA1H/R peptides VLH/RDDLLEAR 
showed weak to intermediate binding to HLA-A3 molecules with IC50 values 
of 15.6 µM and 37.5 µM respectively (figure 1). In agreement with the predic-
tion of the BIMAS software, the nonameric and decameric HA-1H/R peptides 
KECVLHDDL, KECVLRDDL, KECVLHDDLL and KECVLRDDLL showed strong 
binding to HLA-B60 molecules with very low IC50 values of 5.3 µM, 3.9 µM, 1.0 
µM and 1.6 µM respectively (figure 2).  As expected, the original HLA-A2/HA-1H 
CTL epitope, also predicted by the BIMAS software, displayed binding to HLA-A2 
with an IC50 value of 6.4 µM (data not shown).
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Figure 1.
Binding of HA-1H/R peptides to HLA-A3. 
The results are expressed as the percentage inhibition of the HLA binding of the 150 
nM fluorescent reference peptide by the indicated peptides added at serial dilutions (see 
Materials and Methods). Curves were fitted by nonlinear regression and one site binding 
equation. The IC50 value of the HLA-A3 binding positive control peptide KQSSKALQR
9 
was 9.4 µM.  
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Figure 2.
Efficient binding of HA-1H/R peptides to HLA-B60. 
The results are expressed as the percentage inhibition of the HLA binding of the 150 nM 
reference peptide by the indicated peptides added at serial dilutions (see Materials and 
Methods). Curves were fitted by nonlinear regression and one site binding equation. The 
IC50 value of the HLA-B60 binding positive control peptide KESTLHLVL
9 was 1.1 µM.  
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Figure 3.
Stable binding of nonameric and decameric HA-1H/R peptides to HLA-B60. 
The nonameric and decameric HA-1H/R peptides were tested for binding to HLA-B60 (A, 
B) and to HLA-A2 (C) at the indicated temperatures. The results are expressed as the per-
centage inhibition of HLA binding of the reference peptide. Curves were fitted by nonlinear 
regression and one site binding equation.
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Stable binding of nonameric and decameric HA-1H and HA-1R peptides to HLA-B60
The stability of the HLA-B60/HA-1H/R peptide binding was addressed by test-
ing for the HLA peptide binding capacities at 4°C and 25°C. HLA-A2/HA-1H/R 
peptide binding stability was analyzed in parallel as comparison. Increasing the 
temperature from 4°C to 25°C did not affect the strong binding of decameric 
HA-1H/R peptides to HLA-B60 (figure 3A). Less binding was observed with the 
nonameric HA-1H/R peptides to HLA-B60 (figure 3B), which was comparable to 
the nonameric HA-1H peptide to HLA-A2 (figure 3C). Increasing the temperature 
from 4°C to 25°C further decreased the intermediate binding of the nonameric 
HA-1R peptide to HLA-A2 (figure 3C). Thus, the binding of both HA-1H and 
HA-1R peptides to HLA-B60 were stable and not temperature sensitive. 
Proper proteasomal cleavage of the HLA-B60 binding HA-1H/R peptides 
Twenty-nine amino acid long HA-1H/R peptides were subjected to in vitro diges-
tion with EBV-LCL derived 20S immuno-proteasomes. Within a time frame 
of 15 minutes, major peptide fragments were cleaved at the COOH-termini of 
both nonameric and decameric HLA-B60 binding HA-1H/R peptides. The latter 
cleavage products contained the intact HLA-B60 binding sequences with 3-5 
additional amino acid residues at the N termini for the HA-1H and HA1R pep-
tides as demonstrated in tables II and III, respectively. Thus, both the HA-1H and 
the HA-1R products can be effectively cleaved by proteasomes to generate the 
precursors of the peptides that bind to HLA-B60. 
Table II. 
In vitro proteasomal cleavage of a 29-amino acid long HA-1H peptidea
  
          
          
          
 
a The peptide sequences that  bind to HLA-B60 are underlined. The proteolytic fragments 
cleaved at the COOH termini of the HLA-B60 binding peptides are indicated in bold. The 
amounts of the generated fragments after cleavage with 20S immuno proteasomes for 
15, 30 and 45 min are expressed as the percentage of all fragments found in the digested 
substrate.
   G L E K L K E C V L H D D L L E A R R P R A H E C L G E  A
% fragment digested in     
15 min 30 min 45 min         
17.2 22.4 0 G L E K L K E C V L H D D L               
14.7 11.8 14.7 G L E K L K E C V L H D D L L E A R R P R A H E C L G  
13.9 16.4 21.7           H D D L L E A R R P R A H E C L G E  A
13.0 10.3 13.9 G L E K L K E C V L H D D L L E A R R P R A       
10.5 8.3 12.1   E K L K E C V L H D D L L              
9.6 8.8 12.3 G L E K L K E C V L H D D L L E A R R P R A H E C    
8.5 9.2 13.8 G L E K L K E C V L H D                 
7.8 7.4 11.5 G L E K L K E C V L H D D L L E A            
4.8 5.5 0 G L E K L K E C V L                   
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Table III.
In vitro proteasomal cleavage of a 29-amino acid long HA-1R peptidea 
a The peptide sequences that  bind to HLA-B60 are underlined. The proteolytic fragments 
cleaved at the COOH termini of the HLA-B60 binding peptides are indicated in bold. The 
amounts of the generated fragments after cleavage with 20S immuno proteasomes for 
15, 30 and 45 min are expressed as the percentage of all fragments found in the digested 
substrate. 
In vitro induction of HLA-B60 restricted T cells against the nonameric HA-1H peptide 
To test the immunogenicity of both the HA-1H and the HA-1R peptides in the 
context of HLA-B60, PBMCs from three HLA-B60+ HA-1RR and from two HLA-
B60+ HA-1HH healthy individuals were stimulated with autologous DCs pulsed 
with the nonameric HA-1H or HA-1R peptide respectively. After two or three 
rounds of stimulation, the two T cell lines (TCL) induced with the HA-1R pep-
tide contained significant numbers of IFN- producing T cells that recognized 
HA-1R peptide pulsed HLA-B60-transfected T2 cells. Nevertheless, neither TCL 
induced with HA-1R peptide produced IFN- upon stimulation with EBV-LCLs 
that express the natural ligand HLA-B60/HA-1R (data not shown). On the con-
trary, all three TCL induced with the HA-1H peptide contained besides HA-1 
non-specific T cells, a significant number of T cells that produced IFN- not 
only upon stimulation with HA1H peptide pulsed HLA-B60 transfected T2 cells 
but also upon stimulation with EBV-LCLs that express the natural HLA-B60/
HA-1H ligand (figure 4). 
   G L E K L K E C V L R D D L L E A R R P R A H E C L G E  A
% fragment digested in
15 min 30 min 45 min         
26.2 28.0 23.8 G L E K L K E C V L R D D L L E A R R P R A H E C L G 
14.0 16.0 13.5 G L E K L K E C V L R D D L L E A R R P R A H E C L G E 
11.1 14.3 12.7 G L E K L K E C V L R D D L              
7.9 9.6 7.9 G L E K L K E C V L R D D L L E A R R P R A       
6.6 8.6 8.3   E K L K E C V L R D D L L              
6.2 7.5 7.3        C V L R D D L L E A R R          
5.3 7.0 5.7 G L E K L K E C V L R D D L L E A R R P R A H E C L   
4.9 7.1 6.4 G L E K L K E C V L R D D L L E A R R P R A H E C    
4.2 6.1 5.6 G L E K L K E C V L R D                 
3.9 4.2 3.9 G L E K L K E C V L R D D L L E A            
3.6 4.4 4.4 G L E K L K E C V L R D D L L E A R R          
3.4 4.2 3.6 G L E K L K E C V L R D D L L E A R R P R        
2.6 4.2 4.0 G L E K L K E C V L R D D L L E A R R P R A H
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Figure 4.
T cell recognition of HLA-B60/HA-1H ligand.  
T cell lines (TCL) secreting IFN- in response to the target cells are indicated. The EBV-
LCLs (HLA-B60/HA-1RR and HLA-B60/HA-1HR) are derived from HLA-identical but HA-1-
non-identical siblings. The number of IFN- spots per 105 cells is expressed on the Y-axis. 
The SEM was < 5%.
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Discussion
Earlier studies demonstrated the immunogenicity of one allele of the HA-1 lo-
cus i.e.: the nonameric HA-1H peptide VLHDDLLEA presented by the HLA-A2 
molecule2. Here, we show for the first time that the mHag HA-1 locus comprises, 
beside the known HLA-A2/HA-1H T cell epitope, an HLA-B60/HA-1H T cell 
epitope. 
 In search for novel T cell epitopes in the HA-1H/R polymorphic region, 
we studied the binding of polymorphic HA-1 peptides to 11 HLA class I mol-
ecules and analyzed the proteasomal cleavage sites in the HA-1H/R polypeptides. 
These analyses suggested novel interactions of both alleles of the mHag HA-1 
locus with HLA-B60 molecules. Both nonameric and decameric HA-1H/R pep-
tides effectively bind to HLA-B60. In vitro proteasomal analysis showed cleav-
age at the COOH termini of HLA-B60 binding peptides, indicating proper in-
tracellular processing. Functional analyses revealed the immunogenicity of the 
HLA-B60/HA-1H ligand but as yet not of the HLA-B60/HA-1R ligand.
 Both nonameric and decameric HA-1H/R peptides show strong binding 
to HLA-B60, with IC50 values between 1.6-5.3 µM. These HLA binding levels are 
similar to or higher than the HLA binding of the immunogenic HLA-A2/HA-1H 
CTL epitope and of other reported T cell epitopes measured in similar as-
says8-16. Furthermore, we compared the stability of the HLA-B60/HA-1H/R with 
HLA-A2/HA-1H/R peptide interactions by increasing the temperature of the 
binding assays. These assays reveal that unlike the HLA-A2/HA-1R peptide 
interaction, the HLA-B60/HA1H/R and HLA-A2/HA-1H interactions are stable. 
The stability of HLA-B60/HA-1H/R interactions were confirmed in separate ex-
periments using fluorescent HA-1H/R peptides (data not shown). Thus, both 
HA-1H and HA-1R peptides can efficiently interact with HLA-B60, which is an 
important biochemical feature of strongly immunogenic T cell epitopes16. This 
actually predicts immunogenicity of both HA-1H and HA-1R locus products in 
association with HLA-B60.  
 The HLA peptide binding is preceded by intracellular processing of cel-
lular proteins. In the endoplasmatic reticulum (ER), proteasomally cleaved pep-
tides can undergo NH2-terminal trimming by aminopeptidases
17. COOH-termi-
nal trimming in de ER has not been demonstrated. The proper generation of 
the correct COOH-terminus by an early major cleavage site by proteasomes is 
thus a key event for efficient epitope generation as demonstrated by recent stud-
ies18-21. In our in vitro cleavage studies, the correct COOH termini of HLA-B60 
binding sequences of both the HA-1H and the HA-1R allele were generated with-
in 15 minutes. These peptide fragments contained the intact HLA-B60 binding 
sequences. The exact sequences of the HLA-B60 binding peptides were not pres-
ent as proteasomal degradation products. Some additional  cleavage sites within 
the putative T cell epitopes were also observed. Nonetheless, the successful gen-
eration of HLA-B60/HA-1H-specific T cells demonstrates the proper cleavage of 
the HLA-B60 binding HA-1H peptides by cellular antigen processing machinery. 
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Our results confirm the recent reports on the importance of the generation of 
the exact COOH terminus for the intracellular generation of T cell epitopes. Once 
the relevant peptides are generated by proteasomal cleavage, other cleavage sites 
found within the epitope do not prevent the generation of immunogenic T cell 
epitopes expressed on the cell surface13. Based on these results, one may expect 
that the HA-1R peptides are also expressed on the cell surface in association 
with HLA-B60. However, the TCL generated against the HA-1R peptide loaded 
HLA-B60+ stimulator cells recognized only peptide-pulsed stimulator cells, not 
the stimulator cells that naturally express HLA-B60/HA-1R ligand.  It is possible 
that these TCL may have low affinity to the natural HLA-B60/HA-1R ligand. 
Alternatively, the naturally expressed HLA-B60/HA-1H complex may act as an 
altered peptide ligand to antagonize the high avidity HLA-B60/HA-1R-specific T 
cells.  In murine models, it was shown that in vivo expression of altered peptide 
ligand as a natural MHC/peptide complex can antagonize mature T cells specific 
for the agonistic ligand22. The antagonistic complex may also cause negative se-
lection of the high avidity T cells in the thymus23,24. Thus both mechanisms may 
result in the failure of the detection of HLA-B60/HA-1R specific T cells in the 
periphery. However, it may also be possible that similar to the HLA-A2/HA-1R 
ligand, the HA1R peptide is not expressed on the cell surface. HLA-B60 HA-1R 
peptide elution experiments are currently underway, but to date have not 
shown the presence of the HLA-B60/HA-1R peptide. Moreover, we will apply 
a more efficient CTL induction protocol and use HA-1-ransduced DCs instead 
of peptide-pulsed DCs as antigen presenting cells. cDNA-transduced DCs result 
in natural processing and constitutive expression of the mHag HA-1, which is 
more effective than the peptide pulsed DCs in the generation of HA-1 specific 
CTLs25. 
 In conclusion, our analyses reveal a novel HLA-B60-restricted HA-1H 
specific T cell epitope. Herewith, the HA-1-specific immunotherapy for relapsed 
leukemia can be extended to patients who receive HLA-B60-matched HA-1H-
mismatched SCT. 
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Abstract
Umbilical cord blood transplantation is applied as treatment for mainly pediatric 
patients with hematological malignancies. The clinical results show a relatively 
low incidence of Graft-versus-Host-Disease and leukemia relapse. Since mater-
nal cells traffic into the fetus during pregnancy, we questioned whether cord 
blood has the potential to generate cytotoxic T cells specific for the hematopoi-
etic minor Histocompatibility (H) antigen HA-1 that would support the Graft-
versus-Leukemia effect. Here we demonstrate the feasibility of ex vivo generation 
of minor H antigen HA-1 specific T cells from cord blood cells. Moreover, we 
observed already pre-existing HA-1 specific T cells in cord blood samples. Both 
the circulating and the ex vivo generated HA-1 specific T cells show specific and 
hematopoietic restricted lysis of HLA-A2+/HA-1+ target cells, including leuke-
mic cells. The cord blood derived HA-1 specific cytotoxic T cells are from child 
origin. Thus, the so-called naïve cord blood can comprise cytotoxic T cells 
directed at the maternal minor H antigen HA-1. The apparent immunization 
status of cord blood may well contribute to the in vivo Graft-versus-Leukemia 
activity after transplantation. Moreover, since the fetus cannot be primed against 
Y chromosome encoded minor H antigens, cord blood is an attractive stem cell 
source for male patients. 
Introduction
In the last decade, umbilical cord blood transplantation (CBT) is available as 
alternative to HLA matched sibling or unrelated donor stem cell transplantation 
(SCT) for the treatment of hematological malignancies1-7. The clinical outcome of 
transplanted CB grafts with one or two HLA antigen mismatches demonstrates 
a similar risk of developing Graft versus Host Disease (GvHD) as compared 
to HLA-matched unrelated SCT5,6. A significant lower incidence of acute and 
chronic GvHD was reported after HLA identical CBT when compared to sibling 
SCT4. Collectively, these clinical results point to a decreased incidence of GvHD 
after CBT.
 GvHD is often associated with a curative Graft versus Leukemia (GvL) 
response. Minor H antigen disparities between donor and recipient play im-
portant roles in both the GvH and GvL reactivity after HLA-matched SCT 
as reviewed8. One of the well-described minor H antigens is HA-1. The im-
munodominant minor H antigen HA-1 is encoded by a diallelic gene with a 
single amino acid polymorphism9. The HA-1 ‘positive’ allele (HA-1+) contains 
a histidine at position 3 (HA-1H), whereas the HA-1 ‘negative’ allele (HA-1-) 
contains an arginine (HA-1R). The HA-1H peptide is recognized by HLA-A2 re-
stricted CD8+ cytotoxic T cells from HA-1- donors10-12. The expression of HA-1 
is restricted to the hematopoietic lineage and to epithelial carcinomas13,14. This 
restricted expression makes HA-1 an attractive target antigen for GvL and Graft-
versus-Tumour responses15. 
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 Despite the lower incidence of GvHD after CBT, there is no indication 
of increased leukemia relapse rates when compared with sibling or unrelated 
donor SCT3-5. Comparable survival rates point to an as yet unexplored GvL 
potential of cord blood. Relatively little is known about the development of 
antigen-specific T cell responses around birth16. Mature monocyte-derived neo-
natal dendritic cells (DC) are able to efficiently prime antigen-specific cytotoxic 
T cells in vitro17. In bulk cultures, cord blood T cells proliferate in response to 
alloantigen18. Yet, the development of functional alloreactive cytotoxic T cells is 
impaired18-20. Limiting dilution studies have however reported normal precursor 
frequencies of cytotoxic T cells specific for allo-HLA class I and class II in cord 
blood20-22. Thus, the capacity to develop allogeneic cytotoxic T cells is intact at 
birth, despite overall diminished magnitude of responses23.
 It is known that feto-maternal hemorrhage occurs during pregnancy. 
Fetal cells expressing paternal minor H antigens can prime maternal T cells12,24. 
Since cells of the mother also traffic into the fetus during pregnancy, we tested 
the hypothesis that maternal minor H antigens can prime fetal T cells. Fifteen 
HLA-A2+/HA-1- CB samples derived from HLA-A2+/HA-1- or HLA-A2+/HA-
1+ mothers were analyzed for their feasibility to generate HA-1 specific cytotoxic 
T cells ex vivo as well as for the presence of pre-existing HA-1 specific T cells.
Methods
Cord Blood
After informed consent of the mother, cord blood was collected from the um-
bilical cord vein with the placenta still in utero. HLA-A2+/HA-1- CB samples 
derived from HLA-A2+/HA-1- and HLA-A2+/HA-1+ mothers were selected af-
ter high resolution HLA class I typing and HA-1 genomic typing as described 
previously25. Cord blood mononuclear cells (CB-MNC) were isolated by Ficoll-
Isopaque density gradient centrifugation and stored in liquid nitrogen. 
HLA class I/minor H antigen peptide tetrameric complexes
Expression of the T cell receptor specific for HLA-A2/HA-1H peptide (VLHDDLLEA) 
complexes was analyzed by staining T cells with phycoerythrin (PE)-conju-
gated HLA-A2/HA-1 tetrameric complexes (HA-1A2) in combination with al-
lophycocyanin (APC)-conjugated anti-CD8 monoclonal antibody (BD Biosci-
ences, Amsterdam, The Netherlands). Tetramers were generated as previously 
described26. Specificity analysis of the HA-1A2 tetramer was performed in parallel 
experiments using HA-1 specific and HA-1 non-specific CTL clones (data not 
shown).
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Culture, retroviral transduction and maturation of CD34+-derived dendritic cells
CD34+ cells were isolated via positive selection using CD34 magnetic-activat-
ed cell sorting (MACS) beads (Miltenyi GmBH, Bergisch Gladbach, Germany). 
CD34+ cells were cultured in complete IMDM containing 10% pooled human 
serum (HS), 250 U/ml GM-CSF (Leucomax, Novartis, Arnhem, The Nether-
lands), 25 µg/ml SCF (Peprotech, London, UK), 100 U/ml TNF- (Peprotech) 
and 50 µg/ml FLt3 ligand (R&D Systems, Mineapolis, MN). Dendritic cells were 
transduced with retroviral supernatants containing HA-1H encoding cDNA, as 
previously described27, and further cultured in complete medium supplemented 
with 300 U/ml IL-4 (Peprotech). Maturation of HA-1H transduced dendritic cells 
was induced by co culturing immature dendritic cells for 3 days with irradiated 
CD40 ligand-transfected fibroblasts.
Generation of HA-1 specific cytotoxic T cells from cord blood
A slightly modified protocol, originally designed for the induction of minor H 
antigen specific cytotoxic T cells from adult PBMC, was applied11. In short, CD8+ 
T cells were isolated via positive selection using CD8 MACS beads (Miltenyi) 
and cultured with irradiated autologous HA-1H transduced dendritic cells (gen-
erated as described above) at a CD8 to dendritic cell ratio of 5:1 or 10:1 in 
IMDM supplemented with 10% HS, 0.5 U/ml IL-2 (Cetus, Emeryville, CA) and 
1 U/ml IL-12 (R&D Systems). After 3 days, irradiated autologous T helper cells 
were added to the culture at a CD8 to T helper ratio of 10:1. T helper cells were 
generated by stimulating CD34/CD8 depleted CB-MNC with anti-CD3/CD28 
beads according to supplier’s protocol (Dynal Biotech, Smestad, Norway). This 
mode of stimulation results in  80% activated CD4+ T cells that produce IFN-, 
TNF- and IL-2 (data not shown). From day 7 onwards, oligoclonal T cell lines 
were restimulated weekly using irradiated dendritic cells and T helper cells at a 
CD8:T helper:dendritic cell ratio of 10:1:1. Fresh medium containing IL-2 was 
added every 3-4 days.  
 Bulk T cell lines were tested for the presence of HA-1A2 tetramer positive 
CD8+ T cells after 2-4 rounds of stimulation with T helper cells and dendritic 
cells. HA-1A2 tetramer staining cells were subsequently sorted on a FACS Van-
tage (Becton Dickinson, San Jose, CA) and cloned by limiting dilution. Cloned 
T cells were expanded in the presence of 5x104 irradiated allogeneic PBMC and 
5x103 HLA-A2+/HA-1+ EBV transformed B cells (EBV-LCL) and 30 U/ml IL-2.
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Direct isolation and culture of HA-1 specific cytotoxic T cells from cord blood 
The protocol for detection of circulating minor H antigen specific cytotoxic T 
cells in PBMC from healthy multiparous female blood donors was applied12. In 
short, CB-MNC were depleted for various cell subsets using CD4, CD14, CD19, 
CD16 and glycophorin-A MACS beads (Milteny). The depleted fraction was 
subsequently stained with CD8-APC, CD45RA-FITC (BD Biosciences) and PE-
conjugated HA-1A2 tetrameric complexes. Further enrichment of HA-1A2 tetra-
mer positive CD8+ cells was performed on a FACS Vantage cell sorter using the 
“enrich mode”, whereby cells are sorted at 20.000 events/s. The enriched fraction 
was reanalyzed and resorted immediately at 10.000 events/s using the more 
stringent “normal-R” mode. Double FACS-sorted cells were expanded in the 
presence of irradiated autologous HA-1- CB-MNC cells, 1% phytohemaglutinin 
and 30 U/ml IL-2. Fresh IL-2 containing medium was added every 3-4 days.
Cell-mediated lympholysis assay
Standard 4-hour 51Cr-release assays were performed as previously described13. 
Results
Ex vivo generation of HA-1-specific cytotoxic T cells lines from HLA-A2+/HA-1- cord 
blood
Six HLA-A2+ CB samples, four HA-1- and two HA-1+, were used for the ex vivo 
generation of HA-1 specific cytotoxic T cell lines. CD8+ T cells were isolated and 
cultured with autologous HA-1H transduced dendritic cells and T helper cells. 
The generation of HA-1 specific cytotoxic T cell lines was successful in three out 
of four HLA-A2+/HA-1- CB samples, whereas no growth at all was observed 
in the two HLA-A2+/HA-1+ CB samples. Results of two HLA-A2+/HA-1- CB 
samples (I and II) are shown in figure 1. The percentages of HA-1A2 tetramer 
and CD8 double positive T cells are shown after 14 days of culture (figure 1A 
and B). HA-1A2 tetramer staining CD8+ T cells were further enriched after ad-
ditional rounds of stimulation (figure 1C and D). The latter populations were 
FACS sorted, expanded for 14 days, and functionally analyzed. Strong HA-1 
specific lytic activity is demonstrated for both CB-derived T cell cultures (figure 
1E and F). 
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Figure 1. 
Ex vivo generation of HA-1 specific cytotoxic T cells from HLA-A2+/HA-1- cord blood 
Purified CB CD8+ T cells were cultured in the presence of autologous HA-1H expressing 
dendritic cells and T helper cells. Results of two different CB cultures are shown (I and 
II). Samples were stained with HA-1A2 tetramers (x-axis) and CD8 antibodies (y-axis). The 
percentages of HA-1A2 tetramer positive CD8+ T cells are shown after 14 (A, B), 28 (C) or 
21 days of culture (D). HA-1A2 tetramer positive CD8+ T cells were FACS sorted (indicated 
by arrow), expanded and tested for cytotoxic activity (E, F). Target cells: HLA-A2+/HA-1- 
EBV-LCL (dots), HLA-A2+/HA-1- EBV-LCL pulsed with HA-1H peptide (squares) and HLA-
A2+/HA-1+ EBV-LCL (triangles). Data are presented as mean percentage of lysis ± SD.
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Origin of cord blood-derived HA-1 specific cytotoxic T cells
Since cord blood may contain maternal cells, we determined whether the HA-1 
specific T cells were child or mother derived. DNA typing of the HA-1 alleles 
showed unequivocally that ex vivo generated HA-1 specific T cells are from child 
origin  (data not shown).
Hematopoietic-restricted cytolytic activity of HA-1 specific cord blood-derived T cells
T cell clones were generated from CB I (n=5), CB II (n=29) and CB III (n=8) 
and analyzed for HA-1 hematopoietic-restricted specificity and leukemic cell 
lysis. Results of three representative T cell clones (clones 1, 2, 3) are shown in 
figure 2. Clone 1 lysed HLA-A2+/HA-1+ PHA blasts, but not fibroblasts, while 
fibroblasts pulsed with HA-1H peptide were lysed  (figure 2A). Clones 1, 2 and 
3 were analyzed against a panel of HA-1+ and HA-1- leukemic cells. Each clone 
recognized the three HLA-A2+/HA-1+ leukemic targets, whereas HA-1- leukemic 
cells and autologous HA-1- PHA blasts, tested in parallel, were not recognized 
(figure 2B-D). Thus, HA-1 specific cytotoxic T cells can be generated ex vivo from 
HLA-A2/HA-1- CB samples. These T cells display specific and hematopoietic-
restricted recognition.
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Figure 2. 
Hematopoietic-restricted lysis of CB-derived cytotoxic T cell clones
(A) The cytotoxic activity of one representative HA-1 specific T cell clone (1) is shown 
against fibroblasts (closed circles); fibroblasts pulsed with HA-1H peptide (asterisks) and 
PHA blasts (crosses). The fibroblasts and PHA blasts are derived from the same HLA-
A2+/HA-1+ donor. (B-D) The cytotoxic activity of three HA-1 specific cytotoxic T cell clones 
(clones 1, 2 and 3) is shown against three different HLA-A2+/HA-1+ leukemic cells (closed 
squares, triangles and reverse triangles; acute lymphocytic lymphoma cells); HLA-A2+/
HA-1- leukemic cells (open circles) and autologous HLA-A2+/HA-1- CB PHA blasts (open 
diamonds or squares). 
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Figure 3. 
Direct isolation of HA-1 specific cytotoxic T cells from HLA-A2+/HA-1- cord blood
Results from three (A, B and C) HLA-A2+/HA-1- CB samples obtained from HLA-A2+/HA-1+ 
mothers are shown. (A-C) Analysis of cells collected after the first enrichment sort for HA-1A2 
tetramer and CD8+ cells. (D) CD45RA expression on HA-1A2 tetramer positive CD8+ cells 
(gate R1, filled histograms) and tetramer negative CD8+ cells (gate R2, open histograms) 
from CB samples A, B and C respectively. (E-G) CD8 and HA-1A2 tetramer staining of poly-
clonal cultures expanded after the enrichment sort followed by R1 sort of tetramer positive 
CD8+ cells from CB samples A, B and C respectively.  (H) Cytotoxic activity of culture G, 
after a second expansion phase, against various target cells: HLA-A2+/HA-1- EBV-LCL 
(squares); HLA-A2+/HA-1- EBV-LCL pulsed with HA-1H peptide (triangles); HLA-A2+/HA-1+ 
leukemic cells (reverse triangles); autologous HLA-A2+/HA-1- CB PHA blasts (diamonds) 
and K562 cells (circles). Insert in H shows the corresponding HA-1A2 tetramer staining.
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Isolation of circulating HA-1-specific T cells from HLA-A2+/HA-1- cord blood 
The presence of circulating HA-1 specific T cells was analyzed in eleven HLA-
A2+/HA-1- CB samples derived from seven HA-1+ mothers and from four HA-1- 
mothers. All eleven CB samples were stained with HA-1A2 tetramers and CD8 
antibodies, FACS sorted and non-specifically expanded, omitting any in vitro 
HA-1 specific stimulation. Subsequently, HA-1A2 tetramer analysis was per-
formed after 21 days of expansion. Cells isolated from all four HA-1- CB sam-
ples derived from HA-1- mothers failed to grow in vitro, despite a few detectable 
tetramer-staining CD8+ cells. The latter observed events are most likely due 
to background staining. Cord blood samples contain variable percentages of 
CD3-CD8+ NK cells and erythroblasts that display non-specific staining in our 
hands. The level of background tetramer staining depends on the degree of 
depletion of these cells by magnetic bead separation. Yet, a substantial number 
of cells isolated from three out of seven HA-1- CB samples derived from HA-1+ 
mothers stained with the HA-1A2 tetrameric complexes (figure 3A-C, gate R1) 
and expanded to sufficient numbers for tetramer analysis. A variable percent-
age (1-18%) of HA-1A2 tetramer staining CD8+ cells was observed at day 21 of 
non-specific expansion (figure 3E-G). Culture G was expanded non-specifically 
for another 14 days, which resulted in a further enrichment of tetramer posi-
tive CD8+ cells (40%, insert figure 3H). Functional analysis of the latter culture 
showed lysis of HLA-A2+/HA-1+ leukemic cells and HLA-A2+/HA-1- EBV-LCL 
pulsed with HA-1H peptide, while autologous HLA-A2+/HA-1- PHA blasts, 
HLA-A2+/HA-1- EBV-LCL and K562 cells were not lysed (figure 3H).
 CD45RA expression on CB CD8+ cells was determined directly after the 
first enrichment sort prior to in vitro culture (figure 3D). The majority of tetramer 
negative CD8+ cells (figure 3A-C, gate R2) expressed CD45RA (open histograms). 
In contrast, tetramer positive CD8+ cells (figure 3A-C, gate R1) from two of the 
three CB samples clearly expressed lower levels of CD45RA (filled histograms), 
suggesting a primed phenotype at the time of isolation. Thus, antigen-experi-
enced circulating T cells specific for maternal minor H antigen HA-1 can be 
detected in cord blood.
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Discussion
Our study demonstrates the presence of circulating HA-1 specific T cells in HLA-
A2+/HA-1- CB samples derived from children delivered by HLA-A2 matched 
but HA-1 mismatched mothers. We also show that HA-1 specific T cells can be 
generated ex vivo from HLA-A2+/HA-1- CB samples. CB-derived HA-1 specific T 
cells show the expected cytotoxic activity that includes lysis of HA-1+ leukemic 
cells. 
 The majority of unrelated CBT is performed with one or two HLA 
mismatched grafts as reviewed28. An inverse correlation between the number or 
type of HLA disparities and relapse risk was recently found29, suggesting that al-
loreactivity to mismatched HLA antigens contributes to GvL responses. The fact 
that minor H antigen specific cytotoxic T cells are generated across HLA haplo 
barriers and observed in fetal blood underlines the immunogenicity of the he-
matopoietic-specific minor H antigen HA-1. We speculate that pre-existing HA-1 
specific T cells may contribute to GvL reactivity upon CBT in HLA-A2+/HA-1+ 
recipients. Alternatively, HA-1 specific cytotoxic T cells can be generated ex vivo 
and stored for adoptive transfer in case of leukemic relapse.
 The alloreactive potential of cord blood is shaped during pregnancy by 
fetal-maternal interactions. Both fetal and maternal HLA alloreactive T cells are 
however subjected to immune regulatory mechanisms to prevent fetal reactivity 
towards maternal tissues or fetal rejection30-32. Despite the apparent immuno-
logical tolerance, normal precursor frequencies of cytotoxic and helper T cells 
specific for non-inherited maternal HLA antigens (NIMA) can be detected in 
cord blood21,33. Similarly, non-inherited maternal minor H antigens can prime 
fetal cytotoxic T cells, as shown in this study. Whether these T cells have any 
implications for the immunology of the maternal-fetal interface is subject of 
further studies.
 The tetramer positive CD8+ T cells directly sorted from two different 
CB samples clearly expressed lower levels of CD45RA than tetramer negative 
CD8+ T cells. Low CD45RA expression is indicative of recent antigen exposure, 
suggesting that HA-1 specific T cell priming has occurred in utero. Similar fetal 
CD8 T cell responses have been observed in case of maternal infections with T. 
cruzi or cytomegalovirus16,34, as well as allergen- or Epstein-Barr Virus-specific 
CD4+ T helper cells35-37. In line with these observations, our results demonstrate 
that also T cell priming for minor H antigens occurs in utero. This is a remarkable 
finding since allelic variants of minor H antigens can be considered as “modi-
fied self” in contrast to foreign viral antigens. The broadness of the autosomal 
encoded minor H antigen repertoire in CB samples needs to be investigated.
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 Maternal microchimerism is frequently found in CB samples38 and in 
newborn tissue39. Nucleated maternal cells have been found in the fetal circula-
tion as early as the second trimester of pregnancy40. Whether the presence of 
HA-1 cytotoxic T cells is associated with the presence of maternal HA-1 micro-
chimerism in the CB samples is as yet unknown. If so, we will analyze whether 
HA-1 is expressed by professional antigen-presenting cells, as we observed in 
another study41. If maternal cells persist, they could provide a continuous anti-
gen source of HA-1 that may maintain HA-1 specific cytotoxic T cells into adult 
life. This would explain the low but significant precursor frequencies of HA-1 
specific cytotoxic T cells that we observe in some healthy blood or stem cell 
donors (personal communication). Pre-existing cytotoxic T cell precursor fre-
quencies may facilitate the ex vivo generation of HA-1 specific T cells for adoptive 
immunotherapy. 
 Recipients of HLA-identical SCT have a poorer transplant outcome if 
the donor is female rather than male42,43. The explanation of this clinical ob-
servation is that pregnancy can lead to alloimmune responses. Over decades, 
several types of alloimmune responses, varying from immunization against 
erythrocyte- and HLA-specific antibodies44 to alloimmune responses against 
fetal paternal minor H antigens have been reported45. With regard to the latter, 
both autosomal and Y chromosome encoded minor H antigen responses have 
been observed12,24. Evidently, priming of fetal cells restricts itself to the autosomal 
minor H repertoire, since maternal cells lack the Y-chromosome encoded H-Y 
antigens. The absence of fetal anti H-Y priming, disadvantageous for female to 
male SCT, makes cord blood an attractive stem cell source for male patients.
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Abstract
Background and Objectives: Minor Histocompatibility antigen (mHag) specif-
ic graft-versus-leukemia reactivities are observed following unselected donor 
lymphocyte infusion for the treatment of relapse after HLA matched mHag 
mismatched stem cell transplantation (SCT). Adoptive transfer of donor-de-
rived ex vivo generated HA-1 specific oligoclonal T cells or HA-1 peptide patient 
vaccination are currently explored as curative tools for stem cell (SC) based 
immunotherapy of hematological malignancies. Another treatment modality to 
eradicate residual leukemic cells after SCT is the transfer of the HA-1 hemato-
poietic-specific T cell receptor (TCR) into cells of the SC donor. This strategy 
would be particularly useful in case of relapse after cord blood transplantation 
(CBT) and is explored in the underlying study. 
 Design and Methods: HLA-A2- adult and cord blood PBMC were 
transduced with the genes encoding the HA-1 - and  TCR chains derived 
from established HA-1 specific CTL clones. 
 Results: The HA-1 TCR transduced T cells showed consistent marker 
gene expression, but low staining with HLA-A2/HA-1 tetrameric complexes. 
The HA-1 TCR transduced T cells showed hematopoietic-restricted cytolytic 
activity against HLA-A2+/HA-1+ target cells, including leukemic cells.
 Interpretation and Conclusions: Low level of HA-1 specific tetramer 
staining of HA-1 TCR transduced T cells may be caused by hybrid TCR 
formation of the transferred TCR and - chains with endogenous TCR and 
- chains. This may cause unwanted alloreactivity and requires attention. The 
HA-1 TCR transduced T cells show that the HA-1 TCR can be functionally 
transferred into donor PBMC, which can be exploited in immunotherapeutic 
settings of SCT and CBT for hematological malignancies. 
Introduction
The minor Histocompatibility antigen (mHag) HA-1 is a polymorphic antigen 
that is presented in the context of HLA-A21. The tissue distribution of HA-1 is 
restricted to hematopoietic cells and carcinomas2,3. It therefore can function as 
a tumor target antigen for stem cell (SC) based immunotherapy of malignan-
cies. In an HLA matched HA-1 mismatched SCT setting for hematological ma-
lignancies, T cells from the HA-1- SC donor can recognize HA-1 expressed by 
the patient’s leukemic cells4. In vivo and in vitro generation of HLA-A2 restricted 
HA-1 specific CTLs have previously been reported5,6. T cells expressing the HA-1 
specific TCR can be monitored by staining PBMC with HLA-A2/HA-1 tetra-
mers7 and by TCRBV spectratyping8. Both in vitro and in vivo generated HA-1 
specific T cell clones analyzed so far exclusively use the TCR BV7S9 variable 
domain in combination with different TCR BD, BJ, TCR AV and AJ regions8,9. 
The CDR1 region of the TCR BV does however not seem to play a major role in 
the interaction with the HLA-A2/HA-1 ligand10.
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 Donor lymphocyte infusion (DLI) with HA-1 specific CTLs generated 
from adult and cord blood donor cells provides a feasible treatment for relapsed 
HLA-A2+/HA-1+ leukemia patients6,11. Ex vivo CTL induction and expansion for 
adoptive immunotherapy is however time-consuming and not successful in all 
SC donors. Gene transfer of the HLA-A2 restricted HA-1 specific TCR into do-
nor T cells may provide an alternative treatment strategy. Several studies have 
described the transmission of various antigenic specificities by TCR transfer12-15. 
We earlier reported on the successful gene transduction of the TCR specific 
for the mHag HA-2 into peripheral T lymphocytes16,17. Since the hematopoietic 
specific HA-1 antigen is additionally expressed on a series of epithelial carci-
nomas3,18, we studied the feasibility of  HA-1 TCR gene transfer into peripheral 
blood cells derived from adult or CB donors. We chose to transfer the HA-1 
TCR specificity into HLA-A2- donor T cells which enables usage of the HA-1 
specific immunotherapy in HLA mismatched SCT settings. The HA-1 TCR and 
- genes used for transduction were derived from two established HA-1 specific 
HLA-A2 restricted T cell clones 3HA15 and 5W38, previously isolated from dif-
ferent patients after HLA-identical SCT5. Both clones expressed the same TCR 
BV7S9, but different TCR AV chains. The individual genes encoding the - and 
 TCR chains of both CTL clones were cloned into retroviral vectors and speci-
ficity and functional studies on TCR transduced adult and cord blood CD8+ T 
cells were performed.
Materials and Methods
Construction of retroviral vectors and generation of retroviral supernatant
Total RNA from the mHag HA-1 specific HLA-A2 restricted T cell clones 3HA15 
and 5W38 was extracted using Trizol (Gibco, Carlsbad, CA). The mRNA was 
reverse transcribed into single-strand cDNA by reverse transcriptase using oli-
go dT primers (Pharmacia, Uppsala, Sweden). Using primers that cover the 
complete repertoire of known TCR chains, TCR and - usage of the two 
clones was determined. Both T cell clones expressed the TCR BV7S9, as previ-
ously described8,9. T cell clone 5W38 expressed the TCR AV10S1; clone 3HA15 
expressed two in frame TCR chains, TCR AV32 and TCR AV3S1 (data not 
shown). Pilot experiments revealed that TCR AV3S1, in combination with TCR 
BV7S9, forms the functional HA-1 specific HLA-A2 restricted TCR of CTL clone 
3HA15. Two bicistronic retroviral vectors based on the pLZRS backbone19 were 
used, containing an internal ribosome entry site (IRES) and the marker gene 
enhanced green fluorescent protein (pLZRS-eGFP)20 or a truncated form of the 
nerve growth factor receptor (pLZRS-dNGF-R)21. The individual genes encod-
ing the - and  TCR chains were PCR amplified using primers containing 
relevant restriction sites and cloned into the pLZRS-vectors. The 5’ forward 
primer sequences used were ATTGAATTCAGAAGAATGGAAACTCTC contain-
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ing the EcoRI restriction-site for the TCR AV3S1 chain, CGCGGATCCACCAT-
GGTCCTGAAATTCTCCG containing the BamHI restriction-site for the TCR 
AV10S1 chain, TATGGATCCCTGCCATGGGCACCAG containing the BamHI 
restriction-site for the 3HA15 TCR BV7S9 chain and TAGAGAATTCCACCAT-
GGGCACCAGTCTCCTATGC containing the EcoRI restriction-site for the 5W38 
TCR BV7S9 chain. The 3’ reverse primer sequences used were TATCTCGAGA-
TAAATTCGGGTAGGATC containing the XhoI restriction-site for both TCR AV 
chains, GGTGTCGACTGGGATGGTTTTGGAG containing the SalI restriction-site 
for the 3HA15 TCR BV7S9 chain and CCGGAATTCAGAAATCCTTTCTCTGACC 
containing the EcoRI restriction-site for the 5W38 TCR BV7S9 chain (Euro-
gentec, Seraing, Belgium). The TCR AV3S1 chain of 3HA15 was cloned into the 
pLZRS-dNGF-R vector, while the 3HA15 TCR BV7S9 chain was cloned into 
the pLZRS-eGFP vector. The TCR AV10S1 chain of clone 5W38 was cloned 
into the pLZRS-eGFP vector, whereas its TCR BV7S9 chain was cloned into the 
pLZRS-dNGF-R vector. Retroviral vectors encoding eGFP or dNGF-R without 
additional insert were used as control (mock) vectors in the experiments. Con-
trol cycle sequencing was performed after which the constructs were transfected 
(0.66 µg/ml) into the amphotropic phoenix packaging cell line (kindly provided 
by G. Nolan, Stanford University School of Medicine, Stanford, CA) using the 
calcium phosphate transfection kit (Life Technologies, Gaithersburg, MD). The 
phoenix cells were cultured in Iscove’s modified Dulbecco’s medium (IMDM) 
supplemented with 10% FCS. Two days following transfection, 2 µg/ml puro-
mycin (Clonotech Laboratories, Palo Alto, CA) was added and 10 to 14 days 
later 20 x 106 cells were plated per 150 cm2 culture flask (Beckton Dickinson, San 
Jose, CA) in fresh medium without puromycin. The following day the medium 
was refreshed and 24 hours thereafter retroviral supernatant was harvested, 
centrifuged, and frozen in aliquots at -70°C.
Retroviral transduction of TCR deficient Jurkat cells
Prior to transduction of donor T cells, Jurkat clones deficient for TCR (-/-) 
or TCR (-/-) or for both chains (-/-), clone 3, clone 4, and clone 76 respec-
tively16, were transduced using the various viral supernatants according to the 
procedure described below. At day three, correct expression of transduced TCR 
and/or - chains was confirmed by measuring the TCR expression by FACS 
analysis, using PECy5 conjugated anti-TCR moab (Pharmingen, San Diego, 
CA).
Isolation and retroviral transduction of T cells derived from adult- or cord blood
PBMC isolated from HLA-A2- adult or cord blood donors were stimulated with 
800 ng/ml phytohemaglutinin (PHA) and 25 U/ml IL-2 (Cetus, Emeryville, CA) 
in IMDM containing 10% human serum (HS) at a concentration of 1 x 106/ml. 
After 2 days of culture, T cells were transduced with retroviral supernatant us-
ing recombinant CH-296 human fibronectin fragments22 (Retronectin, Takara, 
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Otsu, Japan). Briefly, 0.5 x 106 T cells per well were cultured overnight at 37°C 
together with 0.25 ml TCR- and 0.25 ml TCR retroviral supernatant and 0.5 
ml of fresh IMDM containing 10% fetal calf serum (FCS) and 25 U/ml IL-2 in 
non tissue culture treated CH-296-coated 24-well plates16. Next, the cells were 
washed and transferred to tissue culture treated 24-wells plates at a concentra-
tion of 0.5 x 106 cells per well in IMDM containing 10% HS and 25 U/ml IL-2.
Flow cytometric analysis and fluorescence-activated cell sorting
Transduction efficiencies were measured 3-5 days after transduction by the ex-
pression of the markers eGFP and dNGF-R. T cells positive for both markers 
and negative for CD4 were sorted at 1 or 25 cells/well by fluorescence-activated 
cell sorting using a FACSVantage (Becton Dickinson). PE-conjugated and PECy5-
conjugated antibodies (Pharmingen) were used to detect dNGF-R expression 
and CD4 expression respectively. FACS sorted cells were restimulated with 
30 Gy irradiated randomly selected PBMC, 50 Gy irradiated HLA-A2+/HA-1+ 
EBV-LCLs, 25 U/ml IL-2 and 800 ng/ml PHA.
Tetramer staining and cytotoxicity assay
Expression of the TCR specific for HLA-A2/HA-1 complexes was measured 
by staining the cells with PE-conjugated HLA-A2/HA-1 tetrameric complexes 
(HA-1A2), either or not in combination with APC-conjugated CD8 antibodies 
(BD Biosciences, Amsterdam, The Netherlands). Tetramers were generated and 
validated as previously described7.
 CTL activity was measured in a chromium release assay. HLA-A2+ EBV-
LCLs either positive or negative for HA-1 were used as target cells. Peripheral 
blood or bone marrow containing more than 95% morphologically recogniz-
able malignant cells derived from HLA-A2+ chronic myeloid leukemia (CML) 
patients were used as leukemic target cells. HLA-A2+ fibroblasts derived from a 
HA-1+ donor were used to test hematopoietic-restricted specificity of HA-1 TCR 
transduced T cells. Fibroblasts were treated for 24 hours with 250 U/ml IFN 
and TNF before incubation with effector cells. Target cells were pulsed with 
1 µM HA-1H peptide (VLHDDLLEA) where indicated. Chromium labeled target 
cells were added to various numbers of effector cells and were cultured for 4 or 
18 hours at 37°C. Supernatant was harvested and measured in a luminescence 
counter (Topcount-NXT; Packard, Meriden, CT). The mean percentage specific 
lysis of triplicate wells was calculated using the following formula: 
(Experimental release-Spontaneous release) / (Maximal release- Spontaneous release) x 100%.
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Results
TCR cell surface expression following retroviral transduction into Jurkat cells
Retroviral vectors encoding the different TCR or  chains derived from HA-1 
specific CTL clones 3HA15 or 5W38 were transduced into various Jurkat cells. 
The cell surface expression of the transduced TCR gene products was ana-
lyzed. The TCR deficient Jurkat cells (see Materials and Methods) transduced 
with the HA-1 TCR chain from either HA-1 specific CTL clone 3HA15 (figure 
1A) or 5W38 (data not shown) expressed TCR complexes at the cell surface. 
Similarly, the TCR deficient Jurkat cells (see Materials and Methods) trans-
duced with the HA-1 TCR chain from either HA-1 CTL clone 3HA15 or 5W38 
expressed TCR complexes at the cell surface. These data demonstrate that the 
retrovirally transduced HA-1 TCR chains as well as the HA-1 TCR chains can 
pair with the endogenous Jurkat TCR chains respectively. However, some HA-1 
TCR chain transduced Jurkat cells did not express the HA-1 TCRs or expressed 
TCRs at a low level. Transduction of both the HA-1 TCR and - chain of the 
two different HA-1 CTL clones into TCR deficient Jurkat cells resulted into 
intact HA-1 TCR cell surface expression (data not shown). Thus, the indi-
vidual HA-1 TCR chains pair with each other and are able to form stable TCR 
complexes at the cell surface.
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Figure 1.
TCR cell surface expression upon transfer of HA-1 TCR and TCR chain encoding genes 
into Jurkat cells and adult T cells
TCR or - deficient Jurkat cells (A) or peripheral blood-derived adult T cells (B) were 
transduced with HA-1 TCR and  chains from CTL clone 3HA15. Intact TCR expres-
sion is shown as filled histogram plots. Open histograms represent marker gene positive 
mock-transduced Jurkat cells. HA-1 TCR or mock-transduced adult T cells double 
positive for eGFP and dNGF-R expression were FACS sorted (indicated by arrow), ex-
panded and stained with HA-1A2 tetrameric complexes.
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Transduction of the HA-1 TCR chains into adult peripheral blood-derived T cells
The TCR and - chain derived from the HA-1 specific CTL clones 3HA15 
and 5W38 were transduced into PBMC isolated from various HLA-A2- adult 
donors. The transduction efficiency of the HA-1 TCR chains varied between 
14-23%, whereas the transduction efficiency of the HA-1 TCR chains varied 
between 27-35%. T cells isolated from adult PBMCs that were negative for CD4 
and expressed both marker genes (6-10%) were FACS sorted and expanded (see 
Materials and Methods). Despite stable expression of the marker genes eGFP 
and dNGFR (data not shown), only low numbers of HA-1 TCR transduced 
adult T cells stained specifically with HA-1A2 tetramers (figure 1B).
Functional analysis of HA-1 TCR transduced adult peripheral blood-derived T cells
The HA-1 TCR transduced T cells were subsequently analyzed for their func-
tional activity and specificity. The cytolytic activities of 3HA15 TCR trans-
duced T cells from one representative donor are depicted in figure 2. The 3HA15 
or 5W38 TCR transduced T cells specifically lysed HLA-A2+/HA-1- EBV-LCL 
target pulsed with HA-1 peptide and importantly, the natural ligand expressing 
HLA-A2+/HA-1+ EBV-LCL target cells. Compared with the original CTL clone 
3HA15 analyzed in parallel, the HA-1 TCR transduced T cells required a 
prolonged incubation time to lyse HA-1 expressing target cells. After 4 hours 
of effector and target cell incubation, HA-1 TCR transduced T cells showed 
specific lysis of target cells pulsed with HA-1 peptide, but no lysis on the natural 
ligand. After 18 hours of incubation, HA-1 TCR transduced T cells displayed 
strong and specific lytic capacities on both the peptide loaded and the natural 
ligand target cells comparable to the original CTL clones. The mock-transduced 
bulk population did not lyse any of the target cells. 
 Next, we tested the lysis of leukemic targets by 3HA15 or 5W38 TCR 
transduced T cells (figure 3). Short term expanded HA-1 TCR transduced T 
cells lysed HA-1 expressing leukemic cells, but not HA-1- leukemic cells, after 
4 hours of incubation. Specific and much stronger lysis was observed after 18 
hours of incubation. Similar results were obtained when HA-1 expressing EBV-
LCL target cells were used (data not shown). In line with the results on bulk 
HA-1 TCR transduced T cells, short term expanded HA-1 TCR transduced 
T cells stained low but specifically with HA-1A2 tetramers.
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Figure 2. 
Functional analysis of HA-1 TCR transduced adult T cells
The HA-1 specific cytotoxic activity of HA-1 TCR transduced T cells (C,D) and mock-
transduced T cells (E,F) is shown after 4 and 18 hours of incubation. The original CTL 
clone 3HA15 was tested in parallel (A,B). Target cells: HA-1- EBV-LCL (open dots), HA-1- 
EBV-LCL pulsed with HA-1 peptide (filled squares) and HA-1+ EBV-LCL (filled triangles).
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Figure 3. 
Recognition patterns of HA-1 TCR transduced adult T cells against leukemic cells
HA-1 specific lysis of two representative HA-1 TCR transduced T cell clones was mea-
sured after 4 or 18 hours of effector/target cell incubation at an E:T ratio of 10:1. The origi-
nal HA-1 specific CTL clones 3HA15 and 5W38 were analyzed in parallel. The horizontal 
lines in the left figures represent the background lysis by mock-transduced T cells tested in 
parallel.  Target cells: HA-1+ chronic myeloid leukemia cells (CML, filled bars), HA-1- CML 
cells (open bars). Corresponding HA-1A2 tetramer staining of the 3HA15 and 5W38 HA-1 
TCR transduced T cell clones is shown.
Transduction of the HA-1 TCR chains into cord blood-derived T cells
The TCR and  chains derived from the HA-1 specific CTL clone 3HA15 were 
transduced into PBMC isolated from various HLA-A2- CB donors. The trans-
duction efficiencies of both the TCR and the TCR chains were in the same 
range as observed with adult derived PBMC (15-40%). HA-1 TCR transduced 
CB derived T cells (4-20%) were FACS sorted (depleted for CD4+ T cells) and 
expanded. HA-1 TCR transduced CB T cells displayed low HA-1A2 tetramer 
staining comparable to the HA-1 TCR transduced adult T cells described 
above (data not shown).
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Functional analysis of HA-1 TCR transduced cord blood-derived T cells
The HA-1 TCR transduced CB T cells were subsequently analyzed for their 
hematopoietic-specific lytic capacities (figure 4). HA-1 TCR transduced CB T 
cells lysed HLA-A2+/HA-1+ leukemic cells and EBV-LCL target cells that were 
either pulsed with HA-1 peptide or naturally expressed HA-1. Similar to the 
results obtained with the HA-1 TCR transduced adult T cells, specific and 
strong lysis of HA-1 expressing target cells required prolonged incubation of 
effector and target cells. The original HA-1 specific CTL clone 3HA15 and the 
mock-transduced T cells were analyzed in parallel. Mock-transduced T cells did 
not lyse any of the target cells.
 Besides the recognition of the relevant EBV-LCL and leukemia cells, 
the HA-1 TCR transduced CB T cells were analyzed for their hematopoietic-
restricted specificity (figure 4B). HA-1 TCR transduced CB T cells did not 
lyse fibroblasts derived from an HLA-A2+/HA-1+ donor, whereas these target 
cells were recognized by an allo HLA-A2 specific T cell clone tested in parallel. 
The same fibroblasts pulsed with HA-1 peptide were efficiently lysed by HA-1 
TCR transduced CB T cells. Herewith, the recognition pattern of the HA-1 
TCR transduced CB T cells is indicated to be restricted to hematopoietic sys-
tem specific cells. 
 Collectively, these results show that HA-1 TCR transfer into HLA-A2- 
adult or into HLA-A2- CB T cells results in functional cytotoxic T cells that dis-
play specific reactivity against HLA-A2+ HA-1 expressing target cells including 
leukemic cells.
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Figure 4.
Functional analysis of HA-1 TCR transduced cord blood T cells 
(A) HA-1 specific lysis by HA-1 TCR transduced CB T cells and by mock-transduced 
CB T cells are shown after 18 hours of incubation. The original HA-1 specific CTL clone 
3HA15 was tested in parallel. Target cells: HA-1- EBV-LCL (open dots), HA-1- EBV-LCL 
pulsed with HA-1 peptide (filled squares), HA-1+ EBV-LCL (filled triangles), HA-1- CML 
cells (open diamonds) and HA-1+ CML cells (asterisks). (B) Hematopoietic restricted lysis 
by HA-1 TCR transduced CB T cells is shown after 4 and 18 hours of effector/target 
cell incubation. A control allo HLA-A2 specific CTL clone was tested in parallel. Target 
cells: fibroblasts (filled squares) and fibroblasts pulsed with HA-1 peptide (open squares). 
The fibroblasts are derived from an HLA-A2+/HA-1+ donor.
Discussion
We studied the feasibility of transferring the HA-1 TCR and - chain encoding 
genes into HLA-A2- adult and into HLA-A2- CB T cells and analyzed the HA-1 
TCR transduced T cells for their antigen-specific lytic potential. We here show 
that these HA-1 TCR transduced HLA-A2- adult and CB T cells can indeed 
acquire HA-1 specific and lytic activity. The feasibility of the functional HA-1 
TCR transfer into HA-1 TCR negative cells lays the basis for a potential 
broad spectrum of applications in SC based immunotherapy of hematological 
malignancies and solid tumors. It is worthwhile mentioning that besides the 
hematopoietic-restricted specificity, HA-1 is also expressed on epithelial cancer 
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cells. Moreover, our results set the stage for broadening the use of the immu-
nodominant and hematopoietic specific mHag HA-1 to the HLA mismatched 
SCT setting. It should be noted however that although the specific functional 
activity of the HA-1 TCR can indeed be transferred, significant improvements in 
transduction efficiency, HA-1 TCR avidity for its ligand and relevant expansion 
of HA-1 TCR transduced T cells need to be established before HA-1 TCR 
transduced T cells can be therapeutically applied.
 Endogenous TCR, transduced TCR and hybrid TCR possibly compete 
for CD3 association and therewith for functional cell surface expression23. This 
feature may explain the lack of correlation between the intensity of double mark-
er expression and the cell surface expression, as measured by HLA-A2/HA-1 
specific tetramers, of stable HA-1 specific TCR complexes following transduc-
tion. The presence of other TCRs on the cell surface may also hamper HA-1 TCR 
clustering, lipid raft formation24,25 and rapid activation upon antigen encounter. 
Moreover, the granzyme depot and thus the intrinsic cytolytic capacity of the 
TCR transduced T cells may be inferior compared with the non-transduced CTL 
clones. We also noticed that HA-1 TCR transduced T cells generally require 
more time than the original non-transduced HA-1 specific CTL clones to lyse 
their target cells. We encountered the same phenomenon of low tetramer stain-
ing and ‘slow’ but antigen-specific lysis in our earlier study using HA-2 specific 
TCR transfer16. A single chain construct containing both the TCR and  chains 
combined with strategies that can prevent the formation of hybrid TCR or sup-
press endogenous TCR expression23 is necessary to improve functional HA-1 
TCR transfer. Improved gene expression may be obtained with more effective 
retroviral vector systems26 or a lentiviral-based transduction procedure. Hybrid 
pairing of the different TCR and  chains following retroviral transduction 
may also result in the formation of new TCRs of unknown specificities23. It 
is clear that the above mentioned, as yet unsolved, processes need extensive 
additional analyses before in vivo transfer with TCR transduced T cells can be 
executed. Serious attention should be focused on the potential risks of Graft-
versus-Host-Disease (GvHD) as well as undesired autoimmune reactions that 
may occur upon adoptive transfer of TCR modified T cells. Suicide gene control 
of the ex vivo HA-1 TCR transduced T cells may be included to potentially 
control undesired alloreactivity27,28.
 Foremost, HA-1 TCR transfer may be of special use in the setting of 
CBT. Currently, a treatment for relapsed hematological malignancies after CBT 
is lacking. Cord blood is obtained anonymously and the number of donor 
lymphocytes for the purpose of DLI is far too little. CBT is usually performed 
with 1-2 HLA mismatched grafts29. HLA disparity is however not significantly 
associated with a higher risk of GvHD in this transplantation modality. HA-1 
specific TCR transfer into cryopreserved HLA-A2- CB T cells may be a strat-
egy requiring low numbers of donor cells for immunotherapeutical purposes 
for HLA-A2 positive patients. A universal option would be to generate ‘prefab’ 
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HA-1 TCR transduced T cells derived from HLA-A2- CB donors who have 
frequent HLA-homozygous haplotypes. HLA-A2+ patients who match the re-
maining HLA typing of the CB donor can be treated with these ‘off the shelve’ 
HA-1 TCR transduced T cells. 
 In summary, our results provide the proof of principle that transfer 
of the HA-1 specificity into HA-1 TCR negative cells is feasible. Current studies 
focus on the generation of sufficient numbers of HA-1 TCR transduced CB T 
cells with high ex vivo expansion potential and lytic capacity. 
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Future of minor histocompatibility antigen HA-1 
directed immunotherapy
The minor histocompatibility (mH) antigen HA-1 is an important target antigen 
for the induction of a graft versus leukemia (GvL) response with a low risk of 
graft versus host disease (GvHD). Applying HLA-A2/HA1H specific cytotoxic T 
cells (CTLs) as cellular immunotherapy for relapsed leukemia is an option for 
HLA-A2 HA-1H patients transplanted with HLA-A2 HA-1RR donor stem cells.1,2 
Currently this adoptive immunotherapy is however not available for patients 
not expressing HLA-A2 and further depends on the presence of recipient-donor 
disparity for HA-1. The studies in this thesis were designed to extend the patient 
population that can benefit from HA-1 specific immunotherapy in the future. A 
number of options have been studied.
 First, we examined several possible causes for the absence of cell surface 
HLA-A2/HA-1R expression in order to evaluate the option of HA-1R directed 
immunotherapy. Secondly, we investigated whether the HA-1H/R polymorphic 
region contains peptides that can be presented by MHC class I molecules other 
than HLA-A2. Furthermore, we explored the feasibility of generation of HA-1H 
specific HLA-A2 restricted CTLs from umbilical cord blood (UCB). Finally, we 
investigated whether HA-1 specific TCR transfer may be a useful alternative 
strategy to generate HA-1H specific HLA-A2 restricted adult- or UCB CTLs. Here 
I will discuss the results of this thesis and the possible future of HA-1 directed 
immunotherapy.
7.1 HA-1 peptides potentially suitable for HA-1 
directed immunotherapy
7.1.1 Immunogenic potential of the HLA-A2/HA-1R counterpart
Thus far, HA-1H specific adoptive immunotherapy has been suggested as a fea-
sible option for HLA-A2 HA-1H positive patients who relapsed following a stem 
cell transplantation (SCT) from an HLA-A2 HA-1H negative donor1-3. In theory, 
the reciprocal immunogenicity of the HA-1R allele would also provide an im-
munotherapy option for HLA-A2 HA-1R positive patients who relapsed follow-
ing a SCT from an HLA-A2 HA-1R negative donor. Currently, HLA-A2 HA-1R 
homozygous patients are no candidates for HA-1 specific immunotherapy. Of 
the HLA-A2 positive population 30% is HA-1R homozygous4. The additional 
option of HA-1R specific adoptive immunotherapy would thus mean a consid-
erable expansion of the patient population that can benefit from HA-1 specific 
immunotherapy, providing that an HLA matched HA-1R negative donor is avail-
able. CTLs directed against HA-1R in the context of HLA-A2 have been gener-
ated5. However, these CTLs were only responsive to HLA-A2 positive target cells 
pulsed with the HA-1R peptide. Target cells positive for HA-1R were not recog-
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nized. This may be explained by the fact that the HA-1R peptide is not naturally 
expressed on the cell-surface since peptide elution studies did not detect HA-1R 
cell-surface expression in the context of HLA-A26. It has been demonstrated 
that the HA-1R peptide binds with ten-fold lower HLA-A2 binding affinity as 
compared with the HA-1H peptide6. However this ten-fold difference is unlikely 
to solely account for the absence of HA-1R on the cell-surface. Furthermore, the 
low binding affinity of the HA-1R peptide does not per se result in low HA-1R 
cell-surface expression since MHC-peptide binding affinities are not directly re-
lated to the cell-surface density of the peptide7. In addition, low affinity peptides 
can still represent important T cell epitopes8,9. Therefore, as described in chapter 
2, we studied mechanisms involved in HLA-A2/HA-1R expression in order to 
thoroughly evaluate the option of HA-1R directed immunotherapy. We showed 
that the intracellular processing mechanisms that we have tested did not in-
terfere with the generation or expression of the HA-1R peptide, and were thus 
not responsible for the absence of this peptide on the cell-surface. We found 
however, that the HLA-A2/HA-1R complex was extremely instable, which can 
explain the complete absence of HLA-A2/HA-1R on the cell-surface. Stability 
of MHC-peptide complexes has been demonstrated as an important parameter 
for their immunogenicity10. Therefore, even if this peptide was shortly displayed 
on the cell surface (which could not be detected by biochemical methods), im-
munotherapy directed against HLA-A2/HA-1R is not a feasible option. 
 However, since the HA-1R antigen is processed correctly it could pos-
sibly be naturally expressed on the cell surface in the context of other MHC 
class I molecules. In that case HA-1R could still be capable of triggering HA-1R 
specific CTLs in vivo, necessary for HA-1R directed immunotherapy.  
7.1.2 Expansion of the MHC class I associated HA-1 epitope 
pool
Approximately 45% of the Caucasian population expresses HLA-A211 and is 
thus a potential candidate for HA-1 directed immunotherapy. Of the HLA-A2 
positive population 16% is HA-1H homozygous and 54% is HA-1 heterozygous, 
whereas 30% is HA-1R homozygous4. This suggests that approximately 5% of 
the Caucasian patient population could be candidates for HA-1H specific immu-
notherapy, since 32% of the Caucasian population is both HLA-A2 and HA-1H 
positive and 14% of the population can serve as an HLA-A2 matched HA-1RR 
stem cell donor. The percentage potential candidates for HA-1 specific therapy 
could be increased if the option of HA-1 specific immunotherapy also becomes 
available for patients not expressing HLA-A2. To this end HA-1 epitopes, either 
from the HA-1H or from the HA-1R allele, presented by other MHC class I mol-
ecules need to be identified. The option of HA-1 specific immunotherapy may 
be extended to a large population if HA-1 epitopes are identified that are pre-
sented by highly prevalent MHC class I molecules11. Several cellular processes 
are involved in the formation of an immunogenic epitope. First, the antigenic 
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peptide needs to be correctly processed. Secondly, this peptide should be trans-
located into the endoplasmatic reticulum (ER) were it binds an MHC molecule. 
Subsequently, the MHC-peptide complex stability is an important factor for 
epitope immunogenicity. 
 In order to predict which HA-1 peptides containing the polyporphism 
are naturally cleaved and presented, several peptide processing prediction pro-
grams12 may be used. Some investigators solely rely on the predictions by these 
programs13, however, in chapters 2 and 4 we show that this approach is not 
sufficient. The HA-1R epitope VLRDDLLEA and several other putative HA-1 
epitopes containing the R polymorphism, were properly cleaved by protea-
somes although the PAProc program predicted these epitopes to be destroyed 
by an intra-peptide cleavage site. This can be explained by the fact that once 
the relevant peptides are generated by proteasomal cleavage, other cleavage sites 
within the epitope may be missed14. 
 In order to predict which HA-1 peptides may actually be presented by 
MHC class I molecules, several helpful MHC-peptide binding prediction algo-
rithms15-17 (http://bimas.dcrt.nih.gov./; http://syfpeithi.bmi-heidelberg.com/) are 
available. However, these prediction programs still have significant shortcom-
ings. The contributions to binding of each possible amino acid in every position 
of the peptide are still only partly defined. Therefore, cognate T cell mH epitopes 
do not always confirm the predicted MHC class I binding motifs18,19. Molecular 
modeling systems may partly solve these shortcomings20,21, but actual MHC-
peptide binding experiments remain indispensable to confirm the predictions 
(chapter 3)22. In order to be able to experimentally test the binding capacities of 
various MHC class I-peptide complexes, we developed easy to perform, reliable 
competition-based cellular peptide binding assays for 13 prevalent MHC class I 
alleles, as described in chapter 3. Other peptide binding assays employing either 
cell-bound MHC class I molecules23-28 or solubilized MHC class I molecules29-32 
are available. Nevertheless, the competition-based cellular peptide binding assay 
described in chapter 3 was preferred since there is no need to purify HLA class 
I molecules, or to transfect cells with HLA class I molecules, and no radioactive 
label is used. Moreover, large panels of HLA-typed human B-cell lines are avail-
able as tools for peptide binding to a vast array of HLA molecules.  
 In addition to proper peptide cleavage and MHC-peptide binding, the 
stability of the MHC-peptide complex is an important factor in natural antigen 
presentation. As revealed in chapter 2, rapid MHC-peptide dissociation may re-
sult in the absence of antigen cell surface expression. The peptide configuration 
in context with the MHC class I molecule appears to play an important role in 
MHC-peptide complex-stability33. Therefore, molecular modeling systems may 
be of predictive value20,21. However, dissociation experiments will have to con-
firm the predictions. Finally, before suggesting a newly revealed naturally ex-
pressed HA-1 antigen as an epitope for use of immunotherapy, its immunogenic 
potential needs to be defined. 
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 In chapter 4 we used competition-based cellular peptide HLA binding 
assays to screen all possible HA-1H and HA-1R polymorphic peptides for HLA 
binding. We describe HLA-A3 binding HA-1 peptides and HLA-B60 binding 
HA-1 peptides. Since HA-1 peptide binding to HLA-A3 was weak and instable 
these peptides were unlikely to form HLA-A3 restricted HA-1 epitopes. We 
discovered, however, the HLA-B60 restricted HA-1H peptide KECVLHDDL as a 
novel potential HA-1 T cell epitope. 
 Immunogenic potential of the HA-1R counterpart in HLA-B60 was not 
confirmed although the HA-1R peptides bound equally well and equally stable 
to the HLA-B60 molecule as the HA-1H peptides. T cell lines induced with HLA-
B60 binding HA-1R  peptide recognized HA-1R peptide pulsed HLA-B60 positive 
target cells but not the non-pulsed target cells positive for HLA-B60/HA-1R. 
It is possible that these CTLs are of low affinity. Using antigen presenting cells 
(APCs) that are transduced with HA-1R may increase the success-rate of high 
affinity CTL induction compared with using APCs that are pulsed with HA-1R 
peptide34. It is also possible that the naturally expressed HLA-B60/HA-1H com-
plex acts as an altered peptide ligand to antagonize the high avidity HLA-
B60/HA-1R–specific T cells35. The antagonistic complex may also cause negative 
selection of the high avidity HA-1R specific T cells in the thymus of the HLA-
B60/HA-1HH donor36,37. Alternatively, similar to the HLA-A2/HA-1R ligand, the 
HLA-B60/HA-1R ligand may not be expressed on the cell surface. Proteasome 
cleavage results in combination with the stable binding of the KECVLRDDL 
peptide to HLA-B60 suggest that the HLA-B60/HA-1R complex fulfils several 
criteria to be expressed on the cell surface. However, we have not studied other 
intracellular processing mechanisms, such as TAP-mediated translocation into 
the ER38 and TAP-associated binding39. Unfortunately, as yet HLA-B60 HA-1 
peptide elution experiments failed to show the presence of the HLA-B60/HA-1H 
or HA-1R peptide on the cell surface. Nevertheless, T cells specific for naturally 
expressed HLA-B60/HA-1H were induced. Thus only the  actual induction of T 
cells specific for naturally expressed HLA-B60/HA-1R would  indeed prove the 
natural immunogenicity of the KECVLRDDL peptide. To this end, as previously 
mentioned,  using HA-1-transduced DCs instead of peptide-pulsed DCs as APC 
may provide a more efficient CTL induction protocol. cDNA-transduced DCs 
result in natural processing and constitutive expression of mH antigen HA-1, 
which is more effective than peptide-pulsed DCs in the generation of HA-1-
specific CTLs34.
 Perhaps other not yet identified MHC class I/HA-1R complexes are 
naturally expressed on the cell-surface in a stable fashion which may be capable 
of triggering an immune response from HA-1R specific CTLs. However, since we 
tested the binding of all overlapping nonameric HA-1 peptides containing the 
H to R polymorphism to 11 prevalent MHC class I molecules, it is unlikely that 
additional MHC class I restricted HA-1H or HA-1R epitopes will be revealed. 
Moreover, possibly not the H to R polymorphism itself but the resulting ab-
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sence of the HA-1R counterpart on the cell surface is what causes the immu-
nogenicity of the HA-1H epitope. In that case the HA-1H and HA-1R antigens 
will not act as different epitopes. Therefore, the recently reported additional 
polymorphisms found within the HA-1 locus (http://www.ncbi.nlm.nih.gov/
SNP/snp_ref.cgi?locusId=23526) form an interesting new field of investigation. 
Perhaps these additional D to E or G to S polymorphisms result in additional 
allelic counterparts of HA-1. MHC class I restricted HA-1 peptides containing 
these polymorphisms may act as additional HA-1 epitopes, which may provide 
the option of HA-1 directed immunotherapy for patients negative for HA-1H 
and/or expressing other MHC class I phenotypes. 
7.2 HA-1 directed immunotherapy following UCB 
SCT
Umbilical cord blood (UCB) SCT is becoming a popular alternative treatment 
in case of hematological malignancies when no HLA identical SCT donor is 
available40-43 since reduced severity and reduced incidence of GvHD are ob-
served40,41,44-47. Furthermore, relapse rates following UCB SCT do not seem to be 
higher than relapse rates following adult SCT41. However, if leukemia patients 
relapse after UCB transplantation, donor cells are not available since the anony-
mous UCB donors cannot be traced. As a consequence these patients cannot 
be treated with donor lymphocyte infusion (DLI) or adoptive immunotherapy. 
Thus HA-1H specific HLA-A2 restricted adoptive immunotherapy is not yet a 
feasible option for patients who received an UCB SCT. Even if UCB donor cells 
would be available at time of relapse, the feasibility of this HA-1 specific im-
munotherapy is questionable since UCB T cells are generally thought to be in 
a relatively immature state, which may reduce the possibilities for CTL induc-
tion48-51. However, the generation of both tumour-specific and alloreactive CTLs 
from UCB has been reported previously52-54. Furthermore, adult-like fetal CD8 T 
cell responses against maternal infections have been recently described55,56. Our 
results further question the naïve phenotype of UCB T lymphocytes. 
 In chapter 5 we report the generation and functional characterization 
of hematopoietic cell-specific CTLs from neonate cells directed against HA-1H 
in the context of HLA-A2. These UCB CTLs were generated by mimicking the 
adult  CTL induction protocol34. Furthermore, these HLA-A2/HA-1H specific 
UCB CTLs could also be generated from HLA-A2 HA-1RR typed cord blood 
directly by FACS sorting. The lytic profile of the UCB derived HA-1 specific 
CTLs fully resembled the phenotype described for HLA-A2/HA-1H specific adult 
CTLs. These results demonstrate that UCB has the capacity to generate a GvL 
effect following UCB SCT. Thus, including mH antigen typing for the selection of 
suitable UCB donors for transplantation of HLA-A2/HA-1H positive leukemic 
patients may increase the GvL response. Clinical studies should be performed 
to determine whether HA-1 mismatching has a beneficial effect in UCB trans-
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plantation. Nonetheless, the generation of HA-1 specific CTLs from UCB for 
adoptive immunotherapy is only feasible if sufficient numbers of UCB cells are 
available in addition to the number of cells necessary for successful transplanta-
tion. The cell dose obtained from one UCB donor is low. Furthermore, it is cur-
rently not possible to obtain donor cells again for use of DLI at time of leukemia 
relapse, since UCB is banked anonymously. Studies are ongoing to find ways 
to expand UCB cells prior to transplantation57-60. This may increase the success-
rate of UCB SCT. Furthermore, a portion of UCB cells cryopreserved prior to 
transplantation may be used for HLA-A2/HA-1H specific CTL generation. Thus 
in addition to patients who received an adult SCT, the option of HA-1 specific 
adoptive immunotherapy may become available to HLA-A2 positive relapsed 
leukemia patients who received an HLA-A2 matched, HA-1H mismatched UCB 
SCT. Since UBC SCT is becoming a popular alternative treatment to adult SCT, 
this would considerably extend the patient population that can possibly benefit 
from HA-1 directed immunotherapy.
 Importantly, our FACS sorting results suggest that the UCB CTLs are 
probably expanded from memory precursor cells already present in vivo. We 
suggest that UCB derived HA-1H specific CTLs could be primed in utero against 
HLA-A2/HA-1H expressing APCs of the mH antigen mismatched, but HLA-A2 
matched mother. CTLs from the mother primed against paternal mH antigens 
expressed by the child were already found in various multiparous females61. 
This mH antigen specific CD8 memory is probably maintained by the long term 
microchimerism of cells from child origin found in the circulation of the moth-
er61,62. Likewise, priming of mH antigen specific UCB CTLs possibly depends 
on microchimerism of cells from the mother in the circulation of the child.63,64 
Cells isolated from four HA-1RR typed UCB samples derived from HA-1RR 
typed mothers failed to grow in vitro, despite a few detectable tetramer-staining 
CD8+ cells. Expanding unprimed CTL precursors thus appeared impossible. Yet, 
a substantial number of cells isolated from three out of seven HA-1RR typed 
UCB samples derived from HA-1H typed mothers stained with the HA-1A2 tet-
rameric complexes. These directly obtained HLA-A2/HA-1H specific UCB CTLs 
could be expanded in the absence of HA-1H antigen. Possibly, once primed by 
microchimerism of maternal cells, the generated central memory UCB CTLs 
maintain their HA-1H specificity by self-renewal65. The non-specific expansion 
resulted in a further enrichment of tetramer staining CD8+ cells. Like the in vitro 
generated UCB CTLs, the lytic profile of these HA-1H specific CTLs derived from 
UCB directly, resembled the phenotype described for HLA-A2/HA-1H specific 
adult CTLs. The majority of tetramer negative CD8+ cells expressed CD45RA. 
In contrast, tetramer staining CD8+ cells from two of the three UCB samples 
clearly expressed lower levels of CD45RA. Low CD45RA expression is indicative 
of recent antigen exposure, suggesting that HA-1 specific T cell priming has oc-
curred in utero. Thus, antigen-experienced circulating T cells specific for maternal 
mH antigen HA-1 can be detected in cord blood. Therefore, the selection of 
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HA-1RR typed UCB derived from an HA-1H typed mother may increase the GvL 
response. This option will only be feasible if, next to tissue typing of the UCB 
donors, also tissue typing of their mothers becomes a standard procedure. 
 It has been shown that HA-1 specific CTLs can also be generated from 
HLA-A2 negative individuals66,67. Therefore, not only HLA-A2 positive patients 
who received an HLA-A2 matched HA-1H mismatched UCB SCT but also who 
received an HLA-A2 mismatched UCB transplantation may benefit from HA-1 
specific immunotherapy. Studies are ongoing to generate CTLs that exclusively 
recognize MHC class I/HA-1 complexes in an allogeneous setting.
7.3 HA-1 specific TCR transfer
Since in vitro generation of HA-1H specific CTLs is time-consuming and not 
successful in all donors using the currently available protocols, HA-1 directed 
immunotherapy is not guaranteed for all HLA-A2 HA-1H typed patients trans-
planted with HLA-A2 HA-1RR typed donor stem cells. Therefore, transfer of 
HA-1 directed anti-leukemic reactivity to CD8+ peripheral T lymphocytes by T 
cell receptor (TCR) transfer might be an alternative strategy to generate HA-1 
specific CTLs. For starting generation of HA-1 specific CTLs by TCR transfer 
much lower cell numbers are acquired than for starting CTL induction. There-
fore, particularly in the UCB SCT setting TCR transfer may be a useful option 
for generating HA-1 specific CTLs, since only a limited number of UCB donor 
cells may be available for use of adoptive immunotherapy. 
 In chapter 6 we show that HA-1 specific TCR transfer can redirect 
both adult and UCB CD8+ T cells to antileukemic cytolytic activity. Thus, HA-1 
specific TCR transfer may be a useful alternative strategy to generate leukemia-
specific adult- or cord blood T cells. However, our results indicate a number of 
problems of the TCR transfer strategy as well. First, only a limited number of 
our HA-1 TCR-modified T cells stained HA-1A2 tetramer despite good cytolytic 
activity, an issue that needs to be further clarified. Furthermore, TCR modified 
T cells generally required more time than the original CTL clones to lyse their 
target cells. Similar problems were described for HA-2 TCR modified T cells, 
however optimally functioning HA-2 TCR modified T cells were also found68. 
Possibly, cell surface expression of stable HA-1 specific TCRs following transfer 
may not correlate with double reporter gene expression due to a number of 
reasons. For instance, endogenous- and transferred TCRs may compete for cell 
surface expression. It is conceivable that the separate transferred TCR and - 
chains pair with autologous TCR chains of the modified cells69. T lymphocytes 
may contain two autologous TCR chains70 which even enlarges the number of 
possible TCR and - combinations following TCR transfer. TCR competition 
and hybrid pairing of the different TCR and - chains present in the cell fol-
lowing TCR transfer may thus explain our results. HA-1 TCR clustering could 
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be hampered by the other TCRs expressed on the cell surface or may be im-
paired by the low numbers of HA-1 TCRs on the cell surface. As a consequence 
tetramer staining may be decreased and the appropriate activation and lytic 
function of the T cells may require more time.
 The overall drawback of the currently available TCR transfer tech-
nology is TCR hybrid pairing that may result in the formation of TCRs of 
unknown specificities71. These newly formed TCRs are a possible hazard when 
using the TCR modification strategy for treatment of hematological malignan-
cies, since severe autoimmune reactions or graft versus host responses may 
occur. Another potential mechanism by which TCR gene transfer might result 
in autoimmunity is the genetic modification of ignorant self-specific T cells, as 
these T cells may become auto-reactive after triggering of the transferred TCR69. 
Likewise, TCR transduced naive alloantigen-specific cord blood T cells from 
an HLA mismatched donor, may induce a severe graft versus host response in 
the patient upon transplantation. However, a first survey of autoimmunity in a 
mouse model of TCR gene transfer, in which the donor and recipient were fully 
MHC matched, did not give any clear indication of autoimmune pathology. 
This indicates that these two mechanisms are not likely to result in large-scale 
graft versus host effects after TCR transfer72. The development of strategies that 
can prevent the formation of hybrids or suppress endogenous TCR expression 
remains nevertheless desirable. Thus, prior to using this strategy for treatment 
of hematological malignancies, mechanisms of TCR formation and -triggering 
following TCR transfer into random peripheral T cells should be studied more 
extensively.
 Transducing  T cells with TCR and - chains may prevent the 
problem of hybrid pairing since hybrid pairing of TCR or - chains with TCR 
or - chains is not possible. The numbers of  T cells in the circulation are 
very low73, however only low numbers of T cells are necessary to perform TCR 
transfer. Alternatively, to prevent hybrid pairing the TCR chains may be modi-
fied in vitro in order to restrict their pairing capacity to each other. Nevertheless, 
the function of T cells modified with such redirected TCR chains remains un-
clear and needs to be studied extensively69. 
 The problem of triggering unknown ignorant or naïve TCRs can be 
circumvented by TCR transfer into established memory T cells containing en-
dogenous CMV specific TCRs74. The resulting T cells display dual specificity 
against both hematopoiesis restricted mH antigen and CMV. Stimulating these 
dual specific T cells with CMV antigen results in higher CMV specificity, while 
stimulating these cells with mH antigen results in higher mH specificity. How-
ever, since CMV specific memory T cells are required for this strategy, this is not 
an option when using cord blood cells. Furthermore, although the number of 
possible hybrid formations is restricted using this strategy, hybrid formation of 
TCRs of unknown specificity may still remain a problem. Perhaps, co-transduc-
tion of a suicide gene together with the TCR and - chains may provide a tool 
to eradicate the modified T cells if adverse effects occur75.
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 Another use of mH antigen HA-1 specific TCR transfer may be the 
modification of CD4+ T helper (Th) cells of a known specificity, in order to in-
crease the priming efficiency of HA-1 specific CTLs. In our protocols, priming 
for HA-1 CTLs can be improved by adding Th cells to the CTL cultures (chapter 
5). Currently the Th cells are produced using recall antigens (DKTP vaccine) 
(unpublished) or by non-specific stimulation of CD4+ T cells with CD3/CD28 
coated beads (chapter 5). Gene transfer of HLA-A2 restricted HA-1H specific 
TCRs into Th cells with a known specificity may result in the generation of Th 
cells that can specifically produce helper cytokines in response to the HA-1H 
expressing HLA-A2 positive APCs.  These helper cytokines specifically produced 
in response to the HLA-A2/HA-1H complex may improve HA-1H specific CTL 
priming. Since the Th1 type cytokines IFN- and IL-2 are key players in CTL 
induction, this TCR transfer may be most useful when using Th1 type CD4+ 
T cells. Additional transduction of these CD4+ Th cells with the CD8 and - 
chains may, in addition, lead to cytolytic activity of these cells in response to 
the HLA-A2/HA-1H complex. Thus transduction of for instance tetanus toxoid 
(TT)-specific CD4+ Th cells with both the HLA-A2 restricted HA-1H specific 
TCR and the CD8 and - chains, may result in TT-specific T cells capable of 
producing helper cytokines as well as lysing target cells in response to the HLA-
A2/HA-1H complex.
 
 In conclusion, in order to increase the HA-1 specific adoptive immu-
notherapy success-rate, HA-1 specific TCR transfer may be a useful alternative 
strategy. Not only to rapidly generate HA-1H specific HLA-A2 restricted adult- 
or UCB CTLs, but perhaps also to generate CD4+ Th cells which can increase the 
priming efficiency of HA-1H specific CTLs. Like induction of HA-1H specific CTLs, 
the generation of these CTLs by TCR transfer is only useful in HA-1RR typed do-
nor T cells since HA-1H positive donor T cells may be destroyed by transduced 
HA-1H specific TCRs.
Concluding remarks
All possible options for HA-1 specific immunotherapy presented in this thesis 
require an HA-1H mismatch between patient and donor. Providing this HA-1H 
mismatch, some leading points are now available to extend the patient popula-
tion that can benefit from HA-1 specific adoptive immunotherapy in the fu-
ture.
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aa amino acid
ALL acute lymphoid leukemia
AML acute myeloid leukemia
APC antigen presenting cell
2M 2-microglobulin
B-LCL B-lymphoblastoid cell line
BMT bone marrow transplantation
CB cord blood
CB-MNC cord blood mononuclear cells
CBT cord blood transplantation
CLL chronic lymphoid leukemia
CML chronic myeloid leukemia
CTL cytotoxic T lymphocyte
DC dendritic cell
DLI donor lymphocyte infusion
dNGF-R truncated form of nerve growth factor receptor
EBV-LCL Epstein-Barr Virus transformed B lymphoblastoid cell line
eGFP enhanced green fluorescent protein
ER endoplasmatic reticulum
E:T effector:target
FACS fluorescence activated cell sorting
FCS fetal calf serum
Fl fluorescein
GAP GTPase-activating protein
GvHD graft versus host disease
GvL graft versus leukemia
HLA human leukocyte antigen
HS human serum
IFN- interferon-
IL- interleukin-
IMDM Iscove’s modified Dulbecco’s medium
MACS magnetic activated cell sorting
MF mean fluorescence
mH minor histocompatibility
mHag minor histocompatibility antigen
MHC major histocompatibility complex
moab monoclonal antibody
MoDC monocyte derived dendritic cell
MTA maternally transmitted antigen
NIMA non-inherited maternal antigen
NK natural killer
ORF open reading frame
PBMC peripheral blood mononuclear cells
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PBS phosphate buffered saline
PCR polimerase chain reaction
PHA phytohemaglutinin
SC stem cell
SCT stem cell transplantation
TAP transporter associated with antigen processing
TCL T (lymphocyte) cell line
TCR T cell receptor
Th helper T lymphocyte
TNF tumour necrosis factor
TT tetanus toxoid
UCB umbilical cord blood
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Allogeneic stem cell transplantation (SCT) from a related or unrelated donor 
is a well-established and effective therapy for advanced hematological malig-
nancies. This therapy may -besides the required graft versus leukemia (GvL) 
response- initiate graft versus host disease (GvHD). In order to prevent GvHD, 
T cell depletion of the stem cell graft was introduced. Unfortunately, this not 
only resulted in a dramatic reduction of GvHD, but also in an increase of graft 
rejection and leukemia relapse rates. Relapsed leukemia patients can be success-
fully treated with donor lymphocyte infusion (DLI). The beneficial GvL response 
after DLI is however associated with GvHD. Differences in the major histocom-
patibiliy complex (MHC) molecules between donor and recipient cause this 
graft versus host reaction in case donor and recipient are MHC mismatched, 
however, in MHC identical settings, GvHD is still frequently initiated. In these 
MHC identical settings incompatibility between the so-called minor histocom-
patibility (mH) antigens is associated with GvHD induction. Human mH anti-
gens consist of peptides derived from naturally processed intracellular proteins 
and are presented by MHC molecules. Incompatibilities between mH antigens 
are generally caused by amino acid polymorphisms in these self-proteins but 
can also be caused by gene deletion. 
 Several mH antigens were found to be expressed only by certain cell 
types, while others are expressed ubiquitously. This differential tissue distribu-
tion of mH antigens may be an important feature in targeting specific cell types 
using mH specific donor cytotoxic T lymphocytes (CTLs). For example, the mH 
antigen HA-1 was found to be expressed by cells of hematopoietic origin only. 
Therefore, HA-1 may be targeted specifically to induce a GvL response. The 
immunogenic mH antigen HA-1 was identified as the HLA-A2 restricted no-
nameric peptide VLHDDLLEA derived from the di-allelic KIAA0223 gene. Two 
nucleotide differences in the KIAA0223 sequence resulted in a single amino acid 
sequence difference between the immunogenic CTL epitope VLHDDLLEA  (HA-
1H) and the VLRDDLLEA (HA-1R) counterpart. HA-1H is the most ideal candi-
date for immunotherapy of hematological malignancies since this mH antigen 
is highly immunogenic, hematopoietic restricted, expressed in high levels on 
leukemic cells and its frequency is 69% among the HLA-A2 positive population. 
Large numbers of HA-1H specific HLA-A2 restricted donor CTLs can potentially 
be generated in vitro for the use of adoptive cellular immunotherapy.
 Selectively infusing these HA-1H specific donor CTLs may mediate a 
strong GvL effect with a low risk for GvHD. However, The HA-1H specific im-
munotherapy is currently feasible only for HLA-A2 HA-1HH or HA-1HR patients 
who relapsed following an SCT from an HLA-A2 HA-1RR donor. Thus, the feasi-
bility of this therapy depends both on the presence of recipient-donor disparity 
for the mH antigen HA-1 and on HLA-A2 expression. In addition, the therapy 
is not guaranteed for all of these patients. For instance, the anonymous umbili-
cal cord blood (UCB) donors cannot be traced again for use of DLI or adoptive 
immunotherapy following transplantation. Moreover, the success rate of HA-1H 
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specific HLA-A2 restricted CTL induction is donor dependent. This thesis de-
scribes several attempts and possibilities to extend the patient population that 
can benefit from HA-1 specific immunotherapy in the future.
 Previously described peptide elution studies could not detect HA-1R 
expression in the context of HLA-A2; i.e. beyond 5 copies per cell. In chapter 2, 
we examined several possible causes for the absence of cell surface HLA-A2/
HA-1R expression in order to evaluate the option of HA-1R directed immuno-
therapy. Immunotherapy directed towards the HA-1R counterpart would make 
the HA-1 specific therapy available for HA-1R typed patients who relapsed 
following an SCT from a HA-1HH typed donor. However, chapter 2 reveals that 
HLA-A2/HA-1R specific CTLs are not useful for immunotherapy since the natu-
ral presentation of HA-1R in HLA-A2 is instable. Other not yet identified MHC 
class I/HA-1R complexes that are naturally expressed on the cell-surface in a 
stable fashion, might be capable of triggering an immune response from HA-1R 
specific CTLs. Nevertheless, possibly HA-1R peptides are not capable of serving 
as natural T cell epitopes in any setting. Therefore, the recently reported ad-
ditional polymorphisms found within the HA-1 locus form an interesting new 
field of investigation. Additional allelic counterparts in the HA-1 gene may result 
in additional MHC class I restricted HA-1 epitopes which may provide the op-
tion of HA-1 directed immunotherapy for patients negative for HA-1H.
 Furthermore, we investigated whether the HA-1H/R polymorphic re-
gion contains peptides that can be presented by MHC class I molecules other 
than HLA-A2. To this end, competition-based peptide binding assays for 13 
prevalent MHC class I alleles were developed, as described in chapter 3. In 
chapter 4, using this competition-based peptide-binding assay, we discovered 
the HLA-B60 restricted HA-1H peptide KECVLHDDL as a novel additional HA-1 
epitope. Immunogenic potential of the HA-1R counterpart in HLA-B60 was not 
confirmed. However, proteasome cleavage results and the stable binding of both 
the KECVLHDDL and the KECVLRDDL peptide to HLA-B60 suggested that the 
HLA-B60/HA-1R complex is expressed on the cell surface. Using HLA-B60 APCs 
that are transduced with HA-1R may increase the success-rate of high affinity 
HLA-B60 restricted HA-1R specific CTL induction compared with using APCs 
that are pulsed with HA-1R peptide. 
 In chapter 5 we report the generation and functional characterization 
of hematopoietic-specific CTLs from UCB directed against HA-1H in the context 
of HLA-A2. We suggest that including mH antigen typing for the selection of 
suitable UCB donors for transplantation of HLA-A2/HA-1H positive leukemic 
patients may increase the GvL response following UCB transplantation. Fur-
thermore, like for patients treated with adult SCT, the option of HA-1 specific 
immunotherapy may become available to HLA-A2 positive relapsed leukemia 
patients who received an HLA-A2 matched, HA-1H mismatched UCB SCT. Yet, 
sufficient numbers of UCB donor cells need to be available in order to be able 
to generate HLA-A2/HA-1H specific UCB CTLs for use of immunotherapy. The 
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cell dose obtained from one UCB donor, however, is low. Expanding UCB cells 
prior to transplantation may provide sufficient numbers of cells to increase the 
success-rate of UCB SCT. In addition, cryopreservation of a portion of these 
UCB cells prior to transplantation may provide donor cells at time of relapse, 
which can be used for HLA-A2/HA-1H specific UCB CTL generation. 
 In chapter 6 we show that HA-1 specific TCR transfer can direct non-
HA-1 TCR expressing adult and UCB CD8+ T cells to hematopoietic-specific 
cytolytic activity. Thus, HA-1 specific TCR transfer may be a useful alterna-
tive strategy to generate HA-1H specific HLA-A2 restricted adult- or UCB CTLs. 
However, only a limited number of TCR-modified cells stained HA-1A2 tetramer. 
Also TCR-modified cells generally required more time than the original CTL 
clones to lyse their target cells. This may be caused by low cell surface expres-
sion of stable HA-1 specific TCRs. Endogenous- and transferred TCRs possibly 
compete with each other for cell surface expression. Furthermore, the separate 
transferred TCR chains may pair with the autologous TCR chains of the modi-
fied cells. This hybrid pairing may not only result in a low concentration of 
HA-1 specific TCRs but also in the formation of hybrid TCRs of unknown 
specificities. In addition, ignorant self-specific T cells may become autoreactive 
after triggering of the transferred TCR. Thus, several intracellular mechanisms 
should be studied extensively before the option of TCR transfer becomes clini-
cally available. 
 In conclusion, some important features of the polymorphic mH anti-
gen HA-1H/R locus are now available, which may lead to extension of the patient 
population that may benefit from HA-1 specific immunotherapy.
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Een effectieve therapie waarmee leukemiepatiënten doorgaans worden behan-
deld is allogene stamceltransplantatie. Voordat de stamcellen uit het beenmerg 
van de donor worden getransplanteerd, worden de leukemie cellen in de patiënt 
gedood door middel van bestraling en/of chemotherapie. Ook de gezonde 
bloedcellen van de patiënt worden bij deze behandeling gedood. Na transplan-
tatie zullen de van de donor afkomstige stamcellen groeien en differentiëren tot 
rijpe bloedcellen, zodat het hematopoietische (= bloedvormende) systeem in de 
patiënt herstelt. Vervolgens kunnen bepaalde witte bloedcellen, de T lymfocyten 
oftewel T cellen, van de donor de nog levende leukemie cellen van de patiënt 
herkennen en doden: het zogenaamde graft versus leukemia (GvL) effect. De do-
nor T cellen aanwezig in het stamcel transplantaat kunnen  echter ook gezonde 
cellen en weefsels van de patiënt als vreemd herkennen, wat kan leiden tot graft 
versus host disease (GvHD). Om het ontstaan van GvHD te voorkomen kan het 
stamcel transplantaat vóór de transplantatie worden ontdaan van de T cellen. 
Helaas resulteert dit niet alleen in afname van GvHD maar ook in toename 
van afstotingsverschijnselen en terugkeer van de leukemie. Bij terugkeer van de 
leukemie kunnen patiënten worden behandeld met het toedienen van donor af-
weercellen, oftewel donor lymphocyte infusion (DLI). De beoogde respons tegen 
leukemie na DLI is echter geassocieerd met het ontstaan van GvHD.
T cel receptoren (TCRs) op T cellen herkennen eiwitfragmenten (peptiden) van 
lichaamsvreemde eiwitten (proteïnen). Deze zijn voorbehandeld door een cel 
en worden op het celoppervlak gepresenteerd door een ander molecuul. Dit 
molecuul wordt in de mens human leucocyte antigen (HLA) genoemd en is 
gecodeerd in het major histocompatibility complex (MHC). Met name verschil-
len in MHC/HLA moleculen tussen transplantaat en ontvanger zijn de oorzaak 
van het ontstaan van GvHD. Daarom wordt er zoveel mogelijk getransplanteerd 
met stamcellen van een donor waarvan de MHC moleculen nagenoeg identiek 
zijn aan die van de ontvanger. Ook in een dergelijke MHC identieke situatie kan 
desondanks GvHD ontstaan. In deze situatie is de afweerreactie gericht tegen 
verschillen in andere moleculen dan MHC moleculen. Deze moleculen wor-
den de minor histocompatibility (mH) antigenen genoemd. mH antigenen zijn 
eiwitfragmenten afkomstig van lichaamseigen eiwitten in de cel, die door MHC 
moleculen worden gepresenteerd op het celoppervlak. Verschillen tussen deze 
mH antigenen worden voornamelijk veroorzaakt door kleine verschillen in de 
aminozuren waaruit de antigenen zijn opgebouwd, polymorfismen genaamd. 
In sommige gevallen ontstaat het verschil in mH antigeen presentatie tussen 
donor en ontvanger echter doordat het gen dat het mH antigeen codeert niet tot 
expressie wordt gebracht door ofwel de donor ofwel de ontvanger.
Sommige mH antigenen worden alleen tot expressie gebracht door bepaalde 
specifieke celtypes terwijl andere mH antigenen door ieder celtype tot expressie 
worden gebracht. Deze verschillen in expressie kunnen van belang zijn om de 
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afweerreactie door donor T cellen specifiek te kunnen richten tegen bepaalde 
celtypes, zonder andere celtypes aan te tasten. Het mH antigeen HA-1 wordt 
bijvoorbeeld alleen tot expressie gebracht door hematopoietische cellen, dus 
ook door leukemie cellen. Een specifieke afweerreactie tegen HA-1 zou dan 
ook kunnen leiden tot een GvL effect. Van het HA-1 eiwit zijn twee varianten 
geïdentificeerd die in één aminozuur verschillen, een H of een R (dit wordt ge-
schreven als HA-1H en HA-1R). Ieder mens bezit één van de twee varianten of 
beide. Na transplantatie wordt de H variant als vreemd herkend door T cellen 
afkomstig van een donor die alleen de R variant heeft. Deze H variant is als 
mH antigen geïdentificeerd wanneer het als eiwitfragment gepresenteerd wordt 
door het MHC molecuul HLA-A2. HLA-A2 komt in 49% van de Caucasische 
populatie voor. 69% van de HLA-A2 positieve populatie brengt ook HA-1H tot 
expressie. Leukemie patiënten met deze weefsel typering kunnen wellicht gehol-
pen worden door immunotherapie met donor T cellen die specifiek gericht zijn 
tegen HA-1H in HLA-A2. Aanzienlijke aantallen cytotoxische (= celdodende) T 
cellen met deze specificiteit kunnen worden gekweekt voor deze zogenaamde 
adoptieve cellulaire immunotherapie.
Het selectief toedienen van HA-1H specifieke T cellen zou dus een sterk GvL 
effect kunnen genereren met slechts een laag risico op GvHD. Deze HA-1 speci-
fieke adoptieve immunotherapie is echter alleen beschikbaar voor HLA-A2 
positieve patiënten die HA-1H tot expressie brengen en die getransplanteerd zijn 
met cellen van een donor die ook HLA-A2 positief is maar geen HA-1H tot ex-
pressie brengt. De haalbaarheid van deze therapie is dus zowel afhankelijk van 
dit HA-1 verschil tussen patiënt en donor als van HLA-A2 expressie. Tijdens dit 
promotie onderzoek is gezocht naar mogelijkheden om de patiënten populatie 
die van HA-1 specifieke immunotherapie zou kunnen profiteren te vergroten.
Tijdens eerder onderzoek is expressie van de HA-1R variant in combinatie met 
HLA-A2 niet gevonden. In hoofdstuk 2 wordt een aantal mogelijke oorzaken 
voor de afwezigheid van HLA-A2/HA-1R op het celoppervlak onderzocht. De 
mogelijkheid van immunotherapie gericht tegen de HA-1R variant zou immers 
de HA-1 specifieke therapie beschikbaar maken voor HA-1R positieve patiënten 
die getransplanteerd zijn met cellen afkomstig van een HA-1R negatieve donor. 
De natuurlijke presentatie van HA-1R door HLA-A2 bleek echter extreem in-
stabiel. Daardoor vervalt de mogelijkheid van immunotherapie gericht tegen 
HA-1R in combinatie met HLA-A2. Desondanks worden andere nog niet geï-
dentificeerde HA-1R eiwitfragmenten wellicht stabiel gepresenteerd door andere 
MHC moleculen. Een dergelijke combinatie zou een afweerreactie van HA-1R 
specifieke donor T cellen kunnen uitlokken. Het is echter ook mogelijk dat geen 
enkel HA-1R fragment kan dienen als antigeen. In dit geval kunnen de recent 
gevonden andere aminozuur polymorfismen op verschillende posities in het 
HA-1 gen van belang zijn. Deze ‘nieuwe’ polymorfismen resulteren wellicht 
in een grotere variatie van HA-1 eiwitfragmenten die worden gepresenteerd 
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door MHC moleculen en die kunnen worden herkend door donor T cellen. 
Deze grotere variatie zou immunotherapie mogelijk kunnen maken voor HA-1H 
negatieve patiënten.
De toepassing van HA-1 specifieke immunotherapie zou in de toekomst kunnen 
worden uitgebreid door de therapie ook mogelijk te maken voor patiënten die 
geen HLA-A2 tot expressie brengen. Hiertoe is voor verschillende HA-1H- en 
HA-1R eiwitfragmenten onderzocht of deze kunnen worden gepresenteerd door 
andere MHC moleculen dan HLA-A2. In hoofdstuk 3 wordt de ontwikkel-
ing van het peptide-MHC-bindings experiment beschreven dat hiervoor werd 
toegepast. Dit experiment is ontwikkeld voor 13 verschillende MHC moleculen 
en is gebaseerd op competitie voor MHC-binding tussen een HA-1 fragment en 
een eiwitfragment waarvan al bekend is dat het bindt aan het MHC molecuul 
van interesse. Hoofdstuk 4 beschrijft vervolgens de ontdekking van HA-1 eiwit-
fragmenten waarvan zowel de H als de R variant binden aan HLA-B60. Boven-
dien bleek het mogelijk om een afweerreactie van donor T cellen specifiek te 
richten tegen een natuurlijk HA-1H fragment gepresenteerd door HLA-B60. Een 
dergelijke afweerreactie werd niet gevonden tegen de natuurlijke HA-1R variant 
in HLA-B60. Desondanks wijzen bepaalde bevindingen erop dat ook de HA-1R 
variant door HLA-B60 op het celoppervlak kan worden gepresenteerd. Daarom 
zou het optimaliseren van de kweektechnieken wellicht kunnen leiden tot een 
afweerreactie specifiek gericht tegen natuurlijk HA-1R in HLA-B60. 
In hoofdstuk 5 konden cytotoxische T cellen specifiek gericht tegen HA-1H in 
HLA-A2 worden verkregen uit HLA-A2 positief HA-1H negatief navelstreng-
bloed. Het typeren voor zowel HLA- als mH antigeen expressie lijkt dus niet 
alleen van belang voor het selecteren van een geschikte volwassen donor, maar 
ook voor het selecteren van een passende navelstreng donor. Transplantatie 
van HLA-A2/HA-1H positieve leukemie patiënten met HLA-A2 positief HA-1H 
negatief navelstrengbloed zou kunnen leiden tot een toename van het GvL ef-
fect. Bovendien zou HA-1 specifieke immunotherapie in de toekomst mogelijk 
kunnen worden voor HLA-A2/HA-1H positieve leukemie patiënten die getrans-
planteerd zijn met HLA-A2 positief HA-1H negatief navelstrengbloed. Het kwe-
ken van HLA-A2/HA-1H specifieke cytotoxische T cellen uit navelstrengbloed 
voor gebruik bij immunotherapie vergt echter een groot aantal cellen, boven op 
het aantal dat nodig is voor succesvolle transplantatie. Het celaantal dat wordt 
verkregen uit één navelstreng is over het algemeen laag. Wellicht zal het expand-
eren van navelstrengbloed vóór de transplantatie leiden tot voldoende aantallen 
cellen om het transplantatiesucces te laten toenemen. Verder zou het invriezen 
van een gedeelte van deze navelstrengbloedcellen vóór de transplantatie kun-
nen voorzien in donor cellen wanneer de leukemie terugkeert. Hieruit kunnen 
dan HLA-A2/HA-1H specifieke cytotoxische T cellen worden gekweekt.
150 The human minor histocompatibility antigen HA-1; its processing, presentation and recognition
Hoofdstuk 6 laat zien dat het mogelijk is om HA-1 specifieke T cel recepto-
ren over te brengen naar zowel volwassen als navelstrengbloed T cellen. Deze 
T cellen vertonen vervolgens cytotoxische respons tegen leukemie cellen. In 
tegenstelling tot het kweken van HLA-A2/HA-1H specifieke T cellen is voor 
het verkrijgen van HLA-A2/HA-1H specifieke T cellen door TCR overdracht 
slechts een klein aantal cellen nodig. TCR overdracht zou dus zowel in geval van 
transplantatie met volwassen stamcellen als met navelstrengbloed een bruikbare 
alternatieve strategie kunnen vormen om het welslagen van HA-1 specifieke 
immunotherapie te bevorderen. Vooralsnog moeten er nog diverse hordes ge-
nomen worden. Verschillende aanwijzingen werden namelijk gevonden voor 
de suggestie dat de TCR-gemodificeerde T cellen slechts een klein aantal HA-1 
specifieke T cel receptoren op hun oppervlak tot expressie brengen. Het is mo-
gelijk dat de TCRs die al aanwezig waren in de T cellen competitie aangaan 
met de HA-1 specifieke TCRs die zijn ingebracht, voor expressie op het celop-
pervlak. Verder is het mogelijk dat de beide ketens waaruit de HA-1 specifieke 
TCR bestaat, apart paren met de TCR ketens al aanwezig in de cel. Door deze 
zogenaamde hybride paringen komt slechts een laag aantal complete HA-1 
specifieke TCRs op het celoppervlak tot expressie. Bovendien worden hierdoor 
hybride TCRs gevormd waarvan de specificiteit onbekend is. Daarnaast kan het 
voorkomen dat niet-geactiveerde TCRs in de cel die specifiek zijn voor eigen 
gezonde cellen of weefsels, toch actief worden na activatie van de ingebrachte 
TCR. Om destructie van gezonde cellen tegen te gaan zullen verschillende mech-
anismen in de cel dus uitgebreid bestudeerd moeten worden. Zowel de formatie 
van hybride TCRs met onbekende specificiteit als de activatie van zelfspecifieke 
TCRs moeten worden uitgesloten voordat de mogelijkheid van TCR overdracht 
beschikbaar wordt voor gebruik in de praktijk.
 
Samengevat worden in dit proefschrift verschillende aanknopingspunten ge-
presenteerd die verder kunnen worden ontwikkeld om de toepassingsmoge-
lijkheden voor HA-1 specifieke immunotherapie uit te breiden. De besproken 
bevindingen kunnen de patiënten populatie, die in de toekomst van HA-1 spe-
cifieke adoptieve immunotherapie kan profiteren, vergroten.
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Vanzelfsprekend was dit proefschrift er niet gekomen zonder de bijdrage van 
velen. Een aantal mensen die van groot belang zijn geweest voor de totstand-
koming van dit proefschrift wil ik op deze plaats dan ook bedanken.
 Janine, jou wil ik graag in het bijzonder bedanken voor de fijne samen-
werking en de grote toewijding waarmee je zoveel verschillende experimenten 
hebt uitgevoerd. Zonder jou was het niet tot zo’n goed einde gekomen. Dank je 
wel dat je mijn paranimf wilt zijn. Ook alle andere mensen van de ‘Minor groep’ 
ben ik erg dankbaar: Astrid, dank je wel voor je enorme betrokkenheid! Je 
begeleiding tijdens de laatste periode van dit project is van onschatbare waarde 
geweest. Liesbeth, onze donderdagochtendloopjes (en –gesprekken) waren goed 
voor me. Bedankt voor deze prettige stok achter de deur. Gitte, dank je wel voor 
je hulp tijdens de laatste loodjes. Els, Tuna, Martina, Brigitte, Eric, Lothar, Jos, 
Els, Corine, Ellen, Antoinette, Suzanne, Ilse, Zohara, Rob en Kim, ik heb van jul-
lie veel geleerd en veel hulp gekregen, heel erg bedankt daarvoor. Verder wil ik 
iedereen van de groep bedanken voor de interessante en gezellige gesprekken 
en discussies, niet alleen tijdens het werk maar ook bij een kop koffie of thee of 
bij een etentje. 
 Ik heb ook veel te danken aan bijdragen van IHB’ers buiten de ‘Minor 
groep’ en van medewerkers van afdelingen buiten IHB en buiten het LUMC. 
Deze mensen wil ik dan ook graag bedanken voor hun aandeel in dit project. 
(Namen noemen brengt een groot risico met zich mee om mensen te vergeten.) 
Verder heb ik een lange tijd mogen werken in het viruslab van de afdeling Ex-
perimentele Hematologie. Klein maar fijn was hier van toepassing. Mirjam, Lars, 
Manja, Marleen, bedankt voor jullie gastvrijheid en jullie hulp. De mensen van 
‘het aquarium’ wil ik ook nog noemen: Liz, jij bent al heel snel een hele goede 
vriendin geworden en nu zelfs paranimf, dank je wel. Janine, Linda, Alies, Jeroen, 
Willemien, Peter, Janine, Antoinette en Tjitske, jullie waren hele fijne kamergeno-
ten. IHB is een gezellige en prettig gestoorde afdeling die ik niet zal vergeten.
Mijn nieuwe collega’s bij Crucell wil ik graag bedanken voor hun belangstelling 
tijdens de allerlaatste fase.
 Ik heb veel geluk gehad dat ik mijn promotietijd heb kunnen delen met 
zoveel lieve vrienden: Pauline, Joris, Liz, Bas, Marissa, Marianke, Gwen, Juliette, 
Wietske, Meintje, Myriam, José, Karin, Inge, Karin, Anneke, Sandra, Rudyard, 
Liesbeth, Janine, Amber, Lyvienne, Willemijn, Lonneke, Jeroen, Marc, Mirjam, 
Dennis, Shiva, Mark en Harriette, heel erg bedankt voor jullie belangstelling. 
Ieder van jullie die mijn gezeur wilde aanhoren als ik het weer eens niet zag 
zitten wil ik in het bijzonder bedanken! Manon, dank je wel dat je me hebt ge-
holpen het boekje zo mooi te maken.
 John, je hebt wat met mij te stellen gehad. Het is heerlijk om een klank-
bord te hebben, dank je wel voor je steun! Fien, met jou in mijn buik heb ik veel 
geschreven. Ik geniet enorm van je!
 Ten slotte, papa en mama, ontzettend bedankt voor jullie steun en jullie 
niet aflatende vertrouwen in mij! Het is gelukt!
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De schrijfster van dit proefschrift is geboren op 6 september 1974 in Leiderdorp. 
Zij behaalde haar HAVO diploma in 1991 en haar VWO diploma in 1993, beide 
aan de Louise de Coligny Scholen Gemeenschap in Leiden. Vervolgens heeft zij 
een jaar doorgebracht in Driebergen alwaar zij het Propedeutisch Jaar volgde 
van de Vrije Hogeschool. In 1994 ging zij Biomedische Wetenschappen studeren 
aan de Universiteit Leiden. Tijdens haar studie doorliep zij verschillende stages: 
aan de afdeling Pathologie/Heelkunde van het Leids Universitair Medisch Cen-
trum in de groep van Dr. P. Kuppen, aan de afdeling Medical Microbiology van 
de Edinburgh University in Schotland in de groep van Prof. Dr. M. Norval, 
aan de afdeling Parasitologie van het Leids Universitair Medisch Centrum in de 
groep van Dr. A. Waters en aan de afdeling Immunohematologie en Bloedbank 
van het Leids Universitair Medisch Centrum in de groep van Prof. Dr. F. Claas. 
Het doctoraal diploma werd in augustus 1999 behaald. Hierna volgde het pro-
motieonderzoek dat is beschreven in dit proefschrift. Zij was hiervoor van sep-
tember 1999 tot maart 2004 aangesteld als Assistent In Opleiding (AIO); aan de 
afdeling die inmiddels was omgedoopt tot Immunohematologie en Bloedtrans-
fusie (hoofd Prof. Dr. C. Melief) van het Leids Universitair Medisch Centrum. 
Het promotieonderzoek werd verricht in de groep van Prof. Dr. E. Goulmy, 
onder haar begeleiding en die van Dr. T. Mutis en Dr. A. van Halteren. Sinds 
maart 2005 is zij werkzaam als Scientist Immunolgy bij Crucell Holland B.V.
158 The human minor histocompatibility antigen HA-1; its processing, presentation and recognition
 Curriculum Vitae 159
160 The human minor histocompatibility antigen HA-1; its processing, presentation and recognition
